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Abstract
This thesis presents the synthesis of several structural analogues of the
immunosuppressant compound THI. A number of the synthesised analogues were
found to have higher levels of biological activity of the same type as THI.

Chapter 1 presents an introduction and summary of some of the fundamental
principles behind immunosuppression and the modes of action of a range of known
commercial immunosuppressants. This chapter also looks at the role of
immunosuppression in modern medicine and presents some potential new
immunosuppressants yet to reach the commercial market. The final part of the chapter
provides an introduction to, and background of THI, which leads into the aims of the
project.

Chapter 2 presents the synthesis of five-carbon side chain, 5-thiazole
analogues of THI, with the aim of determining the effect of increasing the length of
the pendant side-chain. The promising biological screening data generated for these
compounds is presented towards the end of the chapter.

Chapter 3 investigates the consequences of reversing the orientation of the
thiazole heterocycle. This synthesis proceeds via a lithium-bromide exchange reaction
to overcome the lower reactivity of the 4-thiazole position (compared to the 5position).

Chapter 4 provides a logical extension of the successful increase in side chain
length from 4 to 5 carbons, by further extending this functionality out to 6 carbons.

This Chapter also includes a more detailed study of metal hydride reductions and the
stereochemical factors associated with these reactions.

In order to determine the role of the absolute configuration of the
polyhydroxyl side chain, Chapter 5 presents the synthesis of another range of 6carbon side chain analogues with different absolute configurations.

A brief summary of the work is presented in Chapter 6, along with some
general observations brought about by the results of the project.
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The underlying issue behind this project was the need for novel
immunosuppressant drugs that have a lower toxicity profile than currently employed
therapies. This introductory chapter provides a basic understanding of the human
immune system and how current immunosuppression therapies interact with it. This is
followed by a brief look at some of the more important medical conditions involving the
immune system, and some of the current therapies available. Finally, the aims of this
project will be presented.

1.1 Defences of the Human Body
Two types of defence mechanisms form a preliminary defence for the body.
These are the "non-specific" or "innate" and the "specific" or "adaptive" mechanisms.
This is outlined below in Figure 1-1.

The Body's Defences

Specific Defences

Non Specific Defences
Tucl. skin, mucous,
phagocytes

Immune system

Humoral Immunity

Cellular Immunity

T c ell s

Antibodies

Figure 1-1 Defences of the H u m a n B o d y
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1.1.1 Non-Specific Defences
The non-specific defences are primarily physical traits of the human body, while
specific defences involves the immune system and its associated cellular defences.
Non-specific defences involve generic responses to microorganisms and include
both passive and active defences. Passive defences include skin, mucous and other
secretions, commensal organisms, acidic environments and mechanical actions.1 Active
non-specific defence relies on the actions of phagocytes.

1.1.1.1 Passive Non-Specific Defences
Intact skin provides an initial physical barrier against microorganism attack.
This mostly impermeable organ surrounds the body and is supported in its defensive

role by the actions of various secretions including lactic and fatty acids in sweat.

is also highly saline, creating a very hostile environment for antigens contacting t
skin.
In areas where the skin is not continuous, such as around the respiratory,
digestive and reproductive tracts, the eyes and ears, the body utilises a range of

secretions that prevent or hinder microorganism invasion. These include saliva in th
mouth; mucous in the airways and reproductive tracts, lysozyme in tears and wax in
ears.1 These secretions are often home to a range of commensal organisms.
Commensal organisms are found in most locations on the body that are exposed
to the surrounding environment, including the respiratory, gastrointestinal and
urogenital tracts, and the skin. On the skin the dominant aerobic species (90%) is
Staphylococcus but there are numerous other species present. The mouth and nose are
home to Streptococcus, Staphylococcus and Bacteroides among others, while the lungs
harbour Pneumocystis species. Perhaps the largest and most widely known of the

normal organism populations is the gut flora. The gastrointestinal tract accommodate

Chapter 1-Introduction

huge populations (as high as 10

10

organisms/g) of Lactobacillus, Streptococcus,

Enterobacteria, Staphylococcus and Pseudomonas species, among others.1 Many of
these organisms directly compete with invading antigens for resources such as space
and nutrients. Some also produce hostile secretions such as acids, which prevent the
establishment of invading colonies.
Acidic environments are found in the stomach, skin, mouth and urogenital tract
and prevent infection simply by maintaining a lower pH at which the invading
organisms cannot survive.
Mechanical actions such as sneezing and coughing are involuntary mechanisms

used to remove larger antigens capable of triggering these responses, as well as muco
that has become heavily laden with trapped antigens. Cilia also serve as mechanical

defences, in sites such as the trachea, by trapping and actively transporting foreign
matter away from the body.

1.1.1.2 Active Non-Specific Defe nces
Should this first line of defence be breached, the body has a range of cells
known as phagocytes which are capable of destroying many times their own number of
organisms through a process known as phagocytosis. Phagocytosis is initiated by
contact between the phagocyte and invading microorganism. This is believed to come

about as the result of a carbohydrate mediated recognition process and can be amplifi
by the actions of the complement molecules.1 The complement pathway uses positive
feedback to distribute complement molecules to areas where phagocytes are required.
The molecules activate and recruit phagocytes to the area.1 Phagocytosis can also be
antibody mediated through the presence of IgG antibodies. IgG attaches to IgG

receptors on the phagocyte surface. The protruding antibodies can then bind selectiv
to antigenic determinants on the surface of specific microorganisms.
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T o achieve phagocytosis, cytoplasmic "arms" extend from the phagocyte,

engulfing the microorganism and enclosing it within a cellular vacuole (Figure 1-2),
structure is called a phagosome. Lysosomes containing microbicidal agents then fuse
with the phagosome, releasing the microbicides and destroying the contained
microorganism.

Figure 1-2 Phagocytosis
Although the bulk of the debris from this process is expelled from the

phagocyte, it is only able to destroy around 20 microorganisms before the accumulate
breakdown products become too toxic and the phagocyte dies.
Phagocytes include the mononuclear macrophages and the polymorphonuclear
neutrophils. Macrophages are formed from cells generated by the bone marrow and are

found in the body's connective tissue, although they are particularly prevalent in t
lungs, liver, spleen and lymph nodes. The presence of macrophages in the tissues of
body allows them to act against organisms that have invaded cells. Neutrophils

3 0009 03317225 0
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dominate the white blood cell population and are primarily responsible for eliminating
antigens in the blood stream prior to their establishment within the cellular matrix.
Natural killer cells are yet another type of cell employed by the innate defence
system. They are large cytotoxic lymphocytes with a potent granular payload whose

role is to seek out and destroy any of the body's cells that are infected by an invadin
antigen, such as a virus. Natural killer cells recognise and bind to glycoproteins and

antibodies (formed on the surface of a cell once it has been attacked), creating contac
between the lymphocyte and its target. The natural killer cell then releases granular
compounds into the pocket between the two cells. These compounds include perforin
molecules, which embed in the membrane of the target cells and polymerise, forming

pores that cause the cell to lyse. Additionally, these granular species include various
toxins that poison the cell, and a range of reactive oxygen species including hydrogen
peroxide, superoxide anions and hydroxy radicals that damage and ultimately destroy
the infected cell.1 These reactive oxygen species are also a major cause of mutagenic
alterations in DNA chains.3
Local inflammation may also occur as part of an innate response, wherein the
blood flow to an area increases, usually in response to tissue damage. This results in

greater number of natural killer cells and phagocytes in the area and also results in a
increase in the temperature of the surrounding tissue which is often enough to slow or
retard the proliferation of invading organisms. It has been noted however, that some
virulent bacteria such as Staphylococci are able to partially inhibit the inflammation
response.1

Chapter I-Introduction
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1.1.2 Specific Defences
The human body has evolved an extremely sophisticated system to protect itself

against nearly all of the pathogens it may face. It is capable of launching a defens
attack against a specific invader, without affecting the body's healthy cells.

1.1.2.1 The Immune System
The immune system is comprised of an extensive network of cells tissues and
organs that are found throughout the body4 and, in fact, so large that on a cellular

it is considered the largest system in the body.2 In contrast to the innate defences,

immune system is a highly specific defence mechanism. It is able to distinguish betw

self and non-self entities and mount a concentrated attack on any invading antigens.

three important functions of the immune system are to recognise, selectively elimina

and then remember foreign antigens. Having detected the presence of foreign antigens
the immune system can utilise one of two responses, the humoral or the cellular
response.

1.1.2.2 Humoral Immunity
Humoral immunity relies on the actions of antibodies (immunoglobulins).
Antibodies are protein molecules secreted by plasma cells. Plasma cells form when B
cells encounter an antigen (Figure 1-3). They immediately proliferate, producing

effector cells (plasma cells) and memory cells. The plasma cells are responsible for
immediate destruction of the invading antigen. The initial antibodies formed by a
plasma cell during an immune response are always IgM immunoglobulins.4

Chapter 1-Introduction
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Antigen

Bcell
with
antibody
Antigen binding by
antibody initiates
cell proliferation
Population of
Plasma Cells
Population of
memory cells

YYYYYYYYYYYYYY
Increase in specific antibody
population

Figure 1-3 Antibody Proliferation in Response to Antigenic Stimulus
At a later stage, the plasma cells start producing different antibodies in response
to a change in their DNA (Table 1-1). This produces antibodies that have different
functionality but have the same antigen specificity, IgA, IgD, IgE and IgG.

Table 1-1 T h e Role of Various Antibodies
Antibody

Biological Role

IgM

Formed during primary immune response. Activates macrophages.

IgG

Majority produced in secondary response. 85% total blood Ig. Activates
complement system. Capable of crossing the placenta to infer passive
immunity on newborn. Promotes phagocytosis, directing innate defence
against specifically bound antigens.

IgA

Present in bodily secretions to aid innate defences

IgD

Activates lymphocytes and is mostly present on lymphocytes membranes

IgE

Involved in inflammatory and allergic responses.
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Once a plasma cell has changed to production of a new type of antibody it

cannot resume production of the previous antibody, as the change in DNA responsible i
a deletion of part of the DNA in that cell.

The memory cells persist in the body for much longer (years) and form the basis of th
"remembering" role of the immune system. Deposits of antigenic debris on follicular
dendritic cells mediate this prolonged memory.5 If the memory cells encounter the

antigen that caused their proliferation, they rapidly launch a response, producing va

numbers of the required plasma cells and, consequently, the required antibodies. This
trait is exploited in the process of immunisation, in which an individual is exposed
weakened strain of an antigen that the humoral immune system is capable of
overcoming. The "acquired immunity" from this treatment means that should the body

encounter an attack from the organism itself, it has a head start in the production o
antibodies.

1.1.2.3 Cellular Immunity
Cellular immunity involves the actions of lymphocytes. Like phagocytes,
lymphocytes are leukocytes, or white blood cells. However, there is a fundamental
difference between these two groups of leukocytes based on their functionality.
Lymphocytes attack specific microorganisms, based on the recognition of surface

molecules. Phagocytes will ingest anything foreign to the body and in medical studies
have even ingested latex beads.1 There are two types of lymphocytes involved in
immune responses, B cells and T cells. B cells are mainly concerned with the
production of antibodies and therefore linked to the humoral response. They

differentiate in bone marrow and the foetal liver, while T cells differentiate in the
thymus. The response of the cellular immune system centres on the actions of the T

cells. T cells form in the bone marrow and migrate to the thymus to develop (hence th
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n a m e " T " cells). There is a range of different T cells that fulfil a variety of different

roles. Cytotoxic or "killer" T cells recognise antigens presented on the surface of cel

invaded by an organism, such as a virus. The cytotoxic T cell binds to the receptors on
the surface of the cell and destroys it through a cytolytic process.2,

4

Helper T cells

recognise foreign antigens presented on the surface of cells such as macrophages that
have succumbed to intracellular pathogens.6 Instead of launching a direct attack they

release chemical messengers that either activate B cells to produce more antibodies, or
activate the infected macrophage containing the pathogen.4 The macrophage responds
by destroying the pathogen. Helper T cells also activate cytotoxic T cells. The third
class of T cells identified is the suppressor T cells. Suppressor T cells moderate the
actions of both T and B lymphocytes. This is believed to be an integral part of the
recognition of self antigens that prevents the immune system attacking the body.2' 4'6

Similarly to B cells, T cells also form memory cells.4 These cells do not play a direct
role in the elimination of antigens but perform a similar duty to memory B cells, that

they are responsible for recognising and suppressing attacks by the triggering antigens

in the future. It has been shown that not only are memory cells able to prompt a faster
attack against future infection,5 but that the progeny of the memory T cells express
multiple functionalities (i.e. helper T cell, cytotoxic T cell, suppressor T cell
functionalities) whereas the "naive" T cells progeny was monofunctional.7 This allows
effector cells generated from memory T cells a much higher degree of utility against

invading pathogens and it is believed that the multifunctional memory effector cells ar
Oil

the primary cells involved in migration across the endothelium. " The reason behind
the longevity of these memory T cells is not well understood although it is suggested
that there is a slow, continuous "turnover" of T cells that may well proceed at a rate

17

Chapter 1-Introduction

sufficient to counter natural cell death and maintain the population at a near constant
level.
During their surveillance of the body, lymphatic cells are constantly transported
in the bloodstream and routinely circulate through the cellular matrix of the connective

tissue.12 In order to move between the bloodstream and the surrounding tissue, a proces
(\ 1 **? •

k n o w n as transendothelial migration is employed by the lymphocytes, '

which

involves an intricate mechanism known as the Leukocyte Cascade Mechanism, or the
Rolling Cascade. This process recruits the lymphocytes from the bloodstream, through
the endothelial walls and into the underlying tissue cells.

1.1.3 The Leukocyte Cascade Mechanism
The currently accepted model for the migration of leukocytes through the
vascular endothelium involves a series of four stages, rolling, triggering, adhesion
migration (Figure 1-4).

12-14

•'•'••'•!•!•'•.-.-A ••••••••••• •••••'A''••'•••'•••'•'•'A-'-'•'•'•' •',•'•'*

Endothelial cells

=.Wt9

T-cells

Figure 1-4 T h e Rolling Cascade Mechanism, Showing Lymphocytes Within a
Blood Vessel
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1.1.3.1 Lymphocyte Rolling
Rolling occurs in response to intercellular recognition between endothelium
cells and lymphocytes and is believed to be mediated by selectin molecules, which bind
to ligands on the cell surface.12"14
When underlying tissue is inflamed, the vascular endothelial cells express
Endothelium (E)-selectins, and Platelet (P)-selectins.14 Lymphocyte (L)-selectins are
expressed on the surface of lymphocytes (excluding memory T cells and activated T
cells)6 and are in extremely high concentration on the tips of microvilli that line the
surface of the cell.15 L-selectin has a very high affinity for CD34 (Cluster Designation
34 - a group of similarly functional antibodies), GlyCAM-1 (a glycosylated cell
adhesion molecule), and MAdCAM (Mucosal addressin cell adhesion molecule), which

are all ligands expressed on endothelial cells.14 E- and P-selectins also have high affini
ligands situated on leukocytes, namely PSGL-1 (P-selectin glycoprotein ligand), CD24
(L-selectin ligand) and ESL-1 (E-selectin ligand)14 which allow reciprocal adhesion
from the endothelial cells to lymphocytes. This combination of selectins and ligands
prompts lymphocytes to leave the vascular flow and commence rolling along the
endothelial surface.
The rolling action comes about due to the rapid "on/off rate of the L selectinligand tether12' 14'

15

with the sequential formation and dissolution of these tethers

causing the lymphocytes to roll (Figure 1-5). Rolling allows the lymphocytes to leave
the high velocity of the bloodstream and come to a complete halt ready for
transmigration without the need for high strength (possibly irreversible) bonds bringing
about a sudden stop to the motion of the lymphocyte. It was assumed that due to the

high shear force of the blood flow in restricted vessels such as capillaries, little or n
adhesion could take place,6 however, other research16'17 has found that not only can this
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occur but that selectin-mediated rolling will not commence until a shear stress thresho

is reached. It has been shown that the clustering of L-selectin on the microvilli allows
1 R

the lymphocyte to overcome these high shear forces.

Endothelium
Figure 1-5 Rolling Mechanism
The rolling stage terminates in response to a triggering mechanism that
delineates between the rolling and tight adhesion stages of the rolling cascade.

1.1.3.2 Lymphocyte Triggering
The exact mechanism behind the triggering of lymphocytes is poorly
understood,12"15 although it is known to involve Intercellular Adhesion Molecules
(ICAM's), Vascular Cellular Adhesion Molecules (VCAM's), integrins and possibly
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chemokines. ' -' The latter group of compounds has been shown to be present in
insignificant numbers on resting leukocytes, and have only low levels of adhesion
insufficient to overcome vascular shear stress.15 Whichever family(s) of molecules is
responsible, the triggering is effected by G-protein coupled transmembrane receptors,
which engage the adhesion molecule thus causing lymphocyte stasis.12,15

1.1.3.3 Lymphocyte Adhesion
Once rolling has ceased and tight adhesion has been triggered, rapidly formed
(yet slower forming than selectin bonds), relatively stable, yet reversible bonds are
formed between various integrins and their ligands.19 Two main classes of integrins are
believed to be responsible for this adhesion,14 although others are known to play
important roles.12 The first of these classes contains a4(31 and oc4pV7 integrins14 which
are also believed to play a role in the rolling process.12 These integrins have a high
affinity for VCAM-1 and MAdCAM respectively.8,12 The second class contains aL$2
and cxMp2 integrins which both bind to ICAM-1 to aid adhesion. With the formation of
sturdy adhesive bonds between the lymphocyte and the endothelial cells, a degree of
deformation takes place in the lymphocyte13,

20

as it is drawn down against the

endothelium. This is believed to be a precursor to transendothelial migration.

1.1.3.4 Lymphocyte Transmigration
Transendothelial migration is the final stage in the rolling cascade mechanism
and realises the aim of the process - the moving of the lymphocyte into the underlying
tissue. The process of migration across the endothelium takes only minutes14 and

electrical resistance studies have shown that the continuity of the endothelial membrane
is maintained.12 This indicates that the migrating cell is connected to both sides of the
intercellular break in the endothelium by some sort of chemical interaction that allows
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not only an electrical continuity but also maintains the vascular wall integrity (Figure
1-6). To do this the lymphocyte must adopt an amorphous structure to allow it to
manoeuvre through the intercellular gap.

Intercellular
adhesion
molecules

Figure 1-6 Transendothelial Migration
Consequently, it is not only the lymphocyte that undergoes physical change
during endothelial migration, but also the endothelium in the inflamed region is
altered.21 This changes the endothelium from its role as a cellular barrier to a
specifically permeable obstruction.
While the exact molecules involved in the migration process have not yet been
determined, it is believed that ocL|32 and ocMp2 integrins with an affinity for ICAM-2,
av|33 integrins with an affinity to PECAM (Platelet Endothelial CAM) and cxM(32
integrins that bind to ICAM-1 are the key components in this stage of the process,8,12
with selectin-Ig super family interactions also playing an important role.12
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Once in the tissue matrix, the lymphocytes are directionally guided by
chemotactic chemicals known as chemokines. Direction and motivation are both
regulated by a chemotactic concentration gradient that need only differ by 0.1 % across
the diameter of the lymphocyte.6 These chemokines are presented differently by
different cells, and also by the same cells at different stages,15 indicating that this is
positive feedback mechanism and as such is directly controlled by the requirements of
the cells involved.
Research has shown that these chemokines are expressed following allograft
transplants, guiding an immune response against the transplanted tissue.22

1.2 Conditions Involving the Immune System

Because the immune system encompasses the entire human body, it is involved
with a huge range of conditions from the "common cold" to heart transplants. In many
cases the involvement of the immune system results in a satisfactory outcome, such as
the end of a fever or the curing of a cold. Unfortunately, the immune system is capable
of doing more harm than good and this fact is manifest in conditions such as asthma,
diabetes, rheumatoid conditions such as fever and arthritis and possibly even multiple
sclerosis.2 One of the more common afflictions involving the immune system is the
allergic response.

1.2.1 Allergies
Although allergic reactions are generally mild, they can, in severe cases, result

in death. The antigens involved in allergies are called allergens. Mild allergic reactions
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include sneezing, watery eyes, and coughing and m a y be induced by dust, smoke or
household pets. The symptoms of these allergies usually work to remove the allergen
and tend to abate when the allergen is removed.
Allergies are associated with elevated levels of IgE in serum. These elevated
levels of IgE are allergen specific and are brought about by the actions of T cells.23
The effects of allergies are usually short lived, however, there are a number of

conditions that persist for the lifetime of the individual. These conditions can be broke
down into two main groups. The first, known as allergic disease or hypersensitivity,
occurs when the body launches exaggerated immune responses. The second,
autoimmunity, occurs when the immune systems recognition of self is faulty and
immune responses are launched against self cells.

1.2.2 Allergic Disease - Hypersensitivity
Hypersensitivity is the mechanism behind allergic disease, and causes the body's
immune system to overreact to antigenic stimulus. Hypersensitive reactions do not

occur on initial exposure to an antigen, rather they are exhibited after repeat exposures

Allergic diseases involving hypersensitivity include asthma, allergic rhinitis and atopic
dermatitis and these conditions are frequently encountered together, a phenomenon
known as the "atopic triad"24 (atopy = "strange disease").
There are 4 types of hypersensitivity, simply labelled Type I - Type IV, which
come about due to different antigens and manifest in different ways. Type IV involves
infected macrophages and is associated with diseases such as leprosy and tuberculosis.
Type III is brought about by residual antibody-antigen immune complexes that are not
removed following an immune response. Damage occurs when these residues are non-

specifically deposited in tissue. It is seen in malaria, haemorrhagic fever and rheumatoi
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arthritis. Type II hypersensitivity occurs w h e n IgG and I g M antibody complexes bind to
specific cells or tissue causing an immune response against those cells. It is most
commonly known for its role in haemolytic disease in newborn children. This
hypersensitivity can be directed against blood borne cells or solid tissue. Type I
hypersensitivity involves an IgE response against otherwise innocuous antigens such as
pollen or dust.6

1.2.2.1 Asthma
Asthma is a Type I hypersensitivity reaction involving inflammation of the
airways in response to an environmental trigger.
In non-asthmatics, the presence of non-infective antigens such as pollens and
dust borne antigens including mites and their faeces, invoke negligible or very minor
responses that may be as extreme as violent sneezing. Asthmatics undergo an
exaggerated immune response mediated by IgE antibodies.24,

25

IgE binds to both

allergens and low affinity sites on cells such as T cells. This activates T cells which

migrate to the affected site and pass through the endothelial walls via the rolling casca
mechanism discussed previously. The T cells involved in this migratory response in an

asthmatic have been shown to be faulty in that they do not express interferon,25 a type of
chemokine, which is responsible for a feedback system that inhibits the recruitment of a
subset of T helper cells.6 Thus, once started, the infiltration of the respiratory tissues
T cells escalates unrestrictedly, causing inflammation of the respiratory tissues and
rapidly compromising the uptake of oxygen by the body. This situation often requires
medical intervention to prevent death due to lack of oxygen. The most common curative
agent used by asthmatics is a cortisone steroid taken as an inhaled vapour that acts to
prevent T cell proliferation.25 However, there is evidence that a large proportion of the
population is developing resistance to glucocorticoids, via a genetic mechanism,
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creating a need for more potent treatments that act at a different stage in the asthmatic
response.

1.2.3 Autoimmunity
Diabetes, rheumatoid arthritis and multiple sclerosis are all cell-mediated,
autoimmune diseases.8,26 They are brought about by a dysfunctional immune response
mechanism and involve serious and debilitating tissue damage via the infiltration of
lymphocytes into the affected tissue.8 Research has shown that there is an abnormality
in the levels of memory T cells in subjects predisposed to diabetes.27 This indicates that
these diseases may be triggered by an immune event that generates antibodies against an
antigen that is similar to a particular self-antigen.26 The antibodies present at the
conclusion of the immune response mistakenly identify self antigen as the invading
antigen and further immune action is commenced against the body's own tissue.

1.2.3.1 Insulin Dependent Diabetes Mellitus
Diabetes mellitus is a condition involving a deficiency of insulin and a glucose
intolerant state.28,29 Insulin is a protein comprised of 51 amino acids in two chains (a
chain: 21 units, b chain: 30 units) linked by two disulfide bridges (Figure 1-7).
Insulin is manufactured in the Islets of Langerhans, also referred to as pancreatic
islets.29 The vast majority of cellular mass in the pancreatic islets is comprised of P
cells, which are responsible for the secretion of insulin.31 Insulin is used by the body to
metabolise sugars.
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Figure 1-7 Insulin Structure
The World Health Organisation subdivided diabetes into two clinically distinct
types in 1979.32 Type I diabetes is classified by its administered insulin dependency and
is further divided into two subclasses based on its epidemiology. Type II diabetes is
non-insulin dependent and is also classified into two subclasses: non-obese and obese
diabetes. Other types of diabetes do exist but they are usually symptomatic of other
28

conditions and exhibit completely different pathogeneses.
Insulin dependent diabetes mellitus (Type I) is the culmination of a multistage
condition with distinctly differing pathogenic phases.33 Stage 1 is merely a genetic
predisposition to diabetes, such as the case of a non-diabetic person with an insulin
dependent diabetic identical twin. Stage 2 is early insulitis and is triggered by an

immune event that leads to destruction of pancreatic (3 cells, but overall maintenance of
P cell mass. Loss of P cell mass denotes progression to stage 3 in which the body is no
longer able to maintain the resident pancreatic P cell population. Stage 4 involves
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uncontrolled i m m u n e attack against the body and immediately precedes clinical insulin
dependent diabetes, stage 5.
The involvement of T cells in diabetes has been well documented.27,28,31,33"38
Unfortunately, not enough is known about their role in the pathogenesis of diabetes to
allow the formulation of specifically targeted pharmaceuticals.
Activated memory T cells are present throughout all stages of the disease in
various tissues of the body and diagnosis usually reveals their presence in the Islets of
Langerhans.34"37 Studies in animal models have revealed that transferral of T cells from
diabetic subjects into unaffected subjects successfully transfers the disease to the
recipient,39,

40

conclusively proving the involvement of T cells in diabetes. The

significance of this lies in the potential for immunosuppressant therapy to treat insulin
dependent diabetes.

1.2.3.2 Rheumatoid Arthritis
Rheumatoid arthritis is a common, chronic, autoimmune disease manifest in the
tissues in and around skeletal joints. It is characterised by severe and persistent

inflammation of the joints that ultimately leads to their destruction. Not unlike diabetes,
it is believed that there is an antigenic trigger for the often rapid onset of rheumatoid
arthritis, and that it entails a highly specific antigen linkage.26 Once again, the role of
cells in the progression of this disease is well documented and supports the idea that the
pathogenesis of this disease involves an antigen mediated immune response out of
control.10,41'43 Cyclosporine A, one of the most successful immunosuppressants known,
is utilised in the treatment of this condition.44
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1.2.3.3 Multiple Sclerosis
Multiple sclerosis is a condition in which the white matter of the central nervous
system is attacked by the immune system.45 It has been assumed that there were only

two possibilities for the initiation of multiple sclerosis, namely the attack of a healt
central nervous system by a dysfunctional immune system, or an immune response
against an unhealthy central nervous system. It has recently been suggested that there
may indeed be a combined trigger, similar to those outlined above for diabetes and

rheumatoid arthritis, in which an antigen bearing entity with antigenic sites similar to

those found naturally in the central nervous system invades the body, resulting in a cas
of mistaken identity, and attack against the immune system. Once the immune response
has been launched against one antigen, the disease spreads due to the similarity of
antigenic sites on other central nervous system components, thus accelerating the

progress of the disease.46 It is also thought that certain viruses cause central nervous
system antigens to be presented in such a way as to activate nai've T cells.

1.2.4 Transplant Procedures
With the advances in modern medical practice, it is becoming increasingly
possible to perform both more, and more complex tissue transplants. The advent of
microsurgery has allowed the frontiers of transplant surgery to extend, with the
successful salvage of damaged ligaments, tendons, blood vessels and even nerves.
The range of conditions that are able to be satisfactorily resolved using
transplantation is increasing in proportion to the advances made in the various
techniques. Table 1-2 exemplifies some of these advances.
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Table 1-2 Conditions and Tissue Involved in M o d e r n Transplantation.
Condition

Tissue

Organ failure

Heart, liver, kidney, pancreas, intestine

A g e related failure

Cornea

Burns

Skin

Cancer

Bone marrow

Disease

Pancreas (diabetes)

Trauma

Digits, limbs, skin, small internal organs.

Transplantations are divided into four types based on the donor-recipient
relationship. Table

1-3 summarises

some

of the more

important aspects of

transplantation procedures.
Autografts involve the use of tissue from one part of the patients' body to
another. This procedure is used with tissue such as skin and cartilage and is highly
successful because there is no genetic variation between the recipient and donated
tissue.
Isografts transplant tissue between genetically identical individuals, such as
identical twins. Similarly to autografts, there is no rejection mechanisms directed
against the transplanted tissue as the tissue is not recognised as non-self.
Allografts are the most c o m m o n clinical transplantations and rely on donor
tissue from within the same species. This tissue is commonly taken from fresh cadavers
or, in the case of tissue the body can afford to do without, from living organ donors.
Close blood relatives are the preferred donors as this minimises the genetic disparity
between donor and recipient, thus minimising the chance for rejection. Unfortunately
the number of potential recipients far exceeds the number of donor organs available,
giving rise to a huge demand for xenotransplantation research.
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Table 1-3 Graft Types A n d Practical Considerations
Graft
Autograft

Example
Tissue

Considerations

transplanted

individual.

Skin

within N o

rejection issues. Donor and

graft for recipient available at same time.

b u m s victim, cartilage graft Doubles surgical procedures for
for reconstructive surgery.
Isograft

individual.

Tissue transplanted between Minimal rejection rate. Does not
identical twins. B o n e marrow place surgical burden of donation
transplant between siblings.

Allograft

and transplantation on patient.

Tissue transplanted between Rejection
individuals

of

the

same Larger

of

tissue

range

of

probable.
procedures

species. Heart, lung or other available due to cadaveric donors.
organ transplant.
Xenograft

L o w supply to demand ratio.

Tissue transplanted between Extreme rejection issues. Donors
species. Use of pig or baboon can be bred "as needed". Supply
hearts for h u m a n recipients.

can meet demand.

Xenografts have the highest prevalence of rejection as the donor organ is

harvested from a species different to the recipient. Initial work in this field concent
on primates as donor subjects as it was believed they offered the greatest chance for
success due to their evolutionary proximity to mankind. However, the transplants were
rejected and man'y other factors such as size disproportions between the more easily
managed primates, and the spread of disease between species, led to the use of pigs as
donor subjects.
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Pig organs are of similar size to h u m a n adult organs and can be grown relatively
quickly. Pigs have successfully been genetically altered so their organs do not trigger
hyperacute rejection in experimental animals. However, research has also established
that porcine retroviral agents may be capable of spreading to humans.49,50
One of the most critical challenges now facing the transplantation field is the
development of more potent, patient-friendly techniques to prevent post-transplantation
rejection of the transplanted tissue.

1.2.4.1 Transplant rejection
Transplant rejection occurs when the recipient body recognises the presence of
non-self antigens and initiates an immune response against the source of the foreign
antigens, the transplanted tissue. There are a number of different types of rejection that
can occur, resulting in the destruction of the introduced tissue. They are differentiated
by the immune elements behind the rejection, and when it occurs. Hyperacute rejection
is the earliest rejection to occur and is caused by natural antibodies and the complement
system, which are also responsible for acute vascular rejection. Acute vascular rejection
can also be mediated by natural killer cells and activated antibodies and occurs at a later
stage than hyperacute rejection. Cell mediated rejection is centred around the actions of
T cells.51

1.3 Immunosuppression and Immunosuppressant
Drugs

Immunosuppression is the inhibition or inactivation of the immune system, or
part thereof. Given the intimate involvement of the immune system in transplant
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rejection, autoimmune

disease, hypersensitivity

and

allergies, the

need

for

immunosuppression is obvious. Using drugs to controllably suppress the immune
system can decrease and possibly eliminate the incidence of rejection, while less potent
immunosuppression could form the basis of treatment for multiple sclerosis, diabetes,
rheumatoid arthritis and asthma.
Immunosuppression had its origins at the turn of the century with the early
literature citing the use of benzene, toluene and sub-lethal full body irradiation in
CO

transplant experiments. Based on the observations that an i m m u n e response triggered
a lymphocyte proliferation, these agents were used in the hope of inhibiting the immune
response by destroying the cells involved. The high mortality and morbidity rates lead
to this therapy being abandoned in favour of drug therapy.
Drug therapy began in the 1950s and has been the most actively pursued option to date
(Figure 1-8).
Mycophenolate
Mofetil

Total Body
Irradiation

Sirolimus

Cyclospohne

Prednisolone
Aniithymocyte
Globulin

Leflunomide
OKT3
2000

1950

•f-">
Azathioprine

Antilymphocyte
Globulin

L-733.725

RAD

Daclizumab

Tacrolimus

Figure 1-8 Chronology of Immunosuppressant Development.52-55 and references therein
While the need for immunosuppression is evident, and drugs capable of
achieving this abound, the search for new immunosuppressants is nevertheless an urgent
task. The major factor spawning this urgency is the fact that the vast majority of
effective immunosuppressants are toxic to the patients they are intended to assist. In
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extreme cases, there is even debate that some immunosuppressants (i.e. cyclosporine A)
may have a role in the progression of specific cancers.53"55
This toxicity is best illustrated by cyclosporine, which is used in operations such

as kidney transplants but is highly nephrotoxic (nephro - pertaining to the kidneys).44,56
61

Other, less severe, adverse effects of some of the more common drugs include

hepatotoxicity {hepato - pertaining to the liver), bone marrow suppression, nausea,
anaphylactic shock, drug-induced diabetes and cardiac complications.61
Current, clinically utilised immunosuppressants act on a range of immunological
mechanisms but predominantly target T cell mediated functions. The main modes of

action involve inhibition of T cell function, proliferation, activation or cytotoxicity,
suppression or depletion of T cell populations. '
The use of multi-drug therapies has become popular practice as it is believed the
combination of target mechanisms, and the lower doses of the individual drugs, will
provide better immunosuppression with fewer toxicity complications.44,

1_

Multidrug

protocols have been refined to the extent that it is possible to produce a "typical"
protocol as seen in Table 1 -4.

Table 1-4 Typical Multidrug Protocol for Transplant Immunosuppression
Treatment Typical Drug
Calcineurin Inhibitor

Cyclosporin, Tacrolimus, sirolimus*

Corticosteroids Prednisone, methylprednisolone
Adjunctive Agent Mycophenolate mofetil, azathioprine
Antibody Induction Daclizumab, OKT3
Calcium Channel Blocker Diltiazem, verapamil
*While not actually a calcineurin inhibitor, sirolimus is usually grouped with this type

of drug.
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The search for new immunosuppressants, while rapidly evolving, has been
hampered by conflicting theories regarding the ideal mechanism or molecule for
immunosuppression. One popular idea is that of selective immunosuppression, wherein

the treatment specifically targets one aspect of the immune system to prevent or cure a
condition.67 However, many of the currently prescribed drugs which are mechanism

specific still cause adverse side effects. Pre-treatment therapy is generating research

interest at this time, but until viability is determined, the major method of achieving
immunosuppression will continue to be post treatment drug therapy such as calcineurin
inhibitors.51

1.3.1 Calcineurin Inhibition
Calcineurin is a calcium and calmodulin dependent protein phosphatase, which
is involved in the signal transduction pathway between the cell membrane and the

nucleus.68 It is responsible for transmitting the cellular information responsible for I

synthesis. IL-2 is in turn, responsible for the growth and proliferation of lymphocytes.
is possible to achieve immunosuppression by inhibiting the production of IL-2.
Calcineurin inhibition forms the backbone of most immunosuppression programs, with
60% of programs based on cyclosporine and the remainder on tacrolimus.69 Drugs such
as cyclosporine A, tacrolimus (formerly FK506) and sirolimus (formerly rapamycin)
inhibit the calcineurin mechanism by forming complexes with immunophilins which

then bind to calcineurin, preventing its further utility in the signal transduction pat

1.3.1.1 Immunophilins
Immunophilins are immunosuppressant-binding proteins.70 There are currently
two known families of immunophilins: the cyclophilins, which bind to cyclosporine;
and the FKBPs (FK506 binding proteins), which bind to tacrolimus and sirolimus.71,72 It
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has been shown that the drugs alone are unable to bind to calcineurin, rather it is the
complexes formed by these interactions that are directly responsible for calcineurin
inhibition.73 Both cyclophilins and FKBPs were first isolated from the human spleen
"71 TJ

and have since been fully characterised. '

Through this work the modes of actions

have been confirmed and the inactivity of the drugs alone explained. The binding of the
immunosuppressants to the immunophilins causes a dramatic change in the
conformation of the drugs. It is this altered conformation that allows the complexcalcineurin interaction by exposing molecular sites that are shielded in the free
immunosuppressant structures. FK506-FKBP complexation causes a large aromaticlined cavity to form in the FK506 structure, which becomes the binding site. In the
case of cyclosporine A-cyclophilin complexes, the altered structure forms an "effector
loop" through the destruction of intramolecular hydrogen bonds. This releases the
molecule from its compact oval shape into a more donut shaped conformation, allowing
71

the freed amino acid residues to protrude from the surface of the complex.

1.3.1.2 Cyclosporine
Cyclosporine A, 1, is an 11 amino acid, highly lipophilic, cyclic polypeptide of
c i •• 61,74

fungal origin.
Cyclosporine was introduced in the early 1980s and resulted in a much higher
graft half-life and patient survival rate than previous therapy. One year survival rates
went from 50% to 80%, an improvement not matched by any of the more recent
immunosuppressants, which have only realised a one year survival rate of 90% when
used in conjunction with cyclosporine A.69 Through its complexation with cyclophilins,
cyclosporine A is able to specifically target T cell proliferation, something not
previously achieved.
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Until recently, cyclosporine A (available only as "Sandimmune") suffered one
major drawback. Its bioavailability was hugely variable, resulting in a large degree of
uncertainty about the effective dose being received by the patient.57,61'62 This called for
constant monitoring of cyclosporine levels in the body and often resulted in
administered doses being consistently higher than required.
This problem has been overcome by the introduction of a microemulsified form
of cyclosporine A ("Neoral"). This new form of cyclosporine A is more readily
absorbed by the body (55% v. 35%) and has a narrower pharmacokinetic variability than
the traditional oil based drug, meaning it can be co-administered as part of multidrug
therapy without the accompanying drugs affecting the effective dose of cyclosporine.
As cyclosporine A is one of the primary agents for multidrug therapy, this is an
extremely valuable characteristic.64,75 The higher bioavailability of this formulation and
the resultant lowering of dosages may have the direct consequence of reducing or
eliminating some of the more adverse effects of cyclosporin A.
Whilst being a highly effective immunosuppressant, cyclosporine A is also
highly nephrotoxic.59,

60, 64

' 76"80 This is believed to be mediated by the binding of
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calcineurin which is k n o w n to have a role in the regulation of renal glomerular
filtration.81 In a recent study, calcineurin inhibitor nephrotoxicity was found in 17% of
patients, and chronic allograft nephrotoxicity in 72% of patients, two years post
transplant.82
Cyclosporine G is an analogue of cyclosporine A that has been shown in recent

studies to lack the nephrotoxic side effects of cyclosporine A. It has also proven to have
a similar efficacy to cyclosporine A at therapeutic levels and these developments may
f\C\ 78

see its emergence in the pharmaceutical market. '

1.3.1.3 Tacrolimus
Tacrolimus, 2, was originally known as FK506. It is a macrocyclic lactone
isolated from an actinomycete in a soil fungus fermentation broth in Japan in 1984.
83

It is similar in its mode of action to cyclosporine A in that it binds to an immunophil

. , . ,. i • • 52,62,71-73,83

and suppresses the IL-2 production by binding to calcineurin.

MeO,,

Tacrolimus is believed to be 10 - 100 times as potent as cyclosporine A in
inhibiting T cell proliferation.68 Tacrolimus binds to the immunophilin FKBP to form a
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calcineurin inhibiting complex. F K B P is believed to alter only a small portion of the
molecule, namely the pyranose ring which swings around to become located within the
macrocyclic frame.84
Recent work has found that tacrolimus has a lower toxicity than cyclosporine A,
exhibiting a much lower level of hypertension and not having the issue of cyclosporine
nephrotoxicity. Tacrolimus has also been put forward as a rescue therapy for kidney

rejection episodes as it is able to reverse rejections where corticosteroids and antibody
therapy have failed. This practice has had a successful rescue rate of 80% with longterm graft stability of 85%. All of these cases would most likely have progressed to total
graft rejection without the tacrolimus intervention.86 Tacrolimus has recently been
shown to allow a dramatic reduction of corticosteroid therapy and even the potential to
eliminate steroid therapy in some cases.87,88
One of the main advantages of tacrolimus is the reduced incidence of drug
induced diabetes, commonly seen in cyclosporine A recipients. The biggest drawbacks
with tacrolimus therapy are its ability to still exert a nephrotoxic effect in some cases
and its extremely variable and unpredictable bioavailability, which ranges from 4% 93%, seriously decreasing the 10 - 100 fold increase in potency. This results in
over/undersuppression of the patient leading to increased infection or increased
rejection rate. The need for constant monitoring to prevent this occurrence hinders the
ease of use and prevents the use of tacrolimus in milder longer term therapies. A recent
study of renal transplantation patients has produced a one year survival rate of 99%,
OQ

with the one year graft survival rate being 9 8 % .
Recent comparisons between tacrolimus and microemulsion cyclosporine A
have shown there is no significant advantage with either of the two drugs.90 Concurrent
work has shown that interruption of tacrolimus treatment with a course of
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microemulsion cyclosporine A can prevent m a n y neurological complications c o m m o n
to both treatments, including psychosis, mania and drug-induced coma.91 Syntheses of
tacrolimus analogues have produced indolyl-ASC, which has been shown in rodent
models to have an even further reduced toxicity with a modest increase in efficacy 92

1.3.2 Sirolimus
Sirolimus (formerly rapamycin) 3, is also an actinomycete-derived macrocyclic
lactone immunosuppressant and is structurally related to tacrolimus.74' 83 It was
discovered in the mid 1970s in a soil fungus sample from Easter Island.
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Despite its obvious similarity to tacrolimus, and the fact that it binds to the same
immunophilin (FKBP), sirolimus acts on a completely different part of the signal
transduction pathway.72 It is known that while the FKBP-sirolimus complex does block
IL-2 production, it does not inhibit calcineurin.
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Tacrolimus and sirolimus compete for the same receptors, and as such have a
complimentary immunosuppressive effect in vivo. Sirolimus however, does not interfere
with the calcineurin pathway, and has a much lower toxicity than cyclosporine A or
tacrolimus, but it is also less effective.83 Sirolimus has been shown to have potency up
to 100 times that of tacrolimus, giving it a potency of up to 10000 times that of
cyclosporine but this advantage is overcome by its lower bioavailability (15%).93 When
taken orally, sirolimus reaches a blood concentration maximum after only 1.5 h, and has
a therapeutic half-life of around 60 h.93 In conjunction with cyclosporine A, the use of
sirolimus has seen a decrease in the number of rejection episodes from 34% to 7%, and
the synergistic interactions of these drugs allows total withdrawal of corticosteroids
from the immunosuppressive regime.94 There has also been no reported incidence of
neurotoxicity associated with sirolimus.95

1.3.3 Corticosteroids
The use of a range of glucocorticosteroids in transplantation began early in the
search for drug based therapies. Corticosteroids were initially used to reverse acute
rejection in patients on long term maintenance doses of azathioprine, and are still used
in rescue therapy today.74 Steroids are also still used in order to reduce calcineurin
inhibitor doses, but the trade-off in side effects is not always successful.96
Steroids work by inhibiting cytokine transcription, including IL-2, but various
combinations of cytokines have been shown to restore T cell proliferation.74 This

reduces the efficacy of the steroid treatment but does not increase the incidence of side
effects.
Side effects due to steroid use include a broad range of neurological, physical
(structural) and physical (cosmetic) factors. Neurological effects include insomnia,
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nervousness, aggression, psychosis and mania and often result in a need for diversional
therapy, counselling and special nursing care. The physical effects of steroid use may
include diabetes, bone necrosis, high blood pressure, osteoporosis, growth retardation
and muscle wasting. Cosmetic effects seen with steroid therapy are weight gain, fat
deposition around the face and on the back ("buffalo hump"), acne and other skin
conditions. The use of corticosteroids is also a major cause of mortality and morbidity
in transplant patients and they seem to compound the side effects of cyclosporine A and
other primary immunosuppressants.97 Because of this, many therapists are advocating
minimalist roles for steroids in immunosuppressive protocols and emerging studies
show no significant drawbacks to the removal of steroids from treatment programs 98,99

1.3.4 Adjunctive Treatments
Mercaptopurine 4a was one of the first drugs to be utilised as an immunosuppressant.
Its toxicity soon led to the search for analogous compounds with greater efficacy and
lesser toxicity.

SH
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Azathioprine 4 b was first synthesised in the 1950s during research into 6mercaptopurine.61 It was found to have a lower toxicity with equivalent
immunosuppression.

61
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Azathioprine is a purine analogue that acts as an antagonist, inhibiting purine
synthesis.74 It has a bioavailability of 50% and has no effect (toxic or metabolic) on
renal function. However, it is not as potent an immunosuppressant as cyclosporine A
and is most commonly used as part of a multidrug protocol, rather than as a standalone
treatment

100, 101

Azathioprine causes severe depression of bone marrow formation,

resulting in leukopenia. Recent work has focused more on the use of azathioprine as a
synergistic agent for primary immunosuppressants and has proven that in the case of
cyclosporine A, immunosuppression is improved with the inclusion of azathioprine. It
has also been discovered that analogues of azathioprine lacking the toxic
mercaptopurine substituent have an equivalent or enhanced potency. For example, 5a
and b both achieve a greater immunosuppression with a lowered toxicity.102
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Following on from the azathioprine experience, mycophenolate mofetil 6 was
approved in 1995 for use as an adjunctive agent with cyclosporine A.52 An ester of
103

mycophenolic acid, it has been shown to have a greater efficacy than azathioprine.
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Mycophenolate mofetil is converted by hepatic enzymes into mycophenolic

acid, which is a reversible inhibitor of purine synthesis.83 It has a bioavailability of 9
and a half-life of 17 h. Unlike other immunosuppressive agents, mycophenolate mofetil
shows two therapeutic concentration peaks (around 2 h and 9 h post administration) due
to hepatic recycling of metabolic intermediates between the ester and acid forms of the
drug.52 Adverse effects exhibited in mycophenolate mofetil therapy are much milder
than most immunosuppressants. They include diarrhoea and gastritis but can also
include leukopenia.74 Similarly to azathioprine, there is no evidence of
nephrotoxicity.104,10
The last two years have seen a steady influx of literature evidence advocating
the use of mycophenolate mofetil as a safe immunosuppressant for inclusion in
multidrug protocols. Combination therapies with tacrolimus have shown low acute
rejection rates (8.6%: down from 18%) and the incidence of drug induced diabetes fell
by 60%.106,107 Perhaps the most promising result is that transplantation patients treated
with mycophenolate mofetil instead of calcineurin inhibitors have shown improvements
in levels of acute and chronic renal failure, due no doubt, to the non-nephrotoxic nature
of the drug.108

1.3.5 Antibody Therapy
Tolerance induction therapy involves the use of a pharmaceutical agent to
"trick" the immune system into accepting non-self tissue (such as a graft) as self,
thereby protecting it from the immune systems surveillance and response mechanism. In
the mid 1980s it was discovered that this tolerance could be induced without physically
depleting T-cell populations 109
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0 K T 3 is a monoclonal antibody directed against the C D 3 molecule found on the
surfaces of human thymocytes and mature T cells.110 OKT3 binds to this site, which is
known to be part of the antigen recognition site, blocking the effector site of the T
cell.111 As well as tolerance induction, OKT3 is often used as rescue therapy during
acute rejection and has had success rates as high as 84.5%. Side effects associated with
OKT3 use include fever, headache and diarrhoea.112
Daclizumab is another monoclonal antibody, differing from OKT3 in that it

binds exclusively to IL-2 receptor sites on activated T cells.63 Rejection rates of patie
treated with daclizumab have been reported as low as 5% with patient survival rates of
99%.63 It has the disadvantage over OKT3 of a long half-life (480 h), resulting in
difficulty in preparing dosing regimes. It has been used in a calcineurin inhibitor free
protocol with steroids and mycophenolate mofetil, achieving short-term patient survival
f.'X

of 1 0 0 % , but an acute rejection rate of 4 5 % .

In studies of liver transplantations, the

use of daclizumab has led to a 50% decrease in the rate of acute rejection when used in
conjunction with tacrolimus or microemulsion cyclosporine A.

1.3.6 Gusperimus
Gusperimus (formerly 15-deoxyspergualin) is a synthetic analogue of spergualin
which was isolated from the culture filtrate of Bacillus latersporus during a screening
program searching for novel anticancer agents.83 It prevents B and T cells from
differentiating into mature effector cells and has been used successfully in steroid-

resistant rejection rescue.74 It has been shown to inhibit antibody responses to antigeni
agents and shows high utility in rescue therapy with remission rates around 88%.
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1.3.7 New Immunosuppressant Agents

1.3.7.1 Leflunomide
Leflunomide 8a is a relatively new immunosuppressant that works by causing a
suppression of dihydroorotic acid dehydrogenase production.114 Rather than having a
cytotoxic effect, leflunomide is cytostatic, making it a true suppressant rather than a
depletive agent.

8
Research has shown that it is actually a metabolite of leflunomide, designated
A771726 8b, that is the active agent responsible for the immunosuppressant property of
leflunomide.115
To date, there have been no major studies done on the clinical use of
leflunomide, but results in animal models have shown it to have the ability to block
allograft and xenograft rejection.115 It has also been shown to have utility in the
treatment of rheumatoid arthritis.83
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Sodium

Similar to leflunomide, brequinar sodium 9 blocks the synthesis of pyrimidine
by inhibiting the enzyme dihydroorotate dehydrogenase.74 Blocking of pyrimidine
inhibits lymphocytes ability to synthesise DNA and RNA.

0^.0" Na+

Animal studies have shown that brequinar has the ability to act as a primary
immunosuppressant and is also able to prevent allograft rejection.116 Toxicity studies
have shown that the primary side effects of brequinar sodium centre around bone
marrow depletion and gastrointestinal problems, causing diarrhoea and nausea.116

1.3.8 2-Acetyl-4(5)-(l,2,3,4-tetrahydroxybutyl)imidazole (THI)
Caramel colour (class III) is a minor component of Coca Cola, and is commonly
found in many brown coloured foodstuffs including bread, beer, gravy, soy based
products, vinegar and soups.117,118 THI, 10, was first isolated from caramel colour (class
III) in 1985, following the discovery in 1977 that caramels produced via the ammonium
caramelisation of glucose had the ability to depress lymphocyte counts in rats.118"120
Later studies showed this to be true for mice as well as rats, broadening the scope for
121

investigation.
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This result has been seen with doses as low as lmg/kg/day with insignificant or
no side effects. •

T H I also has a demonstrated ability to prevent spontaneous and

chemically induced diabetes and has been shown to specifically target T cell
functionality.122,123

OH

N^N

O^

OH

OH

OH

\

10
T H I is formed in the commercial conversion of a sugar to a caramel. The yields
of imidazole derivatives have been shown to increase linearly with an increasing ratio of
ammonia to sugar.119 The concentration of T H I 10 in caramel colour III produced using
the ammonia process has been shown to be hugely variable with concentrations ranging
from 0-600 ppm. 118,124
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Scheme 1-1 Formation of THI During Commercial Caramelisation Process
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T H I is formed in the two most c o m m o n caramelisation procedures, the "open
pan" and the "closed and open pan", both of which employ ammonia, and produce

different types of caramel.119 This explains its wide distribution in common foodstuffs
The process by which THI is formed is outlined above in Scheme 1-1. The starting
sugar is most commonly "invert sugar" which is a mixture of glucose, fructose and
sucrose.119
Given the extensive range of THI in everyday foods, the question arises as to
why there has been no general reduction in immunocompetence in the human
population. This can be answered by looking at the daily consumption of caramel,
which is reported to be around 100-200 mg/kg/day.123 Given that ammonia caramel

comprises (on average) 0.06% THI, this translates to a daily dose of 10.5 g caramel and
6.3 mg of THI, or 0.09 mg/kg/day, for a 70 kg human. Studies in rodent models have
been using doses of 1 mg/kg/day, which would require over 100 g of pure caramel daily
for a 70 kg human. There are no known incidences of humans showing any
lymphopenic effects due to THI.

1.3.8.1 Established Syntheses of THI
The scientific literature presented only two synthetic strategies for THI. The
first, published alongside the discovery of THI in 1985 involves the ammonium acetate

catalysed condensation of D-glucosone 11 with the dithioketal protected pyruvaldehyde
12 (Scheme 1-2).
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Scheme 1-2 Synthesis of THI From D-Glucosone128
The reaction proceeds via the dithiane 13 to give an overall yield of THI of

12%.125 A more efficient synthesis was concurrently described by Halweg a

(Scheme 1-3) involving the addition of D-(+)-glucosamine hydrochloride 14
intermediate 16 formed via the reaction of 2-ethoxyacrylonitrile 15 with
methoxide in methanol126
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OH
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NaOMe

O. „NH2.HOAc
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10
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HO OH
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OEt

MeO

10
17

16
129

Scheme 1-3 Synthesis of THI From Carbohydrates

The yield for this reaction is considerably improved from 19% to 46
126

the use of 1-amino-1-deoxy-D-fructose acetate 17, prepared from glucose.
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1.3.8.2 New Syntheses of THI
In 1995 Cliff and Pyne published a synthesis of THI analogues utilising a

palladium catalysed reaction of a protected iodoimidazole 18 with the vinylstann
to give compound 20.

EtO^^N^N
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(CH?)2OTBDMS

PdCI2(PPh
3) ,
. ,.
2V

3 2

EtO-

-NN^N

20

Bu3SnCH=CHCH2CH2OTBDMS
19
(CH2)2OTBDMS
1. n-BuLi
2. MeCONMe(OMe).
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Dihydroxylationr

EtO-^-N^N
O

OH
22

*K
OH
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HNN^N

OH

OH

oX »
Scheme 1-4 Palladium Catalysed Synthesis of Trihydroxybutylimidazoles

127

The n-BuLi mediated reaction of 20 with N-methoxy-iV-methylacetamide gave
the acetylimidazole 21, which was then asymmetrically dihydroxylated (22) and
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deprotected to yield the individual stereoisomers of trihydroxybutylimidazole 23
(Scheme 1-4).127
This procedure was also performed on a range of alkynes, in place of the
vinylstannanes, to produce other isomers of THI. Further work by Cliff et al. resulted in
198 1*29

the development of this synthesis for the production of tetrahydroxyimidazoles. '
This included the synthesis of THI itself, via the reaction Scheme above, substituting
the protected diol 24 for the alkene 19 used in Scheme 1-4.128,129

Et

p-V

B

24

In order to investigate the structure-activity relationship of THI, the synthesis of
further analogues was required. A comparative study of the biological properties of THI
and the analogues produced would provide an insight into the role of the functionalities
of this family of compounds.

1.3.8.3 Analogues of THI
The generation of analogues of THI is somewhat restricted by a patent owned by
The Coca-Cola Company, which focuses on the imidazole ring.118 To circumvent this,
thiazole was chosen as the base heterocycle.
Ung et al. developed a double asymmetric dihydroxylation synthesis based on the
bromothiazole 26, formed from the known compound ethyl 2-bromothiazole-4carboxylate 25 (Scheme 1-5).130 The Wittig reaction of 26 with allyl
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triphenylphosphonium bromide, yielded the diene 27, which was then asymmetrically

dihydroxylated and protected to give the acetonide 28. Acylation of 28 gave 29 which
after asymmetric dihydroxylation and deprotection gave the THI analogue 2-acetyl-4-

[(IR, 25, 3R, 4-tetrahydroxybutyl]thiazole (THT) 30 and the 2-acetyl-4-[(li?, 25, 35
tetrahydroxybutyljthiazole isomer.130
COOEt
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Scheme 1-5 Synthesis of T H T 130
In order to exercise a greater control over the stereochemistry of the side chain
and to develop a more generic synthesis for the production of THI analogues, the
synthesis shown in Scheme 1-6 was developed by Ung et al. 13° This improved

synthesis also addressed the low overall yield experienced in Scheme 1-5 (1.3%). The

stereochemistry of the final THI analogues was determined by the choice of starting
carbohydrate (35).
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Lithium - bromide exchange of 34 gave the 4-lithio derivative that upon reaction
with lactone 35 gave the adduct 36 and ring-opened ketone 37. Reduction and
deprotection of 36 yielded the tetraol 39 (Scheme 1-6).131
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Scheme 1-6 Carbohydrate Based Synthesis of THT.
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Use of the lithiated species 31 allowed access to the corresponding 5-thiazole
isomers. The overall yield for this synthesis of 39 was 15.8%, a 12-fold increase over
the previous synthetic strategy described.

1.4 Aims of Project

THI is a compound known to produce lymphopenia in rats and mice. There has

been no indication of toxicity or adverse side effects, nor of any carcinogenic properties
If these qualities hold true for human subjects, the potential for THI as an
immunosuppressant drug is enormous. The rodent studies to date indicate THI would
not have the potency of cyclosporine A or tacrolimus, but with its low toxicity and rapid
clearance from the body, it may have a major role as an adjunctive agent, or for long
term, maintenance immunosuppression of transplantation patients.
Currently, very little is known about the mechanism through which THI acts,
although it is believed to inhibit part of the rolling cascade mechanism of T-cells
discussed earlier. By altering the functional constituents and spatial properties of the
molecules, and evaluating the consequent effects on the biological properties, it may be
possible to determine the active or effector sites on the molecule. Even subtle changes
in the structure of a molecule can result in significant biological changes, making the
study of analogues a valuable investigative tool.
There are three main units of THI that can be altered to give a range of isomers,
these are i) the heterocycle; ii) the 2-acetyl group; iii) the polyhydroxy side chain as
shown in Scheme 1 -7.
Work carried out by this group has shown that alteration of the acetyl group

results in little or no biological activity. This work included reduction of the carbonyl
an alcohol or amine, and substitution of the entire acetyl group with benzoyl or alkyl
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Further work has shown that substituting the thiazole ring for the

imidazole has little or no detrimental effect on biological activity.134
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Scheme 1-7 Exploded View of THI

This current body of work, the latest in an ongoing project, aims to synthesise a
range of structurally unique analogues of THI, based on the thiazole heterocycle, by
altering the polyhydroxy side chain. Some of this work will further develop the generic
and highly adaptable synthesis of Ung et al. to allow access to a range of side chain

lengths and stereochemistries. Analogues of THI produced by this project will be sent to
the John Curtin Medical School, Australian National University, Canberra, for
biological evaluation.
In the general synthetic strategy to be employed, the acetylated thiazole ring will
be protected and introduced to the protected carbohydrate as the lithiated species. The
carbohydrate ring will be reduced to the ring opened form and the entire molecule
deprotected to give the final compound (Scheme 1-8).
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2.1 Organolithium Intermediates in Organic Synthesis

Organolithium compounds are one of the more common synthetic reagents used
to create new carbon-carbon bonds. This fact alone would account for the importance of
this family of reactions however, the relative ease with which these reactions can be
carried out in the general synthetic laboratory makes them extremely valuable to the
organic chemist.
First synthesised in the early 1900s, it took decades of work by the likes of
Zeigler, Wittig and Gilman to bring the technology within reach of virtually all organic
synthetic laboratories.135"154
The reaction conditions are relatively mild and yields are quite reasonable. With
the availability and knowledge of modem techniques it is a simple task to carry out
these reactions under totally anhydrous conditions.

2.1.1 Organometallic Reagents and Stereoselectivity
The diastereoselectivity found in reactions where chiral aldehydes and ketones
are employed in organometallic addition reactions was thoroughly studied in the 1950s
through to the 1980s and a range of theories were put forward by such noted chemists as
Cram, Prelog, Felkin, Anh and Eisenstein.
The reaction of organometallic reagents with acyclic carbonyl compounds
having a stereogenic centre adjacent to the carbonyl group can give rise to a
combination of two diastereomeric products in a wide range of ratios. For example, in
155

Scheme 2-1 there are two diastereoisomeric products.
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Scheme 2-1 Diastereoisomers produced by organometallic addition to a carbonyl
group having an adjacent chiral centre (diastereomeric ratios vary from >99:<1, to
10:90, depending on the reaction conditions)

2.1.1.1 The Cram Open Chain Model

The early theory of Cram to explain this
diastereoselectivity was based on an open chain
S
structure whereby the nucleophile attacks the

^

^
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/||\
. S^\y
R

L

carbonyl group in a transition state structure in
, ,.. W T N
*• *• *u~ Figure 2-1 The C r a m Open Chain
, ., , .
&
which the largest a-substituent (L) is anti to the
. ,
„
Model (where "S", " M " and " L "
156158 T
u.
156 8
nucleophile.
In this simple stencally
.
refer to the small, medium and
controlled model, addition takes place from the
_
large substituents on the a-carbon
least hindered face of the carbonyl group (Figure
of the carbonyl, respectively.)
2-1).
However, in cases where R is also a large group, this model fails due to the
steric repulsion between the two bulky groups (R and L).
2.1.1.2 The Felkin/Felkin-Ahn Model
Later work by Felkin led to a different model (Figure 2-2), which places the "L"

group perpendicular to the axis of the carbonyl. When working with the Felkin model
159

is important to ensure the correct orientation of the perpendicularly placed "L" group.
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That is, to minimise steric interaction between the R group and the oc-substituents by
placing the "S" and not the "M" group closest to the neighbouring R group.

O

s 8

M
Nu

R

S

R
Disfavoured

Favoured

Figure 2-2 Felkin Model Showing Favoured V s Disfavoured Orientation
This model was further refined to that which we know today as the "Felkin-Anh
Model", through the work of Anh and Eisenstein.160,161 These workers proposed a slight

change to the model that sees the nucleophilic attack occurring with a positional bias

towards the smaller rather than the median cc-substituent, as opposed to the fixed ang
(90°) proposed in the earlier model. Thus, the attacking nucleophile approaches the
carbonyl group at an angle of about 107°, although this has been shown by Biirgi and
162,163

Dunitz to vary depending on bulk displacement vector of the substituent groups.
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Figure 2-3 Felkin-Anh Model Reinforcing Findings of the Felkin Model
For carbonyl compounds having a non-chelating a-heteroatom (eg. Cl, OR), the

electronegative a-substituent takes the place of the large ligand "L". This minimises
electrostatic repulsion between the heteroatom and the approaching nucleophile.
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Furthermore, in this position there is a stabilising effect in the transition state due to

overlap of the n orbital of the carbonyl group and the o orbital of the C-X (X=C1, OR)
bond.

2.1.1.3 The Comforth Dipolar and Cyclic Chelation Models
Two other important models were developed, based on the findings of Cram,
whose model was expanded through the work of Cornforth in the late 1950s to include

the involvement of both ce-halocarbonyls and a coordinating a-substituent.164 In the cas

of a-halocarbonyls, the carbonyl and carbon-halogen dipoles adopt an anti- relationship
with nucleophilic attack occurring on the least hindered face (Figure 2-4).

Figure 2-4 Cornforths Dipolar M o d e l

Figure 2-5 Cyclic Chelation Model

(where "X" = halogen)

Accompanying this theory was the Cyclic Chelate Model (Figure 2-5), which

accounts for the presence of an a-substituent that is capable of coordinating with the
carbonyl oxygen to the corresponding cation (M+) of the nucleophilic reagent (M* Nu").

Once again, addition occurs at the least hindered face of the carbonyl group, being an
to the large substituent group (L).
Using these models it is possible to explain the different products formed from
the reaction of Grignard reagents (RMgX) with tetrahydrofurfural (Figure 2-6).165 In

this reaction the addition of H M P T (a k n o w n chelation inhibitor) favours the FelkinAnh product. Otherwise, chelation control yields the major isomer.

Felkin-Anh

Chelation Control

OH
HH
With H M P T

+
R M g X (THF)
Figure 2-6 Stereoselectivity Models Explain Isomeric Products
While these models are extremely useful for predicting the stereochemical
outcomes of these types of reactions, it must be stressed that they are only models and
that even the most simple of variations can increase, decrease or even reverse the

predicted stereochemistry. These factors can include temperature, solvent and the natur
166,167

of the organometallic compound itself.

2.1.2 Organolithium Reagents and Aromatic Heterocyclic Systems.
The chemistries of various heteroaromatic compounds are extremely important

in the synthesis of a plethora of valuable chemicals ranging from molecular switches fo
use in fibre optics to medicinal compounds. The syntheses of a wide range of these
compounds utilises organolithium reagents to expand on basic heteroaromatic moieties
to produce the target compound.168"170
Examples exist in the literature of a wide range of heteroaromatic organolithium
compounds including lithiated furans, oxazoles, thiazoles, imidazoles, pyridines,
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pyranosides and trithianes.169'
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Many cases of lithiation of bi- and tricyclic

heteroaromatic compounds are decribed in the literature.177

2.1.3 Novel Organolithiates formed from Aromatic Heterocyeles
It is often the case that in aromatic heterocyclic systems, commonly used
organolithium reagents such as n-BuLi are unable to be used for lithiation via
deprotonation due to their powerful nucleophilicity.178'

179

In these instances, novel,

highly specialised reagents can often be developed that are "tailor-made" to suit the
chosen application.179 A selection of these novel organolithiates are found in Table 2-1
below.
Table 2-1 Novel Organolithium Reagents

Aromatic heterocycle

Organolithium reagent Lithiated Species

Ref
179,

0 ki

n-BuLi / lithium-2dimethylaminoethanolate

0fy
N

«-BuLi / lithium-2dimethylaminoethanolate

171

ki
172,
173

Lithium
tetramethylpiperidine

Li

0—J

168

Lithium diisopropylamine

cr ^ ^

180

cr
Li
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2.1.4 Organolithiated Couplings with Carbohydrates
There is a recent and growing body of literature concerning the reactions of
organolithium reagents and carbohydrates. Driven predominantly by the search for
novel, potent pharmaceuticals, the introduction of aromatic heterocyeles into
carbohydrate skeletons has been heavily pursued as the carbohydrate moiety allows a
great deal of stereospecificity in the final products. This allows diastereoselective
synthesis of a vast array of chiral compounds and eliminates or minimises the need for
labour and time intensive separations and purifications.
One such piece of work has been carried out by Yokohama and coworkers who,
in the search for novel C-nucleosides, have coupled 2-thienyl-, 2-benzothienyl-, 2-furyland 2-indolyl-lithiated moieties to a range of protected furanoses.170 The organolithium
couplings were carried out on furanose to give ring opened products that were cyclized
under Mitsunobu conditions181 to give the desired cyclic products (Scheme 2-2).

PO

Vr
PO

OH

OP

PO

OP

Where P is a
protecting group
PO
het

PO

OP

S c h e m e 2-2 Synthesis of Heteroaryl Nucleosides

DEAD
PPh 3
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Earlier work by the Dondoni group indicated that direct ring-ring coupling
between carbohydrates and aromatic heterocyeles was possible without ring opening of
the carbohydrate where the carbohydrate was oxidised to a lactone form prior to
coupling (Scheme 2-3).182

OBn
O
Li
BnO°''^V^ '''OBn
OBn

OBn

S c h e m e 2-3 Dondoni Coupling of Gluconolactone to Thiazole Exhibiting
Preservation of the Cyclical Structure
This last reaction type will be pivotal in the synthesis of various analogues of
THI. It will allow the coupling of a range of carbohydrates (to provide varying

stereochemistry) to selected substituted thiazole heterocyeles. Other successful studies
the couplings of organolithium reagents to carbohydrates indicate this to be a highly

on

useful approach to complex carbohydrate structures

170,183,184

2.2 Discussion

2.2.1 Rationale
The bioactivity associated with T H I is primarily due to a single biomechanism the promotion of lymphopenia. It is extremely important to develop a greater
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understanding of the in vivo active site and h o w T H I interacts with it. Given the
conformational simplicity of the molecule it should be possible to develop a range of

isomers to assess the structure-activity relationship responsible for the biological effec
of THI. Through the generation of analogues with discreet yet distinct differences to
THI, it is hoped that the relative importance of the functionalities found on the molecule
can be evaluated.
2-Acetyl-5-[(l'S, (VR), TR, VR, 4'R, 5')-pentahydroxypentyl]thiazole 40
consists of a thiazole heterocycle with two substituent groups attached to it. As an
analogue of the lead compound 2-acetyl-5-[(l,2,3,4)-tetrahydroxybutyl]imidazole 10,

the synthetic target is significantly different in that the heterocycle is a thiazole inst
of an imidazole. The polyhydroxyl side chain was also extended by one unit, to allow a
study into the effect of side chain length. Previous work by our group has shown that
exchanging thiazole for imidazole has little impact on the compounds ability to cause
cell aggregation, indicating that further study of this group of analogues is feasible.134
The proposed compounds would be expected to share the same structure-activity
relationship.

OH

N^/NH OH

OH

OH
OH

OH

OH

OH

^K

O

O^
Imidazole Derivative
10

N^/S

OH

Thiazole Derivative
40

Figure 2-7 Comparison of Stereochemical Similarities
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This first synthetic target will allow assessment of the role of the heteroaromatic
ring and also give an indication of the importance of the stereochemistry observed at C1' on the polyhydroxyl side chain. This synthesis can be broken down into three basic
sections, the two protections of the thiazole and carbohydrate ring systems and the
coupling of the rings.

2.2.2 Protection of D-Ribose
Given the (VS, TR, VR, 4'/?) or (17?, TR, VR, 4'/?) stereochemistry desired in
the final product, D-ribose was selected from a range of carbohydrates to ensure and
maintain stereochemical control. Indeed, the use of carbohydrates as chiral precursors
has been extensively studied and D-ribose has shown itself to be amenable to a large
range of protecting group combinations and intermolecular reactions.185 As found in
previous studies it was necessary to protect all functional groups not involved in the
synthetic strategy to prevent unwanted by-products. This was achieved in two stages.
The first involved the cyclic acetal protection of the 2,3-hydroxyl groups on the
carbohydrate heterocycle.

2.2.2.1 Cyclic Acetal Protection of2,3-Diol
The protection of D-ribose 41 by acetone is a well established procedure, having
first been observed in the early 1930s by Levene and Stiller186 and thoroughly studied
since (Scheme 2-4).186"190
This reaction yielded 5-hydroxy-2,3-CMsopropylidene-D-ribose 42 in yields
comparable to those found in the literature (approx. 60%). 19° This procedure resulted in
a mixture of isomers consisting primarily of isopropylidenated carbohydrates, similar to
those found by Hughes et al.190
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HO
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\
OH

OH

42

41
S c h e m e 2-4 Isopropylidene Protection of D-Ribose
In order to increase the yield and eliminate the time consuming chromatography
involved in purifying this compound, the reaction was repeated using a 2.4% solution of
HCI in acetone. However, this resulted in a yield of 35% indicating a negative role
played by water in the reaction. This would result in an unfavourable equilibrium with
respect to the product. Consequently the reaction was repeated again under literature
conditions but using anhydrous acetone. This modification resulted in a yield of 99%.
The success of this reaction was indicated by the appearance of two sharp methyl
singlets (8 1.50 and 1.33) in the JH NMR spectrum, and the consequent loss of two
hydroxyl proton signals.

2.2.2.2 TBDMS Protection of the 5-OH Group
In order to prevent reaction at the 5-OH site, it was decided to protect this
functionality in 42 with a tert-butyldimethylsilyl group.189'

191

'

192

This group is

recognised as having a high complementarity with an extensive range of other

protecting groups and is stable to organometallic reagents, reduction reactions and bas

conditions anticipated for this synthesis.191 Although a host of methods are available fo
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this reaction, the commonly used, imidazole catalysed method was used as it has a
proven utility with this particular sugar.189'19M93

•X,

Q

O

Imidazole,

HO^V%.

TBDMSCI

, HCr V ""\

VL, OTBDMS
Un
42 43
Scheme 2-5 T B D M S Protection of Primary Alcohol
Again, *H NMR analysis provided easy recognition of the final product with the

appearance of the r-BDMS peaks at 5 0.95 (sharp singlet integrating for the nine r-bu
hydrogens) and at 5 0.15 (sharp singlet integrating for 6 Si-methyl hydrogens). The
yield obtained was nearly quantitative (99%) far surpassing previously recorded
189

literature yields that are typically around the 60-70% range.
2.2.2.3 Oxidation of 5-0-(TBDMS)-2,3-0-isopropylidene-D-ribose
To provide the carbonyl functionality required for the reaction of the
carbohydrate entity with the thiazole heterocycle, a simple potassium permanganate
189

oxidation of 43 was chosen based on its ease of use and proven success.

Permanganate oxidation is a classic, fundamental reaction that typically produces high
yields of product. Aside from the readily evident simplification of the *H NMR
spectrum which showed the loss of two proton signals (5 4.85 (OH) and 5.25 (HI)) the
success of this reaction is apparent upon workup wherein the product forms large,
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square plate-like crystals of 5-0-(TBDMS)-2,3-0-isopropylidene-D-ribonolactone 44 in
98% yield after recrystallisation.

0^0

>

°-- v-*.

OTBDMS

44

2.2.3 Protection of 2-Acetyl thiazole
Commercially available 2-acetylthiazole 45 was converted to the dimethoxyketal
using trimethyl orthoformate and p-toluene sulfonic acid in anhydrous methanol. This
type of reaction is typically high yielding (>80%)195 and in this case resulted in 99%
yield of (l,l-dimethoxy)-l-ethyl-2-thiazole 46 (Scheme 2-6). The lH NMR spectrum of
the final product revealed the presence of two newly formed methoxy groups (5 3.23
6H) indicating not only completion but also a close correlation with the reported
spectral data.194'196

N^/S

or

p-TsOH
HC(OMe)3
MeOH

y
O^^O

/ \
45

46

S c h e m e 2-6 Ketal Protection of the Carbonyl G r o u p
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2.2.4 Coupling the Protected Heterocyeles
The 5-lithiothiazole derivative 47 was generated in situ from 46 by treating it
with n-BuLi in THF at -78°C. Treating 47 with 5-[(tert-butyldimethylsilyl)-2,3isopropylidene 44 at the same temperature before quenching with saturated ammonium

chloride solution gave a single isomer of the lactol 48 (Scheme 2-7). The pure produc

48 was obtained as a white crystalline solid in 64% yield after recrystallisation. Th
syn stereochemistry of 48 was established by single crystal X-ray analysis (Figure
2-10).

N

<V

S

*0

X

Xo

v

O

O

o

+
o-

OTBDMS

o
OTBDMS

47

44
48
Scheme 2-7 Organolithium Mediated Coupling

Over multiple repetitions of this reaction, the 1,2-anri-isomer of 48 was not

encountered in any detectable quantity. Molecular modelling of the two isomers, carr

out using the AMI forcefield for semi-empirical geometry minimisation in the program

"PC Spartan" did not provide any insights into the possible reasons for this observa
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Figure 2-8 Geometry Optimised ( A M I ) Structure of 48
The structure shown in Figure 2-8 shows the geometry optimised lowest energy

conformation of the 1,2-syn (48) product from this reaction. The lack of formati
the 1,2-anti isomer of 48 shown below, in Figure 2-9, would appear not to be due

to thermodynamic influences since both isomers have a similar heat of formation (

331.8 kcal/mol for the 1,2-syn isomer, Vs -331.1 kcal/mol for the 1,2-anti isomer

Figure 2-9 Disfavoured l,2-anti-48
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The stereochemistry at the lactol carbon in 48 is most likely under

thermodynamic control since the lactol can undergo epimerisation at this centre via a
ring opening (to a hydroxy ketone) then ring closing mechanism. The bulky TBDMS
substituent would be expected to favour the observed 1,3-anti stereochemical

relationship between itself and the bulky thiazole substituents. It was also interest
note that there were no ring-opened products as was the case with the previously
1 Qn

synthesised analogues.

49

The stereochemistry was opposite to that found for the major isomer 49 in the

production of the 4-carbon side chain analogues, this product however does not have t
bulky J3-TBDMSOCH2 substituent.
The stereochemistry of 48 was determined by single crystal X-ray
1Q7

crystallography data as shown in Figure 2-10.

Figure 2-10 2-Acetyl-5-(l-hydroxy-2,3-isopropylidene-5-terfbutyldimethylsiloxyribonolactol)thiazole (48)
The "H NMR analysis of 48 fully supported the X-ray crystallography data.
Some key chemical shifts from the !H NMR data include the assignment of the
hydroxyl proton at 6 5.65, protons H3 and H4 at 8 4.6 and 4.9, respectively (coupled
with a 5.6 Hz geminal coupling constant), and the assignment of the CH2 via DEPT
analysis and the subsequent correlation to the appropriate protons using HetCor
experiments (Figure 2-11).
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2.2.5 Reductive Ring-Opening Reactions
Reductive ring opening of the carbohydrate heterocycle of 48 was achieved
using sodium borohydride at 0°C. This reaction also behaved in contrast to the
previously generated 4 carbon analogues in that it was not possible to achieve any
significant degree of diastereoselectivity. Interestingly, this result is not in total
agreement with the literature results, which see sodium borohydride exhibiting a
stereoselectivity towards the 1,2-syn diastereoisomer in the reduction of ketones, similar
to that formed upon in-situ ring-opening of lactol 48.198 However, a range of
stereoselectivities was observed (50:50-95:5 for the ratio of antUsyn) following the
addition reactions of 2-lithio-thiazole to a range of related chiral aldehydes.199
The sodium borohydride reduction of 48 yielded two diastereoisomers, 50 and
51 with a total yield of 96%. These isomers were readily separated by column
chromatography on silica gel to give 48% yield of diol 51 and 46% yield of diol 50.

u QH
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'" «HH ?^H
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X
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O H H
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O-SiN^^S O
48
O' *0

O H H

A
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Scheme 2-8 Reductive Ring Opening of 48
The key differences in the !H NMR spectra of these compounds were evident in
the protons in close proximity to the two hydroxy groups (Table 2-2).

Table 2-2 * H N M R (CDC1 3 ) Differences Between 1,2-Syn- (51) and 1,2-Antiisomers (50)

Cl(OH)

l,2-5y«-Isomer (51)
5 (multiplicity, J in H z )
3.27 (d, 77.3)

l,2-A«#-Isomer (50)
5 (multiplicity, J in H z )
4.91 (d, J 3.0)

C1(H)

5.39 (dd, J 1.8,7.3)

5.13 (dd, 73.0, 9.1)

C4(OH)

2.90 (d, 75.6)

3.39 (d, J 3.3)

C4(H)

4.03 (m)

3.87 (m, 73.3)

Assignment

From Table 2-2 it can be seen that the H 1 - H 2 coupling constant for the syn- and

anri-isomers is 1.8 Hz and 9.1 Hz (the other J values correspond to coupling with th
substituent alcoholic protons).
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Figure 2-12 Geometry Optimised ( A M I ) Structure of 51
The computer-minimised structure for the syn-isomer 51 (shown in Figure 2-12)
revealed the dihedral angle for the H1-H2 protons to have an absolute value of 89°,
which is consistent with a small vicinal coupling constant. Conversely, yet

complimentarily, the anti-isomer 50 had a calculated dihedral angle between these tw
protons of 153°, consistent with a larger vicinal coupling constant (Figure 2-13).
This data confers a two-way benefit in that it confirms the stereochemical
outcome provided by X-ray diffraction (see later), which in turn provides validation
the accuracy of the molecular modelling parameters used throughout this work.
Attempts were made to increase the diastereoselectivity of this reduction

reaction through the use of other reducing agents (namely DIBAL and K-, L- Selectrid

but in these cases only starting materials were recovered, suggesting that ring-open
of the lactol to the corresponding alkoxy-ketone was not favourable under these
conditions.
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Figure 2-13 Geometry Optimised (AMI) Structure of 50

Figure 2-14 Single Crystal X-ray Structure of 50
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Modifications to the temperature and rate of addition of the sodium borohydride

did not cause any significant difference in the ratio of the products formed, wit
reactions giving approximately a 1:1 mixture of the diastereoisomers 50 and 51.
The stereochemistry of 50 was confirmed unambiguously by single crystal X-ray

crystallography (Figure 2-14) that clearly showed the (S) configuration at Cl re
for the "anti-" assignment in this instance.
A comparison of the *H NMR spectra of 50 and 51 in the 85.5-2.8 chemical shift

range is shown in Figure 2-15. All signals are clearly resolved with each isomer
a unique coupling pattern.
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2.2.6 Deprotection of the Final Products
In choosing the protecting groups used in this synthesis, care was taken to ensure
complimentary and ready deprotection under nominated conditions. Given the high
prevalence of basic reagents throughout the course of the synthesis, protecting agents
that were acid-sensitive were used. This also allowed for removal of all protecting
groups in a single process. The individual diastereoisomers 50 and 51 were dissolved
separately in acetone prior to dilution with an equivalent volume of 10% hydrochloric
acid solution. The mixture was then heated to reflux.

OH

OH

OH

O-SiN^S

O

O

Acetone/
HCI
91%

N

p
<^/S

OH

0H

OH
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51

OH

O-SiN<v/S 0. .0
0'

"0

X

50

OH

Acetone/
HCI ^
89%

S c h e m e 2-9 Deprotection of 50 and 51
Under these conditions, deprotection was complete after 2 h, and the products
recovered as their hydrochloride salts in yields of 91% and 89% for 53 and 52,
were
spectively. Unfortunately, these compounds were not amenable to NMR analysis,
re
with all peaks showing poor resolution and major overlapping of peaks.
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Figure 2-16 Geometry Optimised ( A M I ) Structures of the 1,2-Syn- (52) and 1,2Anti- (53) isomers.
The geometry-optimised structures of these compounds clearly show that a
stretched out conformation with minimal spatial crowding is readily adopted.
In order to confirm the isolation of the correct products, it was decided to
acetylate the compounds for further NMR analysis.

2.2.7 2-Acetyl-5-[(l'fl, 2>R, 3'R, 4'R, 5')pentaacetoxypentyl]thiazole
In order to more reliably elucidate the structure of the pentahydroxy final

products, 52 and 53 were acetylated using acetic anhydride and glacial acetic acid.

resulted in formation of the corresponding pentaacetyl derivatives 54 (1,2-syn-) an
(1,2-anti-), respectively in yields of 58% and 63%.
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OH
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OAc OAc
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N U .S

OAc

OAc

O
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52 (1,2-syn)
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Scheme 2-10 Acetvlation of 52 and 53

OAc
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As the pentaacetates, the products were readily analysed using H N M R and
were quite distinct from one another (Figure 2-17).
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Figure 2-17 *H N M R (CDC1 3 ) of Syn-pentaacetate 54 (bottom) and Antipentaacetate 55 (top)

The tabulated *H NMR data (Table 2-3) clearly displays both the similarities and

the differences between the syn- and anfi-diastereoisomers. A small amount of im
peaks were observed in the !H NMR of 55 and both isomers showed a small amount

(<5%) of the other isomer in their lH NMR spectra. The coupling patterns were ver

similar, in most cases exhibiting identical peak patterns and minimal difference

coupling constants. As expected, the trend observed for these diastereoisomers w
respect to the :H NMR data for the "a" proton (see Figure 2-17) is in accordance

similar trends observed in the literature, which see a downfield shift of the si
for the 1,2-anti isomer in the *H NMR spectrum.

200

The size of the downfield shi
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8

also similar to those found in some cases in the literature (0.15 ppm compared to 0.2
ppm).

0()

Interestingly, the trend observed with respect to the coupling constants for

same *H NMR signals (syn < anti), is the opposite of that found in the literature (ant

syn), although the difference between 7a>b (7U) in 54 and 55 is only marginal. Table 2shows a comparison of data from JH NMR with molecular modelling data. This is done
by comparing experimental J values from the TH NMR with the dihedral angles
measured from the modelled structures. The Karplus equation infers that the closer a

dihedral angle is to either 0° or 180°, the larger the coupling constant will be. Dih

angles closer to 90° will give rise to coupling constants of lower magnitude. Couplin
constants highlighted in bold denote the coupling responsible for the correlation.

Dihedral angles refer to the angle formed with the previous signal, hence the lack of
angles in the first row.

Table 2-3 * H N M R data (CDC1 3 ) for Pentaacetate C o m p o u n d s 54 and 55

Assignment

Dihedral
angle (°)
with
previous
proton

1,2-syn-isomer (54)
5 (multiplicity, J in

Hz)
a

6.40 (d, / 3.7)

c
d
e

f

•

•

•

•

'

•

'

•

. ' : " . . ' • • : • • • • •

74
(01,2)
161
5.33 (dd, 74.0, 7.6)
(02,3)
174
5.22 (m, J 3.3)
(03,4)
93
4.33 (dd, J 3.3, 12.1)
(04,5a)
144
4.17 (dd, J 7.7, 12.1)
(04,5b)
5.44 (dd J 3.7, 7.6)

Hz)

Dihedral
angle (°)
with
previous
proton

6.25 (d, 74.6)
'

b

1,2-anri-isomer (55)
5 (multiplicity, J in

5.57 (dd, 7 4.6, 6.2)
5.18 (dd, 75.2, 6.2)
5.24 (m, 7 3.3, 6.7)
4.30 (dd, 73.3,12.2)
4.10 (dd, 76.7, 12.2)

96
(01,2)
159
(02,3)
174
(03,4)
120
(04,5a)
117
(04,5b)
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It should be noted that the experimental data correlates very well to the

calculated data. The presence of multiplet signals prevented measurement of J values i
some instances.

Figure 2-18 Geometry Optimised ( A M I ) Structures of 54 and 55

Generally, the experimental data (J values) is in agreement with the coupling

constants expected from the molecular modelling (Figure 2-18), and serves to highligh
the structural similarities between the pentaacetates formed.
It was possible to isolate a suitable crystal of (sy«>2-acetyl-5-[(l.R', 2R', 2>R',

4R\ 5')-pentaacetylpentyl]thiazole 54 for single crystal X-ray crystallography (Figu
2-19). This confirmed the structure elucidated via NMR analysis and high resolution
mass spectroscopy.
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Figure 2-19 Single Crystal X-ray Structure of 2-acetyl-5-[(l'ft, VR, 3'R, 4'R, 5')pentaacetylpentyl]thiazole 54
Having confirmed the structures of both diastereoisomers we were fortunate

enough to have access to biological screening, allowing an assessment of the str

activity relationship changes resulting from the differences between THI and the
newly synthesised chemical entities.

2.2.8 Cell Aggregation studies to assess the bioactivity of 2-Acetyl-5[(1'R, TR, 3>R, 4'fl, 5')-pentahydroxypentyl]thiazole
The diastereoisomers 52 and 53 were assayed alongside THI itself to determine

their relative bioactivity. This allowed a comparison of structure-activity relationshi
and provided a guide as to the approach future analogue syntheses should take. In order

to test for cell aggregation (a function of lymphopenia) the test compounds were applie
to "Huvec" lymphocytes and the degree of aggregation was measured. Huvec cells are
cultured umbilical cord lymphocytes, and the degree to which they aggregate is used as
an indicator of the degree of lymphopenia they would cause in vivo. This was used as

the measure of bioactivity. This study was done in collaboration with Prof. Chris Parish
at the John Curtin Medical Research School at the Australian National University,
Canberra.
This study utilised flow cell cytometry, which is capable of measuring both cell
numbers and size. In short, this technique uses multiple counters to record the number
of cells and their linear height as the cells pass by the counters. By correlating data

multiple counters it is possible to determine the overall size of the cells and hence t
degree of aggregation of the cells.
The data is represented by four numbers representing the number of "events"

recorded in each of four quadrants (Figure 2-20). The larger "events" fall furthest from
the origin, in the upper right quadrant, so the more events (represented by a higher
number) in this quadrant, the more aggregation.
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Figure 2-20 Representation of Flow Cell Cytometry Data

When a cell (or group of cells) passes the detectors in each quadrant it is
registered as an "event". In this study, 10,000 events were charted and from this it was
possible to work out how many small, medium and large events were recorded, as a
percentage of the blank control. This data is displayed in Figure 2-21, which shows the
data as both a percentage of the control and as a percentage of THI.
While there appears to be some irregularity with the control and THI, the
measured results are within the calculated error. The graph clearly shows that the synisomer 52 has a bioactivity around 170% that found for THI and the anti-isomcr 53
140% that of THI. When compared to control levels, this trend is maintained with
activities of 140% and 120% for the syn- and anft-isomers, respectively.
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Figure 2-21 Relative Bioactivities (amount of aggregation) of 1,2-Syn- and 1,2-A»ri2-Acetyl-5-[(l',2'/?,3,/?,4'l?,5')-pentahydroxypentyl]thiazole Isomers Against
and Blank Control

2.3 Conclusion

The successful synthesis of THI analogues with 1,2,3,4,5-pentahydroxypentyl

side chains allowed investigation of the role of the side chain. Based on prel
bioassay data, it was determined that an increase in side chain length led to

in bioactivity. The next logical step in this study of THI analogues was to re

orientation of the heterocycle to determine the biological ramifications of th
manipulation.

Chapter 3
The Synthesis of V. 2,-Sm and \\ V-

A/iri-2-acetvl-4-r(r, VR. 3'/?. 4>R, 5')pentahydroxypentyllthiazole.
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3.1 Introduction
The previous synthesis demonstrated that by increasing the length of the

polyhydroxy side chain it was possible to improve upon the bioactivity seen for not on

the thiazole analogue of THI, but also THI itself! The synthesis examined in this chap

was carried out to explore the effect of altering the site of addition of the carbohyd
backbone to the thiazole ring, namely, from C-5 to C-4.

OH

OH

OH

OH

OH K U / S

cr ^
C-4 Analogue

OH

NU

S

OH

OH

OH

OH

o*
C-5 analogue

Figure 3-1 C-4 vs C-5 Thiazole Analogues
This change was planned to expound the function of the nitrogen in the

heterocycle, which has previously been free from hindrance by the side chain. Nitrogen

atoms in bioactive molecules are known for their role in biological active sites where
they often protonate or hydrogen bond to bioorganic macromolecules.
The selectivity required for the organolithium mediated addition reaction
between the thiazole ring and the carbohydrate moiety will be provided by metalhalogen exchange, on the thiazole ring.
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3.2 Organolithium Reactions
3.2.1 Metallation: Directed Lithiations
The generation of organolithiated species has been extensively researched and
commonly involves simple metallation reactions. These reactions occur at the position
most readily able to stabilise the carbanion intermediate, which in many instances, fails
to be the one desired. For example, metallation of TV-protected imidazole occurs at one
of three possible carbon sites, with an order of reactivity C-2 > C-5 > C-4. ' For

imidazole itself, it is possible for deprotonation at the N-l position and this position has
a higher reactivity than C-2 203

2

Imidazole

2

Thiazole

Figure 3-2 Order of Reactivity of Carbons on Heterocyeles
Similarly, the 2 position in the thiazole ring is the most reactive to metallation,
and the carbon order of reactivity is duplicated in this azole.

N
...
^ N
.
// \\ 1-n-BuLi , // \\
1 • "-Buli »
\„S
2. Me.SiCI N ^ / ^ S i M e , 2. Me3SiCI Me3o.
3S

^
^

SiMe,

S c h e m e 3-1 U s e of Protecting G r o u p s to Direct Reactions o n Thiazoles
In order to direct metallations in azole species, it is common practice to employ
protecting or blocking groups to force lithiation to occur at the desired position.
Obviously, this practice is costly in both time and reagents and, with these reactions
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typically yielding between 10% and 90% of the desired products, requires a larger
amount of starting material to facilitate the generation of a given amount of product.201'
203, 204

Blocking groups range from the more traditional such as trimethylsilyl groups
(Scheme 3-1), to halogens themselves, such as chlorides. Chlorides have sufficiently
low reactivity towards organolithium reagents to enable them to be used to selectively
block specific carbon positions on the parent azole. They m a y also activate their
neighbouring halogen to attack, which is further expounded later in this chapter.
T h e use of protecting groups also gives rise to another consideration, namely the
reactions to be used in the deprotection stage of the synthesis. If care is not taken to
select protecting groups with contrasting labilities to those of the desired functionalities,
it is possible that a multistage synthesis would result in the production of the azole
starting material.

3.2.2 Metal-Halogen Exchange

3.2.2.1 Introduction
A s its n a m e suggests, this reaction involves the exchange of a halogen for a
metal species, and most c o m m o n l y involves the exchange of lithium for halogen on an
sp2-carbon. Lithium-halogen exchange is regarded as a close rival of simple metallation
reactions with respect to its efficiency and utility.205 Interestingly, it w a s discovered
around the same time as organometallic reagents were first piquing the interest of
chemists such as Gilman and Wittig, but was identified as a side reaction to the
metallation reaction.147,150
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Metallation - 4 possible products
M

H H

H

H

M H

H

+
M

M

H

Br

H

H

H H

Br

H

H M
Metal-Halogen Exchange -1 possible product
Figure 3-3 The advantages of Metal-Halogen Exchange Vs Metallation

Aside from access to a range of addition products not available via metalla

the metal-halogen exchange gives a sole product, as the lithium substitutes
location of the halogen, as seen above.

3.2.2.2 Mechanism

Despite the popularity of this type of reaction, the exact mechanism of met

halogen exchange is not yet clear. It has been determined that second order

involved in the overall process, but the lack of concentration dependency co

this finding and prevents definitive classification. These reactions are al

involve free radical formation, but again they do not fit the classical def

radical reaction. It is generally considered to be a concerted reaction wit
intermediate 205
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Figure 3-4 Proposed Mechanisms for Metal-Halogen Exchange
The mechanisms illustrated in Figure 3-4 show three variations on the theme of

four centre transition states, with (a) being the only true concerted four centre p

The mechanism seen in part (b) shows the lithiated species engaged in nucleophilic
attack on the halogen. This is contrary to (c) wherein electrophilic attack on the
species is the driving force. Mechanisms (a) and (b) are favoured over (c).205 The

lithium selectively attaches to the atom most able to delocalise a negative charge,
negating the formation of lithiated halide species.
It is important to note that these mechanisms do not accurately describe the
metal-halogen exchange process. Primarily, the entire process is reversible unlike

nucleophilic reactions wherein at least one step in the reaction is irreversible. '

this reversibility that allows the generation of organolithiated species to be use

"starting material" in further reactions which result in the replacement of the lit
with the desired organic "R" group.
Due to the inductive effect of a halogen on an organic molecule, it would be

reasonable to assume that this type of reaction (the addition of an organometallic

to an organohalide) would lead to alkylation and/or metallation at adjacent, activa
carbons. This is, indeed, the case and metal-halogen exchange reactions owe their
success entirely to the speed at which they occur, allowing them to surpass the
formation of the alkylated and metallated products.
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3.2.2.3 Factors Influencing Reaction rate

Temperature
Low temperature reaction conditions decrease the rates of alkylation and
metallation, while enhancing that of metal-halogen exchange.205 In fact, so rapid is the
metal-halogen exchange that it can be undertaken in the presence of other reactive
functional groups, provided that the reaction is carried out at sufficiently depressed
temperatures.

OMe

OMe
n-BuLi

Br

Li

OMe

OMe

+

n-BuBr

+

n-BuH

(a)

(b)

(c)

S c h e m e 3-2 Variations in Metal - Halogen Exchange Reactions D u e to
Temperature and Duration
In Scheme 3-2 the effects of time and temperature become blatantly evident.
Equation (a), the desired metal-halogen exchange, occurs rapidly and at low
temperatures. However, when the reaction is allowed to continue and/or the temperature
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is increased, the products formed by the reactions outlined in equations (b) (metallation

of site adjacent to reactive functional group) and (c) (H substitution) start to form and
finally dominate the reaction mixture.205

Solvent
The rate of this reaction is also accelerated when it is carried out in electron
donating solvents such as tetrahydrofuran or ethers such as diethyl ether, although the
reaction will proceed in hydrocarbon solvents such as benzene.205'

207 209

-

This fact has

been used to great advantage in the reaction of hydrocarbon soluble alkyl lithium
reagents with aryl bromides or iodides to generate the insoluble aryl lithium reagents
which consequently precipitate out to be isolated via simple filtration. '

Lithium Source
Metal-halogen exchange is disfavoured with phenyl- and methyllithium, which
result in a higher degree of metallation than is found with n-butyl lithium, and menthyl
lithium, which is known to exchange extremely well with bromobenzene.212

Halide
Of the monohalides, iodides and bromides are the most amenable to exchange,
while chlorides exchange with some degree of difficulty. Fluorides are not known for
their metal - halogen exchange facility.213 This is undoubtedly an electronegativity

related effect, as evidenced by the fact that fluorides and chlorides tend to preferential
undergo orf/w-metallation.205 In actual fact, chlorides are so disinclined to undergo
metal-halogen exchange that there are instances of them being used as directing groups
during exchange reactions with a neighbouring bromide (Scheme 3-3).
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Scheme 3-3 Extremely Low Reactivity of Chlorides Being Used as Directing
Groups
When dealing with polyhaloaromatics, the inductive effect imposed by

neighbouring halides is often enough to promote metal-halogen exchange, alth

o/t/zo-metallated products are still present and (depending on the lithium s
even be the major product (Scheme 3-4). '

RLi
THF, -70°C
Cl

Scheme 3-4 Products for Metal - Halogen Exchange with Polyhalogenated Species

3.2.3 Reactions

of Organolithium

Reagents

with

Aromatic

Heterocyeles

Researchers wishing to generate halogenated aromatic heterocyeles face a

similar problem to those wishing to metallate these same species, namely, t

selectivity of the process. Previous work has often focussed on the dehalog
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polyhalogenated starting material, which is extremely inefficient and often involves the
production of neurotoxic trihalogen compounds.215"219 Alternatively, aromatic
heterocyeles are popularly synthesised from the aryl lithium moiety220 or via sequential
metal-halogen exchanges of a polyhalogenated species, until the desired product has
been obtained.221,

222

Obviously, the preparation of neurotoxic entities is best avoided

whenever possible. The use of an aryl lithium species to create a halogenated species to

in turn, react with an aryl lithium species is a protracted and ungainly process, while t
metal-halogen exchange synthesis would involve the neurotoxicity issues discussed
previously.
With the availability of ever increasing ranges of starting materials, it is inevitable
that synthetic strategies will improve over time. Access to reagents such as 2,4thiazolidinedione allows the selective dibromination of the 2- and 4- positions of

thiazole and this is a useful starting material for preparing the thiazole derivative neede
130 223 224

in this project using lithium - bromide exchange reactions.

3.3 Discussion
3.3.1 Rationale
Using literature procedures, it was possible to prepare 2-(l,l-dimethoxyethyl)-4bromothiazole 56 from 2,4-thiazolidinedione.
This reagent was subjected to lithium - bromide exchange to generate the
organolithium entity which was coupled to the protected carbohydrate (5-0-(f-BDMS)2,3-CMsopropylidene-D-ribonolactone) generated in the previous chapter.
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56
Reductive ring opening followed by acid hydrolysis deprotection yielded the
desired 4-thiazole analogues of THI.

3.3.2 Bromination of 2,4-Thiazolidinedione
Following established literature procedures, it was possible to synthesise 2,4dibromothiazole (Scheme 3-5).130'223'224

O.

HO

P^ POBr^ /^
Nv ^S ^
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Bi\
N^.S
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Br

Scheme 3-5 Bromination of 2,4-thiazolidinedione
This was facilitated by heating the reaction mixture of thiazole and phosphorus

oxybromide to 150 °C for a period of 24 h in a sealed reaction vessel. These con

allowed the dihydroxythiazole component of the equilibria to be trapped out by t

phosphorus oxybromide and converted to the dibromidethiazole. Quenching the reac

with ice-cold distilled water deactivated the remaining excess phosphorus reagen

final product was extracted from the reaction mixture via solvent extraction wit
ether. The product of this process was a dark brown-red solid. ]H NMR analysis
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revealed the presence of the signature peak for this compound, that of the H5 proton,
a singlet at 57.21.
The original conditions used for this reaction were as described above, but with

heating at only 110 °C for 3 h. The yield for this literature based procedure was 50

Increasing the temperature to 150 °C for the same duration resulted in a decreased y
(37%), which was elevated to 70% by extending the duration of heating to

approximately 24 h. This was repeated to give a yield of 65%, indicating the robustn
of this method.

3.3.3 Acetylation of 2,4-Dibromothiazole
The synthesis of 2-acetyl-4-bromothiazole from 2,4-dibromothiazole (Scheme

3-6) exploits a number of principles established earlier in this chapter. Namely, the

reactivity of the 2-thiazole position, and the amenability of bromides towards metalhalogen exchange.

Br.
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Br
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NyS
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Scheme 3-6 Lithium-Halogen Exchange
2,4-Dibromothiazole was dissolved in anhydrous diethyl ether under nitrogen
and cooled to -78 °C. Then n-BuLi was added at -78 °C and the reaction mixture was

stirred for 30 min to allow maximal halogen exchange prior to the addition of the 4-
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acetylmorpholine. Following the addition of the morpholine reagent, the reaction was

stirred at -78 °C for 90 min before being worked up. The crude product was purified b
column chromatography on silica gel to yield 56 as a white solid (59%). The melting
point of this compound was measured (87-89 °C) and was found to compare favourably
to the literature value (90-91 °C).130 This purified sample was analysed using !H NMR
and showed identical peaks to those observed for an authentic sample.

3.3.4 Protection of 2-Acetyl-4-bromothiazole
Although there is documented evidence of metal-halogen exchange

outperforming metallation of neighbouring functionalities,205 it was decided to protec
the acetyl moiety to prevent the generation of any unwanted side products.
It was important to ensure that this protecting group was compatible with

planned reactions and also with the planned deprotection of the final product. As aci
hydrolysis was the intended deprotection reaction, the acetyl was protected as its
dimethoxyketal derivative (Scheme 3-7).
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Scheme 3-7 Dimethoxyketal Protection of Thiazole Keto Group
The acetylbromothiazole was dissolved in a 1:8 mix of p-toluene sulphonic acid
and trimethyl-O-formate, and heated under reflux conditions for 24 h. This reaction
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gave a 9 4 % yield of an off white crystalline solid, 57, that was spectroscopically
identical to the literature product.130

3.3.5 Coupling reaction of thiazole ring and carbohydrate
Major isomer

Y
.OH
TBDMSO

/

-o'

•,0 TBDMSO

o

58
O

Br

=* A
N
'V

o

O
44

n-BuLi, -78°C,

+

¥o\

N

v

OTBDMS

s

O'
15%
57
48
TBDMSO

Minor isomer
Scheme 3-8 Coupling reaction of 57 and 44
4-Bromo-2-(l,l-dimethoxyethyl]thiazole 57 was reacted with n-BuLi at -78 C
to generate the corresponding 4-lithio reagent, a transformation indicated by a colour
change of the solution from colourless to a dark brown. This colour change initially
occurred as a rapid change from clear to light brown as the n-BuLi was added, and this
light colouration darkened over approximately 15-20 minutes. A s this was a dark
colouration, it was difficult to identify the endpoint and the reaction was allowed to
proceed for 30 min to ensure that m a x i m u m lithiation has occurred.
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The carbohydrate 44 was then added as an ethereal solution. Chilling of this
solution prior to addition, and ensuring a slow dropwise rate of addition resulted in
cleaner reactions. Upon consumption of the starting material 44 (as indicated by thin
layer chromatography), the reaction was quenched by pouring into saturated ammonium
chloride solution.
Extractive workup yielded a crude product which was shown by "H NMR to

contain the two expected diastereoisomeric forms of the 4-thiazole 58 and 59 in a ratio

of 69:31 (S:R at the anomeric carbon), respectively and also a significant amount of th
5-thiazole product 48. In the synthesis of the 5-thiazole adduct it was noted that the
isomer formed with such dominance as to often totally preclude the formation of the
awri-isomer. The dominance of the syn-isomer 58 may come about as a result of the
longer C-S bond (in comparison to the C-N bond) causing a greater interaction between
the 5-thiazole moiety and the TBDMSOCH2 group. In the case of the current synthesis,
the shorter C-N bond may allow easier access to both syn- and anti-isomevs.

S c h e m e 3-9 Synthesis Showing C-2 Epimerised Product
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Interestingly, there was no evidence of the ring opened hydroxy-ketone form of
the product, as has been witnessed in previous syntheses of related compounds
(although only in low yields ~ 10%).130
The presence of the 5-thiazole moiety in the crude reaction mix of the 4-thiazole

synthesis is possibly explained by Scheme 3-10 wherein the generation of the 5-lit
species would consequentially furnish the 5-thiazole adduct.
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Scheme 3-10 Reasoning behind Presence of both 4- and 5-thiazole isomers
Not surprisingly, given that the only difference was the positioning of the

carbohydrate, the 4- and 5-coupled thiazole lactol derivatives gave very similar re

with respect to their modelled structures. Not only did the .yy«-(58) and anti-(S9)

thiazole lactols have similar heats of formation (as seen previously with the 5-cou

entity), but the heat of formation for the 5-thiazole analogues (48) (-331 kcal/mol)
quite close to that of the 4-thiazole lactol compounds (-326 kcal/mol).
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Figure 3-5 Geometry Optimised ( A M I ) Structures for 59 and 58
Given that the next reaction, reductive ring-opening, proceeds via a carbonyl

intermediate, it was decided to use the diastereoisomeric mixture of the 4-thiazole

products 58 and 59 for further reaction. However, it was necessary to remove the 5-

isomer 48 and this was carried out using column chromatography through a silica gel

column. Elution with 30% ethyl acetate in hexanes yielded two fractions, the 5-thia

product 48 in 15% yield and the diastereoisomeric mixture of 58 and 59 in a 69:31 r
(44%).
A small amount of this mixture was separated by more careful column
chromatography to give samples of 58 and 59 for spectroscopic analysis. The purity

these samples was sufficient to allow characterisation of each isomer, but both sam
contained amounts of the other isomer.
Syn- and a«ri-configurations were assigned based on comparison with literature

data as well as data from other syntheses in this current body of work. The next re

was carried out on a mixture of 58 and 59. As would be expected, the major differen
found between the *H NMR spectra of the two compounds was in the chemical shifts
for the H2' and OH1' signals. These differences are outlined in Table 3-1.
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Table 3-1 Key *H N M R Signal Differences between 58 and 59
58

59

H2'

4.75 (d, 75.8)

4.98 (d, J 6.8)

OH1'

4.53 (s)

5.26 (s)

3.3.6 Reductive ring opening
This reaction was initially tried with the commonly used DD3A1-H, which was
added to an anhydrous ethereal solution of the mixture of 58 and 59 under a nitrogen
atmosphere. After extractive workup, the crude product contained only one compound
that was readily identifiable, namely a mixture of 58 and 59 - starting material. It

decided to try the smaller and often conversely diastereoselective sodium borohydride
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Scheme 3-11 Reductive Ring Opening of 58 and 59
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This reaction was much more successful, yielding 65% of a diastereoisomeric
mixture of the 15"-(61) and li?-(60) isomers (59:41). This was separated by column
chromatography on silica gel. Elution with 25% ethyl acetate in hexanes gave both the
IS isomer and the 1R isomers, isolated in yields of 30% and 21%, respectively, of the

theoretical yield. The bias of this ratio tallies with the results from the aforemention
literature on a 2-thiazole analogue,198 although the ratio is somewhat dissimilar (67:23
15: li?).
It was hypothesised that the failure of the DB3A1-H reaction may be due to the
formation of a strongly chelated complex involving the thiazole nitrogen and the lactol
oxygen that prevents formation of the open ketone form and thus the reduction product
(Scheme 3-12). It is noted that previous syntheses similar to this one have not reported
successful reduction with DD3A1-H.

OTBDMS

OTBDMS

Th = thiazole moiety

S c h e m e 3-12 Carbonyl Transition State of Reductive Ring Opening

As expected, the *H NMR spectra of 60 and 61 were very similar. The
exchangeable hydroxyl protons (H4') varied in their chemical shifts, and there was also
a significant difference in the HI' chemical shifts.
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Figure 3-6 Comparison of *H N M R (CDC1 3 ) data for 60 (top) and 61 (bottom)
Analysis of the !H NMR spectra of the purified isomers revealed the typical

result seen for diastereoisomers of this type.130 Namely, the HI' signal for the syn(lS)-isomer 61 has a chemical shift of 8 5.33 where the anti- or (lfl)-isomer 60 is
further upfield at 8 5.07 (Figure 3-6).
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Figure 3-7 X-ray Diffraction Structure of 60.
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A single crystal of the 60 was grown over a period of many weeks in a darkened,

capped vial containing an ethereal solution of the compound. The single crystal X-

diffraction structure confirmed the assigned stereochemistry of the molecule (Figu
3-7).

Figure 3-8 Geometry Optimised ( A M I ) Structures for 61 (top) and 60 (Bottom)
As further confirmation of the structure, and in support of the *H NMR data, the
geometry optimised structures (AMI) for both 60 and 61 were derived (Figure 3-8).
From these structures, it was possible to calculate the dihedral angles about HI'
and H2'. These values (shown in Table 3-2) are complementary to the !H NMR, as
shown by the Karplus equation.
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Table 3-2 *H N M R Vs Molecular Modelling Data
Isomer Hl,-H2) Coupling Constant (Hz) Hl,-H2> Dihedral Angle (°)
Syn (61) 1.8 87
Anti (60) 9.1 168

The slight preference of the isomer 61 in the reduction of 58 and 59, via the

ring-opened ketone derivative can be rationalized by the Felkin-Ahn transition sta
model (Figure 3-9).

TBDMSO

Ho.«

H"
Figure 3-9 Felkin-Ahn Transition State

3.3.7 Deprotection
The deprotection of the compounds 60 and 61 was carried out under conditions

identical to those reported earlier, and were carried out separately for each of t
isomers.
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Scheme 3-13 Deprotection of 60/61 (isomers not shown)
Again, the products were not amenable to lU NMR analysis and it was necessary

to reprotect the hydroxyls as their acetate derivatives, to unequivocally assign t
to the structures.
However, the (15)-isomer (63) was suitably resolved to allow preliminary

assignment of nearly all of the peaks, based on the coupling constants observed (F
3-10).
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Figure 3-10 Tentative Assignment of *H N M R (D 2 0) Data for 63
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Due to the lack of resolution with this compound, it was not possible to confirm
these assignments with 2 dimensional NMR.

Figure 3-11 Geometry Optimised (AMI) Structures of the Pentols 62 (left) and 63
The energy minimised structures for the pentols (Figure 3-11) indicated that (as
expected) they adopt an elongated form creating minimal spatial hindrance between
substituent groups. Mass spectrometry of these compounds also proved difficult with

the parent-daughter scans revealing strong signals at higher molecular weights (m/z x
2n) in both positive and negative electrospray modes. This is consistent with

polymerisation involving loss of water and structures as great as tetramers were read
observed, decreasing in intensity as molecular weight increased.

3.3.8 Acetylation
In order to determine unambiguously the structure of these compounds, it was

necessary to acetylate the pentahydroxy products. These protected derivatives are muc

more open to analysis through 'H NMR and offer better resolution and peak separation.
The acetylations were carried out in parallel as in previous syntheses, under
identical conditions as outlined in Scheme 3-14.
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Scheme 3-14 Synthesis of Acetate Derivatives 64 and 65

It was possible to fully assign all !H NMR signals to the molecule, overcomin

the inherent ambiguity seen in the spectra for the pentol derivatives. The a
are seen below.
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Figure 3-12 Comparison of X H N M R Spectra (CDC13) for 65 and 64 (protons
omitted for diagram clarity)
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These assignments were further supported by the calculated dihedral angles from

the geometry optimised structures generated using "PC Spartan". This data, along with
the *H NMR assignments, has been tabulated and presented below in Table 3-3.
It should be noted that the experimental data correlates very well to the

calculated data. That is, the coupling constants match closely to the values expected

from the dihedral angles according to the Karplus equation. Higher coupling constant

correlate to dihedral angles closer to 0° or 180°. The coupling constants denoted by
text indicates the coupling responsible for the dihedral angle.

Table 3-3 *H N M R Data Vs Calculated Dihedral Angles

Assignment

1,2-syn-isomer (65)
8 (multiplicity, J in

Hz)

Dihedral
angle (°)
with
previous
proton

1,2-anrt-isomer (64)
8 (multiplicity, / in

Hz)

Dihedral
angle (°)
with
previous
proton

a

6.25 (d, 7 4.6)

b

5.57 (dd, 7 4.6, 6.2)

77

5.44 (dd, 7 3.7,7.6)

108

c

5.18 (dd, 75.2,6.2)

88

5.33 (dd, 74.0,7.6)

172

d

5.24 (m, 3.3, 6.7)

164

5.22 (m, 7 3.3, 11.0)

90

e

4.30 (dd, 73.3, 12.2)

66

4.33 (dd, 7 3.3, 12.1)

89

f

4.1 (dd, 7 6.7,12.2

170

4.17 (dd, 77.8, 12.1)

148

6.40 (d, 7 3.7)

It is readily apparent that not only have the molecules been correctly
characterised, but the utility and accuracy of the molecular modelling software have

been confirmed yet again. The optimised structures from which the dihedral angles are
derived are seen below in (Figure 3-13).

Chapter 3 - The Synthesis of2-Acetyl-4-[([l', 2 'R, 3 'R,4'R,5'] -pentahydroxypentyl) thiazole

115

Figure 3-13 Geomtery Optimised ( A M I ) Structures of the Pentaacetate Dervatives
64 (left) and 65

3.3.9 Biological Activity
Unfortunately, we were unable to access biological testing for further
compounds as the industry partner terminated the research contract for the biology
team. However, at the time the previous isomers were tested, samples of 2-acetyl-4-

[(VR, (l'S = 66, not tested) 2'S, VR, 4')-tetrahydroxybutyl]thiazole 67 were tested,
having been prepared through previous work in our group.

OH
S^>N

OH
OH

OH

*K

O

67
These analogues revealed that addition of the carbon side chain in position 4
results in a decreased activity compared to THI with respect to cell aggregation.

Chapter 4

The Synthesis of 1'. 2,-S\n- and 1\ V-

Anti.2-2Lcet\l-5-UV. VR. VS. 4>R. 5>R.
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4.1 Introduction
Having established that the result of extending the length of the polyhydroxyl side

chain, is an increase in the bioactivity, this project investigated the effects of reversi
the orientation of the thiazole heterocycle. This was shown to cause a reduction in the
level of bioactivity (as measured by the degree of aggregation). Given these two
valuable structure-activity relationships, it was decided that it would be of value to
further extend the length of the polyhydroxyl side chain. Also, through the careful
selection of starting material, inversion of the stereochemistry of C3' (compared to 5carbon side chain analogues) was induced in the final products to determine the role of
the stereochemistry in the binding of this family of compounds, to the active site.

OH

N^.S

OH

OH

OH

OH

69

+

O
OH

N.>^s
>v .S

OH

OH

OH

OH

OH

OH

70

68

0
S c h e m e 4-1 Starting Materials and Final Products
The starting material 68 seen in Scheme 4-1 is a well studied compound of proven
value in organic synthesis and it was anticipated that this would allow ready access to
225-230

protected derivatives of this compound for further synthetic manipulation.

Chapter 4-The Synthesis of 2-Acetyl-5-l(V, TR, 3'S, 4'R, 5'R, 6')-hexahydroxyhexyl] thiazole

4.2 The Synthesis of l,2:3,4:5,6-tri-0-ispropylidene[D]-Gluconolactone

4.2.1 Introduction
D u e to its stereochemistry, availability and length of carbon chain, gluconolactone
was selected as the starting sugar for this synthesis, a-[D]-gluconolactone 68 was
chosen over glucose to eliminate the need for an oxidation step, such as was required in
the earlier syntheses.

HO^^r^'OH
OH
68
T o use this compound in the generic synthesis it was necessary to protect all of
the hydroxyl groups. This was attempted with a number of groups before a satisfactory
protection was completed.

4.2.2 Ether Protections
In order to protect the alcohol groups to limit reaction to the anomeric carbon, the
literature w a s searched to provide a known and reliable protection strategy that was
compatible with the reactions proposed for this synthesis.
Ethers are the most utilised form of protecting group for alcohols.1

Ranging

from simple methyl ethers to complex heteroatomic units with multiple substituent

118
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groups, they are added and removed under a wide range of conditions. They can be

manipulated in high, often quantitative yields and are frequently very clean reacti

Many of the larger, high molecular weight groups, particularly the silyl ethers, re

the formation of spectacularly crystalline products that are highly amenable to sin
crystal X-ray diffraction studies, especially when used on carbohydrates.
Silyl ethers have amongst their ranks some of the more popular and broadly
compatible protecting groups used in organic synthesis.195 Not only are many siloxy

groups compatible with other, different silyl groups, but there are countless examp

their use in conjunction with other families of protecting groups. The highly utili

terr-butyldimethylsilyl group was identified as a workable candidate for this synth

4.2.2.1 Tert-butyldimethylsilyl Ether

O^^O
HO
HON>

V
OH

'//,

"OH

Imidazole,
TBDMSCI,
DMF
or
T B D M S triflate,
pyridine,
acetonitrile

^^Si
/ xO
\ |
-Si-Ox

68

71

Scheme 4-2 Protection of a-[D]-gluconolactone with /-Butyldimethylsilyl ethers

Using Imidazole and tert-butyldimethylsilyl chloride
The commonly used imidazole mediated synthesis was selected based on its
compatibility and stability under the anticipated reaction conditions, as well as

that reagents were at hand.195 According to literature procedures, a solution of 68,

imidazole and tert-butyldimethylsilyl chloride in dimethylformamide was stirred at

room temperature for 24 hrs. At this stage thin layer chromatography indicated tha
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of the starting material had been consumed and the reaction was extracted with hexane.

Thin layer chromatography of this extract indicated that a number of compoun

been formed. This reaction was repeated numerous times with varying molar ex

of the silylating reagent, but in all cases multiple products were formed an

able to be adequately resolved on such a small scale. The products from mult

attempts at this reaction were combined and passed through a silica gel colu

with 10% ethyl acetate in petroleum spirits and 640 mg of the desired compou

isolated as a single product (overall yield of approximately 11% from 9 reac

reaction was abandoned due to its poor yield, without further analysis or re
The ]H NMR and MS analysis of 71 was consistent with its structure.

2 13
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Figure 4-1 Selected *H N M R (CDC13) assignments for 71

Using TBDMS

Triflate and Pyridine in Acetonitrile

In order to increase the degree of completion of this protection it was dec

try a more reactive silylating agent. Thus TBDMS triflate was added to a st

solution of gluconolactone, pyridine and acetonitrile at 0 °C. The reaction

slowly to room temperature and stirred until thin layer chromatography indi

starting material remained. lU NMR spectroscopy was used to identify the pr
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indicated that the desired fully protected lactone was the major product. Column
chromatography on a silica gel column gave the desired compound as a pure compound
in 59% yield.
Having optimised the protection of gluconolactone, it was decided to attempt the
organolithium based coupling of the gluconolactone 71 to the protected thiazole moiety
46. Unfortunately, the gluconolactone did not undergo the desired addition reaction,
with !H NMR showing predominantly 71 and degraded thiazole products. One possible
explanation for this is the steric effects induced by the TBDMS groups. It has been
observed previously, that the incorporation of tert-bntyl groups into a silyl protecting
group results in a dramatic change in the reactivity of those species under condensation
conditions.231 !H NMR analysis of the crude reaction mixtures indicated that no product
had been formed whatsoever. Small amounts of the starting material (thiazole) were
recoverable.
One possible explanation for the unsuccessful reaction is p-elimination, although
none of the elimination product could be isolated (Scheme 4-3).

O^ / O
+

P = TBDMS

S c h e m e 4-3 (3-Elimination of Protected Gluconolactone

46
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After repeating this reaction numerous times in an attempt to generate the bicyclic
product, this protected form of the gluconolactone was abandoned.

4.2.2.2 Trimethylsilyl Ether

68

72

Scheme 4-4 Protection of oc-[D]-ghiconoIactone with Trimethylsilane

Using Triethylamine
In order to overcome the steric effects assumed responsible for the failure of 71 to
react with the thiazole heterocycle, it was decided to attempt protection with the
smaller, but more labile trimethylsilyl group. Following a literature procedure191
utilising triethylamine and trimethylsilylchloride in dimethylformamide, the reaction
showed no starting material after 20 h, when analysed using thin layer chromatography.
Extractive workup yielded a clear oil which, by *H N M R , did not appear to be the
desired product.

Using Hexamethyldisilizane
Another silylation technique was sought and, based on available reagents, it was
decided to attempt the reaction using hexamethyldisilizane.183 The product of this
reaction was a mixture that was believed to contain the desired product. Given the
lability of the trimethylsilyl group, distillation was chosen as the purification technique.
This was carried out under vacuum using a Kugelrohr oven but was unable to provide
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adequate purification. The thiazole coupling was attempted with the distillate mixture,
but again, no coupling product was detected.

4.2.2.3 Benzyl Ether

S c h e m e 4-5 Benzylation of a-[D]-Gluconolactone
Following the lack of any real success with the use of silyl ethers, benzylation was
attempted as it had been shown to successfully mono-protect gluconolactone.232 The

reaction conditions called for the dissolution of the sugar in anhydrous tetrahydrofuran.
In the literature procedure the gluconolactone was already partially protected, enabling

this solution to be formed. In this synthesis the starting material was totally unprotect
and would not dissolve in the THF. Following reaction with sodium hydride,
tetrabutylammonium iodide and benzyl bromide were added. After stirring at room
temperature for 8 h, *H NMR analysis indicated that total protection had not occurred
and the majority of the starting material had degraded.

4.2.2.4 Acetonides-Isopropyliden e
Cyclic acetals and ketals are one of the most common families of protecting
groups used to protect diols. By far the most abundant in the literature is the acetonide
group which is simply an isopropyl group bonded to two adjacent alcohols.
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Benzylidene
Figure 4-2 S o m e C(isopropylidene)
o m m o n Alkylidenes used in the Protection of Diols
Protection conditions for diols commonly involve an acid catalyst and acetone,

and under these conditions five-membered rings (1,3-dioxolanes) are preferential
formed. Six membered rings (1,3-dioxolanes) are possible but usually require at

one of the alcohols in the diol system to be a primary alcohol. Seven membered ri
have also been observed in the literature (Figure 4-3).1

Primary O H

O. .0
4,6-O-isopropytidened-gluconolactose

1,5-0-benzylidene-2,3-0isopropylidene-D-Ribofuranose

Figure 4-3 Literature Examples of Cyclic Acetals Showing 7- (bold), 6- and More
C o m m o n 5-Membered Rings191'234
Given the polyhydroxyl nature of carbohydrates it is hardly surprising to note

that there is a significant body of literature evidence for the use of cyclic a
233

ketals to protect both cyclic and acyclic carbohydrates.
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Using Acidified Acetone

68

74

Scheme 4-6 Anticipated Product of Isopropylidination of cc-[D]-gluconolactone
The use of isopropylidene groups has been successfully accomplished in earlier

chapters of this work. It was decided to attempt protection using this group, des

irregular stereochemistry of the carbohydrate ring that would possibly prevent o
the formation of such groups. The expected structure was based on literature

structures190 and was a logical utilisation of the existing stereochemistries foun

carbohydrate ring. The synthesis chosen was identical to those used earlier, bein
stirring an acidified acetone solution of the carbohydrate, until thin layer

chromatography indicated completion. "H NMR analysis indicated that these condit
resulted in the destructive breakdown of the carbohydrate skeleton.

Using Ferric Chloride

O
H0

i

I

HO^ Y""OH

FeCI,

OH
68

75

Scheme 4-7 Expected Product F r o m Literature Procedure
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The discovery of literature claiming total isopropylidination of the glucose moiety
from milder reaction conditions prompted a final attempt to protect and utilise the
gluconolactone heterocycle.234 According to the literature, the product of this reaction
would be that shown in Scheme 4-7, which would maintain the stereochemistry sought.
The literature claimed yields of between 8 2 % and 9 2 % of crystalline products.234 The
reaction was carried out using anhydrous ferric chloride, and the reaction product was
analysed by ! H N M R . Examination of the *H N M R data indicated that the reaction had
produced at least three distinct compounds as well as a host of what appeared to be
degradation products. This was in contrast to the literature findings and the reaction was
repeated using freshly purchased ferric chloride. Again, the product was analysed using
*H N M R , which revealed that the expected product 75 was not present in the crude
product (Figure 4-4).

Water in C D C I 3
6 C H 3 Signals

6 H Signals
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Figure 4-4 ! H N M R (CDCI3) of Ferric Chloride Reaction Unexpected Product
There did appear to be a single compound that was extremely predominant in the
spectrum and the decision was m a d e to chromatograph the mixture through a silica gel
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column. However, on standing overnight, large plate-like crystals were observed to have
formed from the reaction mix. These crystals were washed with ice cold diethyl ether,
dried under vacuum and analysed using !H NMR. Unexpectedly, given that a literature
procedure had been followed and a pure crystalline compound had been isolated, the H
NMR analysis revealed that product had not two but three isopropylidene groups.
The "H NMR indicated the presence of 6 individual protons, and 6 methyl groups
(from the three isopropylidenes). This was unexpected, as the literature product 75
should have given 6 individual protons and 4 methyl groups.
Also, the experimental melting point (92-96°C) differed significantly from the
literature value (110-111°C). In order to investigate further, 13C NMR analysis was
carried out and gave the spectrum shown in Figure 4-5.
This spectrum revealed the presence of 15 carbons, not the expected 12,
supporting the data from the !H NMR that suggested the presence of another
isopropylidene group.

Figure 4-5 1 3 C N M R (CDC1 3 ) of Ferric Chloride Reaction Product
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A D E P T N M R experiment was carried out to try and elucidate the carbon
skeleton and confirm the presence of the third isopropylidene unit (Figure 4-6).
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Figure 4-6 D E P T N M R (CDC1 3 ) Data for Ferric Chloride Reaction Product

Having confirmed the presence of three isopropylidene groups via the presence of
6 methyls and 3 unprotonated carbons, it became impossible to propose a cyclized

structure. This is because the presence of three isopropylidene groups incorporates si
otherwise free hydroxy groups, a combination that cannot be found in a cyclized
derivative of this carbohydrate system.
The two non-protonated carbons around 5110 and a third at 8111 indicated that
three five-membered cyclic acetals had been formed. The structure 77 was more likely
than 76 (Figure 4-7).
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Figure 4-7 A Proposed Structure (76) of Acetonidation of Gluconolactone
The literature indicates that the quaternary carbon of five membered acetals is
found further downfield (5C ~ 109) than that of the corresponding carbon in a six
membered acetal (6C ~ 98).

77

Figure 4-8 T h e Confirmed Structure (77) of Triisopropylidene Gluconolactone
This finding is further supported by molecular modelling data. The minimal
energy conformations of both structures were generated using the "PC Spartan"
program and revealed the heat of formation for 76 (-298kcal/mol) to be greater than

found for 77 (-308kcal/mol). The increased degree of free rotation around bonds in 77
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results in the complete lack of steric interactions between any of the isopropylidene

rings. In order to confirm the structure we sought to grow a single crystal small enough

for single crystal X-ray diffraction analysis. This was achieved with some difficulty an
a small, square plate-like crystal was analysed and gave the structure below.

Figure 4-9 X-ray Diffraction Structure of l,2:3,4:5,6-triisopropylidene-DGluconate 77
A literature search of this structure revealed the compound to have been
prepared previously, and also allowed comparison of the *H NMR data, which was
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identical to the literature data.

"

Also reported in the literature was a very similar

synthesis of this compound, using zinc chloride in place of ferric chloride239

4.2.3 Coupling of Carbohydrate to Thiazole
77

0,

78

47

Scheme 4-8 Direct Coupling of Triisopropylidenegluconolactone to Thiazole

In order to couple the carbohydrate 77 to the thiazole 47 it was decided to employ
the same techniques that had successfully accomplished this coupling in previous

syntheses. This however, was not successful despite repeating the reaction a numb

times. !H NMR of the crude reaction products revealed the original thiazole materi
and the gluconolactone in varying states of deprotection.
O

V-°!

X

H^/^0
HO
^ O
77

79

Scheme 4-9 Possible Elimination Reaction of 77
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These deprotected compounds were suspected to include the elimination product
79 shown in Scheme 4-9, however 79 could not be isolated from the crude reaction mix.

This would occur under reaction conditions where the lithiated thiazole acted as a bas
rather than a nucleophile, and attacked the a-hydrogen instead of the carbonyl.

4.2.4 Amide Chemistry and Carbohydrates
4.2.4.1 Introduction
At this stage it was decided to attempt an amination reaction of the cyclic ester
functionality of 77 and convert it to the corresponding Weinreb amide.
The reaction of amines and esters to form amides is well established and of the
form shown in Scheme 4-10.

O
U

R"

R'^T)'

+ NHR"'R""

O
11

*•
R'

+

R"-OH

NR^R""

Where R', R", R1" and R""are organic moieties.

Scheme 4-10 Generic Reaction of Amine and Ester to form an Amide and an
Alcohol
Early synthetic strategies included the use of magnesium halide, sodium and
lithium salts of primary amines.244"246 Later syntheses utilise sodium hydride or boron

tribromide to bring about the aminolysis of esters to give reasonable yields (up to 94
of the corresponding amides.247'248 However, the generation of amides from esters was

only accomplished under relatively harsh conditions (heat, extended duration and highly
reactive reagents) until the development of Weinreb methodology in the late 1970s.249

4.2.4.2 Weinreb Methodology
Dimethylaluminium amines (Me2AlNR1R2) are commonly used as a mild generic
reagent for the aminolysis of esters to yield amides. Although often associated with the
work of Weinreb, dimethylaluminium amides were actually first prepared by
Hirabayashi and Gilbert in the late 1960s.250"252 These workers found that the reaction of
trimethylaluminium with any non-tertiary amine (1:1 ratio) at room temperature in
dichloromethane yielded the corresponding dimethylaluminium amide.
In 1977, Weinreb and coworkers discovered a novel use for dimethylaluminium
amides, namely, the aminolysis of esters to give amides.249 This methodology has
provided the organic chemist with a highly generic method for this conversion without
the need for harsh reagents or conditions. The years following the discovery of this
methodology saw refinement of the process until its utility and ease of use made it an
extremely versatile synthetic tool.249'

253 255

~

The major refinement to the synthesis was the use of the readily available and
much more easily handled hydrochloride salts of the initial amines. This eliminated the
need for the use of highly volatile, low molecular weight amines. Fortunately, this
refinement did not come at the expense of yield, with yields for the reaction of benzyl
methanoate with the dimethylaluminium amide reactive species changing from 78%
(using the original methodology) to 83% under the improved synthesis.249'253
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Scheme 4-11 Modern Weinreb Reaction

Weinreb aminolysis of esters typically occurs according to the reaction se

Scheme 4-11 which represents the later synthesis incorporating the hydrochl
rather than the free base form of the initial amine.

4.2.4.3 General Utility of the Weinreb Synthesis
The use of Weinreb methodology has been proven on a range of organic

substrates.253 These substrates vary from simple acyclic esters, through non
cyclized esters, to simple cyclic aromatics and even heterocyclic aromatic
83, as seen in Figure 4-10.

O

O^ X H ,

Cl

O'

.ca

O
81

80
O
^CH3
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82
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CH,

83

Figure 4-10 Examples of Weinreb Amenable Organic Moieties

Having developed a successful synthetic strategy for the formation of amid
from esters, Weinreb and coworkers sought a similarly universal synthesis
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from esters. The reaction of esters with organometallic reagents to give ketones often
gives tertiary alcohols since the initially produced ketone is more reactive than the
starting ester 256

OH

0
R-^0'

' + R"M+X-

R"
R"

R

R'

S c h e m e 4-12 Over-addition Product from the Reaction of Esters and
Organometallic Reagents
In order to overcome the need for strict stoichiometric control of
organometallated acylations, Weinreb developed a synthetic strategy that utilised Nmethoxy-iV-methylamides (Weinrab amides) to direct the monosubstitution of an

organic moiety via a chelated intermediate. The intermediate is stable under the reactio
conditions and breaks down to the ketone upon acidification of the reaction mixture.

O

R^Nv

O-CH,
+ R'M+XCK

O
R'

-M
O-CH.
N/
CH,

H"

3

O

R^R'

Scheme 4-13 Weinreb A m i d e -directed Acylation Showing the Chelated
Intermediate
With the methoxymethylamides being readily available via Weinreb
methodology from MO-dimethylhydroxylamine hydrochloride and an acid chloride, this
process is convenient and entails little in the way of specialised handling and storage.
Similarly to the discovery of the initial Weinreb methodology, this synthetic strategy
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was rapidly adopted as a routine technique for the formation of ketones, and its
generality was proven over a range of organic substrates.254'257"259

4.2.5 The Synthesis of Gluconolactonoamides

4.2.5.1 Introduction
In order to facilitate organolithium attack on an amide moiety, we required the
amide derivative of the protected gluconolactone.

R1
i

f"
PO^

YV

P*^y o

XJ

P = Pr
Protecting group

O^

Figure 4-11 Amide Derivative of Protected Gluconolactone

4.2.5.2 Methoxymethyl Amides
Using Weinreb methodology253 the methoxymethyl amide derivative of the
gluconolactone was synthesised. This involved first preparing a stock solution of
chloromethylaluminium methoxymethylamide 84 in benzene (0.67M).

Cl
OMe
Al—N
Me
Me
84
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This procedure followed a literature process, which called for the reaction of the
hydrochloride salt of methoxymethylamide with trimethylaluminium in cooled
anhydrous benzene.

OMe
H-N
Me

Cl.

OMe

.HCI AIMe, (in toluene), » \,_ N '
x
anhydrous benzene^. /

Scheme 4-14 Formation of chloromethylaluminium methoxymethylamide

The reaction was complete when gas evolution had ceased and was not checked

for purity or status due to the unstable nature of the amide. Rather, its e
confirmed when the solution was successfully used in the aminolysis of the
gluconolactone 77, in the subsequent reaction (Scheme 4-15).

OMe

P^y o
MeCIAINMeOMe>
Benzene, 24 h
75%

HO^X^O

X

77

X

O

"'0

O

85

Scheme 4-15 Weinreb Amide form of the Protected Gluconolactone
Column chromatography through a silica gel column was used to isolate the

product from the crude reaction mixture, in a yield of 75%, as a yellow oil

NMR showed expected signals for the iV-methyl and iV-methoxy groups, as wel
loss of two isopropylidene methyls. The

13

C NMR spectrum indicated the prese
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of the carbonyl moiety (171 ppm) as well as characteristic signals at 8 33 ppm (NMe)
and 61 ppm (OMe).

O

r ™ £ L TBDMSO

\^

Imidazole
Anh. DMF
99%

X

86

p^y o
O"

Scheme 4-16 (1', VR, 3'S, 4'R, 5'R, 6')-hexahydroxy-3,4:5,6-di-0-isopropylidene-2terf-butyldimethylsiloxy-1-lactonohexyl) methoxymethylamide (86)

The resultant product 85 required protection and the ferr-butyldimethylsilyl e
was chosen due to its history of successful protections in this project.

r\

n-BuLi, T H F

OP O. .0
'O

^

r

47

O'

86

X
87

Where P = T B D M S protecting group

Scheme 4-17 Coupling Reaction of Weinreb Amide and Protected Carbohydrate
Using the proven methodology employed in earlier syntheses, imidazole and

TBDMSC1 were used to introduce the protecting group. With no purification other

the washes employed during the workup, the desired product 86 was isolated in 9
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yield and of a suitable purity for the compound to be used in the following reaction. The
successful formation of the product was readily identified by the appearance of typical

silyl tertiary butyl group and silyl methyl group signals at 0.9 and 0.1 ppm respectivel
and the disappearance of the alcohol (OH) doublet at 3.5 ppm, in the !H NMR spectrum.
The protected amide was reacted with the lithiated thiazole species 47 in an
attempt to generate the coupled species using established methodology.
The desired compound 87 was isolated from the reaction but the best yield
obtained was 11%. Consequently, this amide was abandoned and another was sought.
The structural elucidation and discussion of this compound, being identical to that
obtained with a more successful synthesis, will be discussed later. Suffice to say that
analysis of compound 87 was identical to the data found for the compound discussed
anon.

4.2.5.3 Morpholine

Amides

The literature provides evidence of the satisfactory use of morpholine derived
amides in organolithium reactions and proposes a chelated intermediate that would
promote the formation of the desired product.

H+

where P = T B D M S protecting group
S c h e m e 4-18 Reaction Showing Intermediate Role of Morpholine
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Turning once again to the Weinreb style synthesis, the gluconolactone was

reacted with trimethylaluminium and morpholine.249 It proved impossible to force th

reaction to completion and the product contained large amounts of starting materia

After many attempts to force this reaction to completion, the decision was made to

combine morpholine and the gluconolactone 77 in a thick walled, sealed glass tube
heat vigorously.261 When heated to 100 °C this would have resulted in pressures

exceeding six atmospheres. This was carried out over 24 h after which time the rea
was quenched as per the Weinreb process.249
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77 88
Scheme 4-19 Reaction of Morpholine with Protected Carbohydrate

The product from this reaction was a dark yellow oil which by lH NMR analysis
was pure enough to require no further purification.
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Figure 4-12 Geometry Optimised ( A M I ) Structure of 88
The jH NMR spectrum for this compound showed not only the appearance of

the morpholine signals, but also the disappearance of two of the isopropylidene met

peaks. These features are illustrated in Figure 4-13. The yield for this reaction w
impressive 95%, far exceeding that obtained using the Weinreb methodology.

Broad
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Figure 4-13 *H N M R (CDC1 3 ) of Morpholine Derivative of Triisopropylidene
Gluconate 88
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The proposed structure 88, confirmed by the spectral data, can be rationalised on
the basis of the reaction mechanism illustrated below in which the nucleophilic attack
by the morpholine heterocycle results in charge migration, leading ultimately to the
expulsion of acetone as the 1,2-acetonide is eliminated from the molecule. This restores
the net charge balance on the molecule, giving rise to the stable compound isolated as
the product.

S c h e m e 4-20 M e c h a n i s m of Reaction Between Morpholine and 77

4.2.6 rert-butyldimethylsilyl Ether Derivative
Protection of the hydroxyl moiety 88 that resulted from the removal of the

isopropylidene unit in this amination, as the ferr-butyldimethylsilyl ether, was achieve
with a yield of greater than 97% using standard synthetic procedures to give 89.
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This silylation reaction took a considerable amount of time to reach completion

(72 h), possibly indicating a higher degree of steric impediment from neighbouring
groups, as the morpholine and TBDMS groups competed for space around the carbonyl
end of the molecule.
O'

O

N

N ^ O

Y°

H O ^ O

j ™ * ^
97%

TBDMSO

f

0 - / "O

X o-

X

88

89

Scheme 4-21 Protection of Morpholine Amide of Gluconolactone Species

The } H N M R spectrum (Figure 4-14) for 89 contained the characteristic tert-

butyldimethylsiloxy peaks at 8 0.9 (ferf-butyl group) and the two methyls close to
The presence of the terf-butyldimethylsilyl group had a marked effect on the
morpholine !H NMR signals, causing them to spread out significantly and resolve
slightly better than in the corresponding spectrum for the previous species.
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Figure 4-14 *H N M R (CDC1 3 ) of the TBDMS-Morpholine Derivative 89 of
Gluconate
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This compound, as with m a n y of the silyl ether protected derivatives, was highly

crystalline and it proved relatively trivial to grow a crystal suitable for single crystal
ray diffraction studies. This analysis resulted in the structure shown below, confirming
the structure elucidated from NMR.

Figure 4-15 X-ray Diffraction Structure of 89
It is interesting to note that the crystal structure of 89 indicates the presence of
two rotameric forms about the Si-0 bond, indicating a range of low energy
conformations with very similar energies.
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Figure 4-16 Geometry Optimised ( A M I ) Structure of 89
One such structure is shown above, the geometry optimised structure generated

by PC Spartan. It should be noted that the structure derived by the molecular modell

software compares very well to that seen in the X-ray diffraction structure, with bo
adopting a conformation involving minimal bending or torsional strains.

4.2.7 Coupling of Carbohydrate to Lithiated Thiazole
The coupling of 89 with the lithiated thiazole 47 was attempted in the hope that
the new functionality of the carbohydrate would promote the reaction and allow a
greater yield and purity than had been obtained using the Weinreb amide.
The compound shown in Figure 4-17 is the energy minimised conformation of
the expected product.
The reaction behaved in a similar fashion to the Weinreb amide in that the
reaction could not be driven to completion. However, the reaction was cleaner and it
was possible to recover the starting materials.
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Figure 4-17 Geometry Optimised ( A M I ) Structure of the Thiazole Coupled
Carbohydrate Species (87)
The crude yield was twice that found for the methoxymethyl amide however,

discounting the recovered starting material, the morpholine amide reaction yielde

times (63% compared to 11%) the amount of product obtained via the Weinreb amide.
This would suggest confirmation of the reaction proceeding via the chelated
intermediate as shown in Scheme 4-22.
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Where

P = TBDMS protecting group

Scheme 4-22 Reaction of the Morpholine Amide with Protected Thiazole
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A s would be expected the substitution of the morpholine heterocycle for the
thiazole, having far fewer protons, resulted in an improvement in the quality of the H
NMR data obtained. The absence of the multiple, broad peaks allowed a more accurate
interpretation of the data.
The presence of the downfield singlet in the :H NMR spectrum of 87 at 8.7 ppm
indicated that the thiazole species has been monosubstituted (the unsubstituted species
has 2 doublets at 7.8 and 7.3 ppm). The doublet labelled (b) is shifted downfield by the
presence of the adjacent carbonyl group, indicating the carbonyl has not been reduced
during the reaction.
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Figure 4-18 *H N M R (CDC13) of 87

I.
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As has been demonstrated repeatedly throughout this work, the TBDMS
derivatives of many carbohydrates are extremely crystalline and this was found to be the
case for this molecule. A suitable crystal of 87 was grown and analysed to give the
structure seen below (Figure 4-19).

Figure 4-19 X-ray Diffraction Structure of the Thiazole Coupled Gluconone
Derivative 87.
In the coupling of thiazoles to carbonyl functionalities, the formation of alcohols
is the more common result.182'

199

'

200, 262

There is a small amount of literature that

includes the formation of ketones as by-products of this reaction and some evidence of
the targeted formation of ketones via oxidation.197*

223

'

263

However, the direct and

targeted synthesis of heterocyclic ketones of carbohydrates may allow access to a wide
range of synthetic molecules via the preservation of the carbonyl functionality
throughout the organolithiation process.
This synthetic strategy was concurrently employed by another group in the
formation of a-amino ketones from amino acids, during the course of this project. These
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compounds are sought after as they possess an inhibitory role against a range of

biological activities. The reactions in this work are of the general form se
Scheme 4-23 and have proven successful for a wide range of amino acids with
ranging from 35-80%.
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Scheme 4-23 Generic Formation of oc-Amino Ketones

4.2.8 Reduction of Ketone Derivative

DIBAI-H or
N a B H 4 or
K- or LSelectride

Where P = T B D M S

Scheme 4-24 Reduction of 87
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In this study it was found that a range of reagents could be used to successfully

reduce the lactone 87, with varying degrees of diastereoselectivity. Four reducing ag
were used to explore a range of stereochemical outcomes. The use of DIBA1-H
produced a single isomer of the compound. The reaction was carried out in anhydrous

diethyl ether at -78 °C and gave a yield of 90% of anti-91 a single isomer. When carr
out at 0 °C using sodium borohydride, a mixture of isomers 90:91 (S.R 87:13) was
produced in 86% yield. Both K- and L-Selectride were also used at -78 °C and
produced mixtures of isomers (90:91 = 82:18 (83% yield) and 90:91 = 83:17 (88%

yield), repectively for K- and L-selectride). The differing stereoselectivities are due

the various transition states involved in the transformations and will be discussed l
in this chapter.

Table 4-1 Yield ratios of Syn and Anti Products for a R a n g e of Reagents
Ratio Anft'-(91):
Reagent

Transition State

Yield
Syn-(90)

DIBA1-H / -78°C

90%

100:0

P-chelation

Sodium Borohydride / 0°C

86%

13:87

Felkin-Ahn

L-Selectride / -78°C

83%

17:83

Felkin-Ahn

K-Selectride / -78°C

88%

18:82

Felkin-Ahn

It was noted that when using DIBA1-H it was possible to get a 50:50 mixture of
syn- and anfi-isomers if the DIBA1-H solution was not pre-cooled or not added
dropwise to the ketone 87. This allowed an excellent comparison of the ]H NMR data
for the two isomers (Figure 4-20). The best results were obtained by adding DIBA1-H
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slowly dropwise down the side of the cold (-78°C) flask rather than directly into the
solution.
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Figure 4-20 X H N M R (CDC1 3 ) of a Mixture of Isomers (90 and 91) from Reduction
of 87 with DIBAL-H without careful cooling of reagents

The quite distinct differences between the two isomers can be seen at "b",

indicating the Cl' protons, and also at the two "c" signals from the oc-hydroxyl group

less distinct, yet definite difference was found in the signals for the thiazole proto
"a", indicating a small degree of shielding is felt even at a distance of three bonds
(Figure 4-20).
It is readily evident from the separate *H NMR spectra for the two isomers that

the most discernible difference lies in the position of the hydroxy (OH) signal (Figur
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4-21-signal labelled "c"). This allowed convenient measurement of the ratio of products
formed in this reaction.
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Figure 4-21 J H N M R spectra (CDC1 3 ) of Pure 90 (anti, above) and 91 (syn, below)
Isomers
It should be noted that with the carbonyl reduced, there is a lower degree of

downfield shift of the thiazole proton signal, now observed in the vicinity of 7.

Figure 4-22 Geometry Optimised ( A M I ) Structures of 90 (left) and 91 (right)
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The overlapping signals in the experimental spectra prevented a meaningful

comparison between the calculated dihedral angles and the coupling constants f

'H NMR spectra. However, the data from the molecular modelling (see Figure 4-2

followed the trend seen in earlier syntheses wherein 90 the anti-isomer (dihed

-64°) had the dihedral angle close to 90° (giving a low J value), and 91 the yy

(dihedral angle = 175°) has a dihedral angle close to 180° (resulting in a hig
constant).
The reduction of related 2-thiazole ketones is a reaction about which a

significant amount of data has been presented in the literature but about whic
trend has yet to emerge.197"199,263

Reducing agent

\\,
^v.N

l

\

O

i^
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Anti- (minor isomer)

=

Syn- (major isomer)

N OR

198

Scheme 4-25 Generic Literature Reduction Reaction as found in Dondoni et al

A recent paper by Dondoni et al. reports hydroxyl inversion via oxidation of an

alcohol to a ketone followed by reduction to give various ratios of isomers o

compounds using four different reducing agents (sodium borohydride, Red-Al, L
K-Selectride) (Scheme 4-25)199
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Figure 4-23 Felkin-Ahn Transition State Relevant to S c h e m e 4-25

The Felkin-Ahn model of the transition state for the Dondoni work positions the
ct-benzyloxy group anti- to the incoming nucleophile (Figure 4-23). Only 11 of the
possible 24 conversions were reported and gave the syn isomers, possibly indicating that
the remaining 13 reactions produced the anft'-isomer over the syn product. Given this

current and somewhat inconclusive body of information, it is very difficult to predict t
preferred stereochemistry of the reduction reaction.
Fortunately this was not a problem as it was possible to isolate a single crystal of
the major isomer produced by the sodium borohydride reaction. This allowed access to
the X-ray diffraction structure shown below in Figure 4-24, revealing the isomer to be
the yyn-isomer.
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Figure 4-24 X-ray Diffraction Structure of 91
Given the degree of freedom of rotation around the a,p-keto-alcohol system
found in the gluconolactone synthesised here, there is a much wider range of potential

transition states that would allow access to both a$-anti and a,$-syn products. Some of
these structures are shown in Figure 4-25 wherein the gluconolactone system has been
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rotated around the a-p bond. The front half of the projection has been highlighted to
clarify the diagram.

'•BH /i-Bu
H-AI

>-"">

i-Bu

Felkin-Ahn, syn favoured

p-Chelation, syn favoured

(oc)-Chelation, anti favoured

Figure 4-25 Possible Transition States for 87

The Felkin-Ahn transition state, showing nucleophilic attack between the small
and medium sized groups (where the OTBDMS group is considered as the large group)
at an angle of approximately 107° (as discussed in chapter 2) to the carbonyl oxygen,
would give rise to the syn-isomer, as noted in Dondoni's paper.198 Similarly, the typical
^-chelation transition state results in the jyn-isomer. Indeed, it was noted that with
sodium borohydride and both K- and L-Selectride, the majority product was the synlsomer.
While the anti-isomer would be expected from the cc-chelation model (Figure
4-25) such a transition state is highly unlikely with a bulky T B D M S group

264
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Thiazole
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Figure 4-26 Possible Chair and Boat (3-Chelated Transition States for Reduction of
87 with DIBAL-H.

For the reduction of 87 with D I B A L - H a P-chelated transition state remains the
most likely possibility because of the Lewis acidity of the aluminium.264 The transition
state A (Figure 4-26), having adopted the chair configuration, looks unlikely because of
severe 1,3-diaxial interactions between the pseudo-axial j'-butyl substituent on the
aluminium and the bulky chelated 1,3-dioxolane ring. These destabilising interactions
are absent in the related boat chelated transition state B and this conformation may
allow hydride addition to the chelated carbonyl group in B from either the face syn to
the flagpole wo-butyl substituent "a" on the aluminium or syn to the pseudo-axial
substituent "b" on the chelated 1,3-dioxolane ring as indicated in Figure 4-26.
Inspection of the molecular models indicates that the interaction of the hydride
species with the flagpole iso-butyl substituent would be less favourable and thus
formation of the onri-isomer 90 in the reduction of 87 with DIB Al-H can be explained.
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4.2.9 Deprotection of oc-Hy droxy Species

Following the successful reduction of the ketone, it only remained to deprotect
the molecule to yield the final compound. This was carried out using acidified
as this technique had already proved successful for the previous reactions.

HO

oK

OH

> - \

O

0
N^/S

.0

N^

N^.S

<K

O

*0
91
Q

X

OH

10%HCI
acetone

TBDMS
O'

OH

0H

0H

0H

OH

OH

98%

93
O

OH
10%HCI>

O .0 acetone* / _,,

N/

N^/S

OH

O

96%

OH

OH

TBDMS
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Scheme 4-26 Deprotection of alcohols 90 and 91

The protected hexols 90 and 91 were separately dissolved in a 50:50 mixtures of

10% HCI solution and acetone at a concentration of approximately 1.5mg/mL. The

solutions were then heated to reflux for 2 h. The acetone was removed from the

reaction mixture in vacuo and the remaining aqueous solution was washed in tri
with 25mL portions of fresh diethyl ether. The remaining water was removed in

to give the desired free hexols 92 and 93 respectively, as hydrochloride salts
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compounds were isolated as clear yellow oils in 9 8 % and 9 6 % yields for the syn- (92)
and anfi-isomers (93) respectively.
The !H NMR spectra of hexols 92 and 93 were very similar (Figure 4-27) but
not identical.
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Figure 4-27 Comparison of Alkyl *H N M R Signals (D 2 0) for Anti (top) and Syn
(Bottom) Isomers 93 and 92

4.2.10 Acetate Derivatives

In order to confirm the identity of the compounds, it was necessary to synt

the hexaacetate derivatives of both isomers. This was carried out, as befor

anhydride. A perchloric acid-acetic anhydride catalyst (1 g of 70% perchlor

g acetic anhydride) was used and the reaction proceeded under ambient condi
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h. The hexaacetates 94 (syn-isomer) and 95 (anti-isomer) were obtained in
75% and 71% respectively after purification by preparative TLC.
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Scheme 4-27 Acetylation of Hexols 92 and 93

The "H N M R for the actetate derivatives were quite similar, as found with
previous syntheses in this work.

Figure 4-28 Geometry Optimised (AMI) Structures of Pentaacetate Derivatives 94
(left) and 95 (right)

1
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The structures shown in Figure 4-28 allowed an estimate of of the Hl'-H2' dihedral
angles and comparison with the experimental !H NMR coupling constants, as has been

done in previous chapters. This data is shown below in Table 4-2. The *H NMR spectr
of 94 and 95 are shown in Figure 4-29.

Table 4-2 Comparison of Calculated Dihedral Angles and Experimental Coupling
Constants

Assignment

1,2-syn-isomer (94)
5 (multiplicity, J in

Hz)

Dihedral
angle (°)
with
previous
proton

1,2-anft-isomer (95)
8 (multiplicity, J in

Hz)

Dihedral
angle (°)
with
previous
proton

a

6.34 (d, 73.9)

b

5.58 (dd, 73.9, 6.8)

74

5.67 (dd, 74.2, 7.0)

165

c

5.87 (dd, 7 3.7, 6.8)

48

5.81 (dd, 7 3.4, 7.0)

77

d

6.01 (m)

158

6.06 (m, 73.4)

151

e

5.49 (m, 7 3.35, 7.6)

151

5.41 (m, 7 2.9, 6.3)

124

f

4.41 (dd, 7 3.35, 11.9)

83

4.39 (dd, 72.9, 11.1)

76

g

4.14 (dd, 7 7.6, 11.9)

154

4.15 (dd, 76.3, 11.1)

161

6.23 (d, 7 4.2)

Once again, comparison of the experimental and calculated data reveals a
reasonably close correlation. However, poorly resolved peaks prevented coupling
constants from being measured in all cases.
Comparison of these *H NMR signals with those found for the corresponding

pentaacetates (Figure 4-29) revealed some interesting trends which will be discuss
part of the concluding chapter.
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5.1 Introduction
In order to gain access to molecules with different stereochemistries and to allow
assessment of the role of the C'2 alcohol, the C6 side chain synthesis was repeated
using a mannose derived starting material.

OH

OH

OH

OH

OH

OH

OH

N^/S

OH

OH

OH

OH

OH

96/97

92/93
0'
Glucose Stereochemistry

Mannose Stereochemistry

Figure 5-1 Differing Stereochemistries of Products from Glucose and Mannose
Carbohydrates
There is uncertainty surrounding the exact mechanism through which THI type
compounds exert their bioactivity. The synthesis of this compound would allow access
to information regarding the relative binding affinity of this compound, which could

compared to the data for the previous C6 side chain compound, thereby elucidating the
role of the C'2 position in the binding site for this family of molecules.

5.1.1 Oxidation of 2,3:5,6-Diacetone-D-Mannose
In order to carry out the lithium directed coupling of the protected thiazole
moiety to 2,3:5,6-diacetone-D-mannose it was necessary to oxidise the hydroxyl group
on the anomeric carbon to a carbonyl functionality.
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98

99

Scheme 5-1 Oxidation of Diacetone-D-Mannose

This was attempted with a range of reagents before a successful reaction was
achieved.

5.1.1.1 Using Potassium Permanganate
The reaction of the parent carbohydrate with potassium permanganate was
carried out as in previous syntheses within this project, but for an extended period of 48
h. After this time, both thin layer chromatography on silica gel plates, and 'H N M R
showed the reaction to remain incomplete. In order to try to force the reaction to
completion, it was repeated with twice the prescribed amount of permanganate. After 48
h this reaction was also shown to be incomplete with a large amount of starting material
still present. Attempts to separate the starting material from the product using column
chromatography were unsuccessful as the product appeared to degrade on the silica gel,
with no eluted fractions containing the product as seen in the ] H N M R spectrum of the
crude product.

5.1.1.2 Using Pyridinium Dicht-ornate
This reaction was carried out according to the work of Corey et al. who devised
a method for using this reagent in aprotic media.265' 266 This was important as the
starting material did not appear tolerant of the conditions employed when using aqueous
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solvents and this adapted technique allowed dissolution in dichloromethane and reaction
at room temperature. However, despite literature yields as high as 98% for various
alcohols, it did not prove possible to drive this reaction to completion either. At this
stage, attempts were made to separate the alcohol from the lactone using selective
crystallisation.
This was carried out by dissolving the mixture in minimal hot ethyl acetate and
adding hot petroleum ether until a white precipitate was observed. A few drops of ethyl
acetate were added to redissolve the precipitate and the solution was allowed to cool.
Unfortunately, using this and conventional single solvent methods, the alcohol and
lactone crystallised simultaneously and were physically indistinguishable.

5.1.1.3 Using Silver Carbonate on Celite
This reagent has a proven history of use with isopropylidinated carbohydrates
with yields as high as 98%.228'

267

Silver carbonate on celite is formed through the

reaction of silver nitrate and potassium hydrogen carbonate in a suspension of celite in
distilled water.
The oxidation of 2,3:5,6-diacetone-D-mannose with silver carbonate on celite
was carried out as per literature methodology.228'267 Whilst the literature claims to be
able to drive this oxidation to completion, this was not found to be the case when used
with this compound. However, with a ratio of starting material to product of 7:93, this
reaction was far superior to the previous methods attempted which produced as little as
50% product at best.
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Ag2CQ3/Celite
Benzene

98

99

Scheme 5-2 Successful Oxidation of Diacetone-D-Mannose Using Silver carbonate
on Celite
Removal of the remaining starting material was accomplished during workup.

The reaction mixture, which had been heated at reflux, was cooled to room temperat
At room temperature, a fine white precipitate resulted which was readily filtered

the supernatant. Washing of this solid with hot benzene redissolved the product fa

than the starting material and by repeating these steps, and combining the washing

concentrating in vacuo, it was possible to isolate the pure final product as a whi
powdery solid in 90% yield.
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Figure 5-2 Composite X H N M R (CDC1 3 ) Showing both Diacetone-D-Mannose 98
(Top) and its oxidation product, the lactone 99 (Bottom)
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Figure 5-2 shows the readily apparent differences between the ] H N M R spectra
for both the starting lactol and the oxidised lactone forms of the molecule. The more
striking differences (highlighted by arrows) were used to monitor the progress of the

reaction, with most attention focussing on the doublet (middle arrow) as it proved to

the most sensitive of the three signals. This peak was still present in a mixture of t
two compounds after the other two signals had disappeared. The 13C NMR spectrum of
99 showed the expected carbonyl group resonance at 8 174.

5.2 Coupling of Thiazole to the Mannose Species
Coupling of the lithiated protected thiazole species (as described in previous

chapters) to the now fully protected and functionalised carbohydrate at -78 °C yielde
the desired product 100. This compound proved amenable to purification using column
chromatography through silica gel. Gradient elution (100% hexanes to 100% ethyl
acetate in 10% increments) afforded the pure product in 84% yield.

0^0

f=\
n-BuLi, T H F

99

A

Scheme 5-3 Lithium Directed Coupling of 46 to Protected Carbohydrate 99
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The lH N M R of 100 showed resonances for both the thiazole and mannose
moities (Figure 5-3), while the 13C NMR and DEPT spectra of this compound showed
the expected number of methyl, methylene, methine and quaternary carbons.

2xOMe
4 x OCMe
CH3

J
^

JJU'L

Figure 5-3 *H N M R (CDC1 3 ) of 100

Interestingly, in a similar occurrence to that found in the five carbon side chain
syntheses (and conversely to previous work by this group that produced four carbon

side chain analogues), only one diastereoisomer was produced. In the earlier synthesi

this was confirmed by the X-ray structure of the compound. In this instance, it prove

impossible to grow crystals of the molecule so the stereochemistry was determined by
NOESY NMR experiments.
The lactol isomer 100 would be expected to be favoured on thermodynamic

grounds since in this isomer, the bulky thiazole group is anti to all the lactol ring
substituents.
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Figure 5-4 N O E S Y Correlations of compound 100
The NOESY NMR experiments showed no trace of a cross peak from the

anomeric hydroxyl group to any of the other protons (see Figure 5-4). Given tha
the other protons resided on the same side of the carbohydrate, this indicated

tertiary hydroxyl was most likely on the same side of the molecule as the prote
groups themselves.

Figure 5-5 Geometry Optimised Structures ( A M I ) of the T w o Possible Isomers of
100 from the Coupling Reaction

Further support for the formation of a single isomer was found in the geometry
optimised (AMI) structures, which revealed a significant difference in the heats of
formation for the two possible isomers. The 1,2-anfi-isomer (left, above) has a heat

formation of -307kcal/mol whereas its 1,2-syn counterpart has a value of-257kcal/mol

5.3 Reductive Ring Opening
The reductive ring opening of 100 occurred in the presence of sodium
borohydride in methanol solution at 0 °C. The resultant product was formed as a pair
isomers in a ratio of 101:102 = 84:16 about the Cl' position (Scheme 5-4). This major
product, being of the syn-configuration, was expected based on the Felkin-Ahn
transition state theory.

OH

OH

X X
NaBH 4 ,
MeOH, 0°C
v ,s

+

101

101:102 = 84:16

*—0

100
*0

X X

102

Scheme 5-4 Reductive Ring Opening Showing the Major (101) and Minor (102)
Isomers
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Due to the fact that the two isomers co-eluted under all of the chromatographic

conditions tried, it was not possible to totally separate out the minor isome
the major isomer 101.
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Figure 5-6 X H N M R (CDC1 3 ) of the Major Isomer 101.

The *H N M R spectra for the minor isomer 102 showed traces of 101 but were
sufficiently clean to allow identification.
In the case of both isomers, there was a degree of }H NMR signal overlap that

hindered assignment of all signals. The major isomer 101 (Figure 5-6) includ
overlapped protons, whereas the minor isomer had only four.
It was not possible to obtain a really clean sample of the minor isomer due
low quantity available and the nature of the compounds which caused them to

This meant that the analysis of 102 had to be carried out on a mixture of th
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strongly favoured 102. However, extensive analysis of their 2 D N M R spectra overcame
this problem and all peaks were confidently assigned for both isomers.
Again, it was not possible to determine the relative stereochemistry of these
isomers via X-ray crystallography as a suitable single crystal could not be obtained.
Accordingly, NOESY NMR experiments were used to confirm the orientation which
was made abundantly clear by a number of correlations to the Cl' proton (Figure 5-7).

H

H

,H

1> n

O

O

/

H

Figure 5-7 Informative C O S Y and T O C S Y (T) data (left) and N O E S Y (right)
cross-peaks in the NMR spectra of 101

The N O E S Y correlations between Cl'-C2\ Cl'-C3' and C3'-C4' provide clear

evidence that all of the protons on this side chain lie on the same side of the molecu

indicating a syn-configuration, and it is possible that the Felkin-Ahn transition sta

giving rise to this structure is further aided by a y-alkoxy chelating interaction (F
5-8).
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Figure 5-8 Expected Transition States T o Give Rise T o 102
Further proof of the assignment of stereochemistry can be found in a comparison
of molecular modelling with the *H NMR data.

Figure 5-9 Geometry Optimised ( A M I ) Structures of 102 and 101

Compound 102 (left, Figure 5-9) had a calculated Hl'-H2' dihedral angle of 170°
which correlated to the coupling constant seen in the experimental data, of 8.2

Similarly, the coupling constant found for 101, being 3.0 Hz, corresponds with d
angle, found to be 85°.
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5.4 Deprotection of Diols 101 and 102
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Scheme 5-5 Deprotection of Diols

The use of acid labile protecting groups throughout this synthesis allowed the

use of a single, all encompassing deprotection using hydrochloric acid/acetone solutio

heated to reflux for 2 h. This gave the title compounds in yields of 81% and 88% for t
1R- and 15- compounds (103 and 104), respectively, from their corresponding diols.
As found in the previous synthesis, the !H NMR spectra for these isomers were

extremely similar and the lack of resolution, so characteristic of these spectra, prev
meaningful analysis. To confirm the identity of these compounds, the acetate
derivatives were synthesised.
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5.5 Acetylation of Final Products
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Scheme 5-6 Acetylation of Hexols using Perchloric Acid Catalyst
The use of perchloric acid to catalyse the acetylation of 103 and 104 in

anhydride allowed access to the final products 105 and 106 without the ne

pyridine catalysis, which is one of the more favoured methods. Although th

perchloric acid has its downfalls, the quantity required is far more easil
the amount of pyridine required to catalyse the same reaction.
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a

,—rb^ch^V^
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Figure 5-10 Structure of Deprotect Hexol Showing *H NMR Labelling
The !H NMR spectra of the two acetate derivative 105 and 106 isomers were
similar but more readily resolved than those found for the polyhydroxyl compounds.
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Figure 5-11 *H N M R (CDC1 3 ) of 105 (top) and 106 (bottom-also shows small
amounts of 105))
The JH NMR spectra (Figure 5-11) obtained for these analogues was consistent

with the propsed structures. Clearly evident were an AB-X (Hf, Hga and Hgb) co

system and four other single protons, as well as 6 acetate CH3 peaks and the t
methyl.
In this final synthesis, as in those shown previously, molecular modelling was

utilised as a way of confirming the structural assignments. The geometry optim

structures are shown below in Figure 5-12 and it was from these structures tha
measurements of dihedral angles was taken.

Figure 5-12 Geometry Optimised (AMI) Structures of the Hexa-acetates of 106
(left) and 105 (right).
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This data is tabulated and presented below in Table 5-1. It should be noted that
many of the correlations between the calculated data and the experimental values for
syn-isomer can only be assumed based on the accuracy of earlier evidence, as the
overlap of many signals in the *H NMR spectrum prevented the measurement of
coupling constants for those peaks. Consequently, coupling constants in bold are not
shown for every dihedral angle as they could not be unambiguously determined.

Table 5-1 Comparison O f Dihedral Angles and Coupling Constants

Assignment

1,2-syn-isomer (105)
5 (multiplicity, J in

Hz)

Dihedral
angle (°) 1,2-an/i-isomer (106)
with
5 (multiplicity, J in
previous
Hz)
proton
6.17 (lH,d, 73.2)

Dihedral
angle (°)
with
previous
proton

a

6.17 (d, 74.0)

b

5.73 (m)

69

5.68 (dd, 73.2, 5.8)

65

c

5.73 (m)

127

5.83 (dd, 75.8, 6.4)

54

d

6.12 (dd,/2.1, 5.6)

87

6.12 (dd, 76.4, 7.0)

41

e

5.61(m, 74.2,5.6,7.3)

166

5.54 (m, 74.1)

173

f

4.33 (dd, 74.2, 10.5)

101

4.40 (dd, 74.1, 10.2)

63

g

4.11 (dd, 7 7.3, 10.5)

137

4.09 (dd, 7 6.9, 10.2)

174

A comparative table of N M R data for the acetate derivatives will be presented in
the conclusion. There is a strong indication that *H NMR may be useful in predicting
the relative stereochemistries of these compounds.
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6.1 General Remarks
In conclusion eight novel thiazole analogues of THI have been synthesised in a
stereochemically defined manner (Figure 6-1).
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The stereochemistry of the compounds has been determined from a combination
of JH NMR analysis, X-ray structural analysis and molecular modelling. The biological
activities of two analogues (52 and 53) have been determined and were shown to be at
least as active as THI itself. Indications from the preliminary bioscreening suggest these
analogues have a greater degree of activity. Unfortunately, biological testing was halted
before the 6 carbon side chain analogues could be assessed, in spite of the enhanced
activity found in the 5 carbon side chain analogues. This prevented access to knowledge

pertaining to the biological importance of further extension of the side chain, and also of
the importance of the relative stereochemistries around Cl', C2' and C3'.
The reductive ring opening of lactols 48, 58, 59 and 100 proceeded with
different diastereoselectivities, with the major product being the 1,2-syn product
according to the Felkin-Ahn transition state rule.
Although the stereochemical outcomes of the reduction of ketone 87 were
unexpected, they provided a challenging insight into the idiosyncrasies of transition
state theory.

6.2 Biological Implications
Given the structural plasticity of these molecules it is not possible to state with
any certainty whether it is the additional length, or the additional functionality which
results in the enhanced activity. Given that these bioactive molecules may bind
predominantly through hydrogen bonding it is likely to be a combination of these
factors. The extra carbon chain length would allow access to suitable hydrogen bonding
sites, unreachable by the shorter analogues, thus increasing binding affinity and
therefore increasing the degree of aggregation seen.
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It is also plausible that the extra length m a y allow access to a more compact
conformation of the molecule through the extra degree of freedom that results from the
addition of another non-restrained bond. This may allow the molecule to fold or bend to
a more amenable shape and more closely follow the contours of the binding site, or even
to bend with it after binding, thereby assisting in the maintenance of a high binding
affinity.
Despite the tendency of previous work in this area to focus on the 15-isomer (as
found in THI produced via commercial caramelisation processes), this work has shown
that both the 1R- and lS-isomers of the C5 side chain analogues are capable of causing

cell aggregation to an equal if not greater degree than THI itself. This indicates a les
degree of importance may be ascribed to the stereochemistry of the Cl' position.
The synthesis of the 6 carbon side chain analogues successfully produced the
desired compounds which may have an activity in excess of those compounds tested to
date. These analogues would also allow a study into the role of the relative
stereochemistries around the C2' and C3' positions.
The act of reversing the heterocycle had a markedly noticeable effect of
decreasing the levels of lymphocyte aggregation. This indicates that the heterocyclic
nitrogen, present in all compounds of this type synthesised to date (including THI
itself), plays a critical role in the bioactivity of this compound. Nitrogen groups are
typically found intimately involved in biological binding sites. This would appear to
hold true for these molecules, where the nitrogen was heavily hindered by the side
chain, leaving a sulfur atom in its place on the unhindered face of the heterocycle.
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6.3 Synthetic Implications
The synthesis used in this project was broadly applicable to a range of
carbohydrates and compatible with a range of protecting groups. The functionalities
investigated indicate there may be an even broader application of this synthesis in
coupling a heterocycle to a functionalised alkyl chain.
Yields for the final products were generally moderate with most of the syntheses
having at least one problematic reaction which either required extensive
chromatography or recrystallisation to obtain pure products. However, the majority of
the reactions were found to be quite efficient and amenable to use in any organic
synthetic chemistry laboratory. No one synthetic methodology was found that could be
used in all instances. The general procedure, as outlined in Chapters 2, 3 and 5 is
suitable to a large range of carbohydrates but in some instances, such as those where
protection of the carbohydrate involves ring opening or rearrangement around the
anomeric carbon, it may be necessary to seek alternative chemistries. In the case of
gluconolactone, the conversion to an amide functionality served this purpose admirably,
allowing access to analogues not available under the generic methodology.
The use of carbohydrates as starting materials allowed the incorporation of the
desired stereochemistry in the final products.
Although there were some instances where the accepted transition states were
unable to fully explain the stereochemical outcomes following the reduction reactions, it
should be noted that, for the majority, they allowed accurate and reasonable
explanations and prediction as to the expected products.
Although the polyhydroxyl moieties proved problematic to analyse, the acetate
derivatives provided ready analysis. Examination of the tabulated data (Table 6-1) for
the acetate derivatives revealed that the lB. NMR signal for the HI' proton in syn-Hl'-
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H 2 ' isomers were consistently found to be 0.05-0.15 p p m further downfield than the
corresponding anri-isomers. This was the case over multiple analyses of the same
compounds, as well as over the range of analogues tested.
This information could prove valuable as a preliminary or confirmatory
analytical tool for stereochemical configurations for compounds of this type.
It was noted that in most cases (excluding 54/55) that the VS- isomer had a
lower 7r-2' coupling constant than its 1' ^-counterpart. However, given that this
represents only a 75% compliance to the trend, a larger learning set of molecules would
have to be investigated to confirm the generic utility of this analysis.
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Table 6-1 Table of *H N M R (CDC13) Chemical Shifts for Acetate Derivatives of
Polyol Compounds
H4

H1'

H2'

H3'

H4' H5a' H5b' H6a' H6b' CH3

7.94

6.40

5.44

5.33

5.22

4.33

4.17

2.68

7.90

6.25

5.57

5.18

5.24

4.30

4.10

2.69

7.53

6.24

5.70

5.35

5.21

4.37

4.15

2.68

7.59

6.18

5.75

5.40

5.29

4.35

4.07

2.63

7.91

6.34

5.58

5.87

6.01

5.49

4.41

4.14

2.72

7.87

6.23

5.67

5.81

6.06

5.41

4.39

4.15

2.74

7.87

6.17

5.68

5.83

6.12

5.54

4.40

4.09

2.69

7.85

6.11

5.71

5.76

6.05

5.61

4.33

4.11

2.72

(or 5)
OAc OAc

N^S

OAc

OAc

OAc

A 54
OAc OAc

OAc

/=<VV
N^S

OAc

0X

OAc OAc

S

OAc

55

N^N

o^

0A

°

OAc

0A

°

65
OAc OAc

S^N

OAc

0X

64

OAc

OAc

OAc OAc

N^S

OAc

OAc OAc

OAc

<A 94
OAc OAc

N^S

OAc OAc

0X

95

OAc

OAc OAc

OAc

OAc

N^^S

OAc OAc

0X

105
OAc OAc

N.^.S

OAc OAc

0X

106

OAc

OAc

OAc

186

Chapter 6 - Conclusion

Table 6-2 Jv.r Coupling Constant for Polyacetate Derivatives

Jv-z Configuration
OAc OAc OAc

N^S

OAc OAc

4.6

VS, 2'R

3.7

YR,2'R

4.1

VS,2'R

5.5

VR,2'R

3.9

rs,2'R

4.2

VR,2'R

4.0

VR,2'S

3.2

VS,2'S

cA 54
OAc OAc OAc

0X

55
OAc OAc OAc

S^N

OAc OAc

0X

65
OAc OAc OAc

s

v^N

o^

0Ac

0Ac

64
OAc OAc OAc

r-rVrS
N^,S

0X

OAc OAc OAc

94

OAc OAc OAc

N^S

OAc OAc OAc

0X

95
OAc OAc OAc

N^,S

OAc OAc OAc

0X

105
OAc OAc OAc

N^S

OAc OAc OAc

| 0 X 106
The chemical shifts found for the reduced species followed the same trend as
was observed for the polyacetates, possibly furthering the evidence that the relative

positioning of the HI' proton signal in the *H NMR spectra for the two isomers could be
useful in determining the relative stereochemistry about this position. This trend was
also found in the reduced species, prior to deprotection, as seen in Table 6-3.
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Table 6-3 Tabulated *H N M R Data (CDC13) for the Reduced Species
H4 (or
H1'
5)
OH

H2'

H3'

H4'

H5a' H5b' H6a' H6b'

OH
,OTBDMS

N

vs CV°
A
OH

7.69

5.39

4.35

4.11

4.03

3.79

3.65

7.78

5.13

4.27

4.13

3.87

3.91

3.66

7.31

5.33

4.67

4.14

4.08

3.85

3.71

7.26

5.07

4.53

4.21

3.98

3.92

3.73

7.64

5.17

4.00

4.15

3.88

4.00

4.00

4.00

7.67

5.04

3.79

4.07

3.96

3.88

3.96

3.88

7.75

5.30

4.42

4.43

4.05

3.64

4.10

4.10

7.76

5.27

4.28

4.44

4.02

3.95

4.06

4.06

61
OH
OTBDMS

OH

OH
OTBDMS

OH

OH
, OTBDMS

S

N^ N ° Y °
O
\

A

50

OH

OH

OH

OH
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Table 6-4 Jv.v Coupling Constants for Reduced Species
Jr.a- (Configuration
OH
^L
N

OH
.^^OTBDMS

V S °V°

I

2.8

VS,2'R

9.2

VR,2'R

1.8

VS,2'R

9.14

VR,2'R

2.8 or
1.1

1'S, 27?

5.1

17?, 27?

8.2

17?, 27?

3.0

1'S, 2'S

A

f^\
OH

61

OH
s*^s OTBDMS

Jl

Xs ° v °
o" °^

60

/

OH
OH
_JL_A^,OTBDMS

r N

* <v°

o"
/
OH
S^

OH
J^s OTBDMS

S N

Y °Y°

0' "°
v
/

50

A

HO

S—J

H~\ °V°
y

TBDMS

'»

fr\

90

X

H0>)—J

N*.^S

y

'
TBDMS

fT^
OH

A
'»

91
OH

N y S 0^0 0^0

o" ^

101

/

OH

OH

N y S 0*^0 0^,0

o"
/

^

102
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The 7r-2' coupling constants for the reduced species were observed to follow the
same trend first noticed in the polyacetate species (Jr.? anti >JV-T syn) possibly
furthering evidence towards the generic utility of the use of 7 values as a preliminary
analytical tool. Unfortunately, some ambiguity is introduced by the lack of resolution
that lead to some coupling constants (as for 90) being deduced.
This current work brings to a close the search by this research group for novel
anti-inflammatory drugs based on the THI lead compound.
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7.1 General Procedures
Melting points were determined on a Gallenkamp hot-stage apparatus and are
uncorrected.
All NMR spectra were recorded on either a Varian Unity 300 FT. NMR
Spectrometer operating at 300 MHz (]H NMR) or 75MHz (13C NMR) or a Varian Unity
400 FT. NMR Spectrometer operating at 400 MHz (!H NMR) or 100MHz (13C NMR).
Chemical shifts (8) are reported in parts per million (ppm). Tetramethylsilane (TMS)
was used as the nominal internal standard for all spectra recorded in deuterated

chloroform (CDCI3) and is referenced at the residual solvent singlet at 8 7.26 ppm in

proton spectra, and for carbon NMR, at the central of three residual solvent signals
77 ppm. Proton spectra recorded in deuterated water (D20) were referenced against the
residual solvent peak at 8 4.75 ppm. NMR data is recorded in the following format:

chemical shift (8) (integrated intensity, multiplicity (s; singlet, d; doublet, t; tr

quartet, m; multiplet, b; broad signal, dd; doublet of doublets, and so on), coupling
constant (where applicable) (Hz), and assignment). Chemical shifts and coupling
constants for multiplets may be approximate values. Carbon spectra are reported a
follows: chemical shift (8) (assignment based on DEPT analysis).
Chemical shifts are reported to two decimal places except where peak proximities

require further elucidation. In such cases, these values are reported to three decima
places.
1 IT

Pulse sequences used during one- and two-dimensional N M R included H,

C,

Correlated Spectroscopy (COSY), gradient Correlated Spectroscopy (gCOSY), Nuclear
Overhauser Effect Spectroscopy (NOESY), Heteronuclear Multiple Quantum
Correlation (HMQC), Heteronuclear Correlated Spectroscopy (HETCOR),
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Heteronuclear Multiple Bond Correlation ( H M B C ) , Distortionless Enhancement by
Polarisation Transfer (DEPT), gradient Heteronuclear Multiple Quantum Correlation
(gHMQC) and gradient Heteronuclear Multiple Bond Correlation (gHMBC).
Low resolution mass spectra were recorded on a VG Quattro triple quadrupole
mass spectrometer. The protonated molecular ion (M+ H+) and other significant
molecular peaks (where present, or relevant) are reported in the following order:
(Ionisation type), m/z value, ion fragment (relative intensity).
Microanalyses were performed by the Microanalytical Service Unit, Queensland
University, Queensland.
Thin Layer Chromatography was carried out using plastic or aluminium sheets
coated with a 0.2 mm thick layer of Merck Kieselgel 60 F254. Developed sheets were
visualised under shortwave ultraviolet light and peaks noted before staining with
ammonium molybdate dip. A heat gun was used to dry the plates and peaks were noted.
Column chromatography was performed under gravity pressure using Merck 60 silica
gel, or under hand pump pressure using Merck 40 silica gel, compounds were eluted
using AR grade solvents as indicated.
Where required, solvents were purified using established techniques. Both
tetrahydrofuran (THF) and diethyl ether were dried and distilled as required. THF and
diethyl ether were dried over sodium wire and distilled from a dark blue solution of
sodium-benzophenone ketyl, under a nitrogen atmosphere. Dichloromethane, N,N-

dimethylformamide and acetonitrile were distilled from calcium hydride and stored ove
molecular sieves (4A) under nitrogen. Methanol was purified by distillation from
magnesium methoxide. All dry solvents were handled under anhydrous conditions.
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All reactions, particularly those involving anhydrous reagents, were carried out
using glassware that had been oven dried and cooled to room temperature in a
desiccator under nitrogen, prior to use.
Organic extracts were dried over magnesium sulfate before filtering and
concentrating in vacuo on a Buchi rotary evaporator. High vacuum was used to remove
the last traces of solvent. Compounds required as anhydrous reagents were dried under
high vacuum in a Buchi Kugelrohr rotary oven.
Molecular modelling was carried out using the "Spartan" software package. The
MM1 forcefield was chosen as the most appropriate set of parameters based on the
molecular weight and functionalities of the compounds studied.

7.2 Experimental Procedures

7.2.1 Synthesis of 2-acetyl-5-[(l', TR, 3'R, 4'R, 5')-pentahydrox
pentyl]thiazole
2-(l,l-Dimethoxyethyl]thiazole(46) 194, 269

I
N

\
V

S

cr ^
45

NU

S

TMOF. p-TsOH,^
MeOH(anh)

O

/

\
46

T o a solution of commercially available 2-acetylthiazole 45 (5.00 g, 39.3 m m o l )
in dry methanol (125 cm3) was added trimethyl orthoformate (46.7 cm3, 41.7 g, 393
mmol) and p-toluenesulfonic acid monohydrate (6.75 g, 39.3 mmol, 1 equivalent). The
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mixture was heated under reflux conditions for 24 h, before cooling and pouring into

saturated sodium bicarbonate solution (250 cm3). The reaction mixture was extract

with diethyl ether (3 x 150 cm3). The organic fractions were combined and then wa
sequentially with IM sodium hydroxide (3 x 100 cm3) and saturated sodium chloride

solution (3 x 100 cm3) before drying over magnesium sulfate. Concentration in vacu
yielded 46 a light brown oil (6.749g, 99%) that was spectrally identical to that

in the literature.194'm 8H (300MHz; CDCI3;) 7.81 (1H, d, 7 2Hz, NCH), 7.31 (1H, d, 7
2Hz, SCH), 3.23 (6H, s, 2 OMe), 1.72 (3H, s, Me).

2,3-0-Isopropylidene-D-ribose (42)189,190'192

HO
HO ^/°Y^OH
^/°\^OH cone HCI.

r

\J

\ I acetone c '-

HO OH jC
42
41

Commercially available D-ribose 41 (12 g, 79.9 mmol) was suspended in a

mixture of acetone (240 cm3) and concentrated hydrochloric acid (3 cm3) and stirr

1 h. The mixture was then neutralised with solid sodium carbonate and filtered t
celite. Concentration of the mixture in vacuo yielded the crude product 42 as a
yellow oil (15.125 g, 99%), which was used as such for the next reaction.
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5-0-(tert-Butyldimethylsilyl)-2,3-0-isopropylidene-D-ribofuranose(43)189192

HO

TBDMSO

OH

SV
c

L/°yOH
TBDMSCI,
Imidazole, D C M *

\

\
/

/
\

°x°

°x°

42

43

2,3-O-isopropylidene-D-ribose 42 (15.465 g, 81.3 mmol) was dissolved in
dichloromethane (75 c m ) at room temperature and imidazole (13.84 g, 203 mmol, 2.5
equivalents) andterf-butyldimethylchlorosilane(13.47 g, 89.4 mmol, 1.1 equivalents)
were added to the solution which was left stirring for 3 h. The mixture was then
quenched with water (25 c m ) and extracted with ethyl acetate (3 x 75 cm ). The
combined organic extracts were washed with water (3 x 75 cm 3 ), dried over magnesium
sulfate and concentrated in vacuo to yield 43, a light yellow oil (24.557 g, 99.2%) which
was used crude in the next reaction. *H N M R analysis of the crude product showed the
expected peaks for the desired product.192 8 H (300 M H z ; CDCI3) 5.28 (1H, d, 7 11.8 Hz,
HI), 4.78 (1H, d, 7 11.8 Hz, O H ) , 4.69 (1H, d, 7 5.9 Hz, H2), 4.49 (1H, d, 7 5.9 Hz, H3),
4.35 (1H, m, H4), 3.75 (2H, m, OCH2), 1.49 (3H, s, CMeMe), 1.31 (3H, s, CMeMe),
0.95 (9H, s, CMe 3 ), 0.15 (6H, s, SiMe2).

5-0-(ter^Butyldimethylsilyl)-2,3-0-isopropylidene-D-ribonolactone(44)189

TBDMSO

TBDMSO

^/°N^OH
\
c

j
'-.

43

V
KMn0 4>>
Acetone

t>

X
44
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5-0-(ferr-Butyldimethylsilyl)-2,3-0-isopropylidene-D-ribofuranose 43 (23.9 g,

78.5 mmol) was dissolved in reagent grade acetone (100 cm3) and the mixture wa

stirred at room temperature until no solid remained. Potassium permanganate (1

117.75 mmol, 1.5 equivalents) was added over 1 h and the mixture was then stir

further 2h. The reaction mixture was diluted with water and extracted with die

(3 x 100 cm3). The combined organic extracts were washed with water until colo

then dried over magnesium sulfate before concentrating in vacuo to a clear oil
of 44 formed on standing, which were recrystallised from 1 % ethyl acetate in

ether (23.304g, 98.2%). mp: 68-70 °C (lit.189 69-70 °C) 8H (300 MHz; CDCI3) 4.72
(2H, m, HI, H2), 4.61 (1H, br.t, 7 2 Hz, H3), 3.85 (2H, ddd, 7 2 Hz, 12 Hz, 29
OCH2), 1.48 (3H, s, CMeMe), 1.39 (3H, s, CMeMe), 0.88 (9H, s, CMe3), 0.075 (3H, s,
SiMe), 0.06 (3H, s, SiMe).

2-(l,l-Dimethoxyethyl)-5-[(5-0-(tert-butyldimethylsilyl)-2,3-0-isopropylideneribonolactonojthiazole (48)

O

-.2* ;3

=
N/ \g n-BuLi, THF(anh.)v HO,
X

TBDMSO

4

5,

w

°N^O
O

'°\

/

46

O

~ T
2

OTBDMS

s

rv i

1

°\/ 0

44 A

/^

O' O\

/

48
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A solution of n-butyllithium (3.54 cm 3 , 1.4M in hexanes, 4.95mmol, 1.5
equivalents) was added with stirring to a cooled (-78 °C) solution of 2-(l,l-

dimethoxyethyljthiazole 46 (570 mg, 3.3 mmol, 1 equivalent) in dry tetrahydrofur

cm3). After stirring for 40 min, a solution of 5-0-(fe^butyldimethylsilyl)-2,3isopropylidene-D-ribonolactone 44 (995 mg, 3.3 mmol, 1 equivalent) in dry

tetrahydrofuran (10 cm3) was added dropwise and stirring at -78 °C was continue
90 min. The reaction was quenched by pouring into saturated ammonium chloride

solution (50 cm3) and was extracted with dichloromethane (3 x 50 cm3). The comb
organic extracts were washed with saturated sodium chloride solution and dried

magnesium sulfate, before concentrating in vacuo to yield a white crystalline s

Recrystallisation from ethyl acetate / hexanes yielded pure 48 (1.001 g, 64%) m

149°C. (Found: C, 52.98; H, 7.89; N, 2.84% Calc. for C2lH37N07SSi: C, 53.03; H,

7.84; N, 2.94%) 8H (300 MHz; CDCI3) 7.90 (1H, s, H4), 5.65 (1H, s, OH), 4.90 (1

dd, 7 1.5, 5.7, Hz, H3'), 4.59 (1H, d, 7 5.7 Hz, H2'), 4.42 (1H, br.s, H4'), 3.

H5a' and H5b'), 3.24/3.22 (6H, 2s, (0-Me)2), 1.75 (3H, s, Th-C-Me), 1.50 (3H, s, O-C
Me), 1.25 (3H, s, O-C-Me), 0.98 (9H, s, C-Me3), 0.19 (3H, s, Si-Me), 0.18 (3H, s, Si-

Me); 8C (75.6 MHz; CDCI3) 172.6 (C), 141.8 (CH), 137.4 (C), 113.1 (C), 105.2 (C
101.1 (C), 88.3 (CH), 86.2 (CH), 81.9 (CH), 64.6 (CH2), 49.4 (Me), 49.4 (Me), 26.6
(Me), 25.8 (Me3), 25.1 (Me), 24.2 (Me), 18.3 (Me), -5.6 (Me), -5.7 (Me) HRMS (ES
+ve) m/z 476.2138 (M+H+; C2lH38N07SSi requires 476.2138), 444 (100%).
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2-(l,l-Dimethoxyethyl)-5-[(l'S, VR, 3'R, 4'/?)-tetrahydroxy-2',3'-CMsopropylidene

-5'-(0-terf-butyldimethylsiloxy)pentyl]thiazole (51) and 2-(l,l-Dimethoxyethyl)-

[(VR, VR, 3'R, 4'/Jj-tetrahydroxy-2',3'-0-isopropylidene-5'-(0-te^-butyldimethyl
siloxy)penty!lthiazole (50)

0^0
OH
HO.
r° O
H
N^,S

X

1
NaBH4,
p=\ n ] \ *
OTBDMS MeOH,o'°C* N<s/S 0
0
1
3^^
*

48
0

o

o^

OH

(1'S)-50

'9 (1'fl)-51

/

Sodium borohydride (596 mg, 15.7 mmol, 7.5 equivalents) was added to a
stirred solution of 48 (1 g, 2.1 mmol) in dry methanol (50 cm3) at 0 °C over a

1 h. The reaction was left for 3 h at 0 °C before quenching with saturated ammon

chloride solution (50 cm3). Extraction with dichloromethane (3 x 50 cm3) yielded

organic fraction which was washed with saturated sodium chloride solution and d

over magnesium sulfate before concentrating in vacuo. The crystalline crude pro
(961 mg, 96%) was purified by column chromatography using silica gel (1:1 ethyl

acetate/hexane) to yield two isomers 51 (461mg, 48%, fine powdery solid, mp 150

°C) and 50 (442 mg, 46%, crystalline solid, mp 88-89 °C). 51 8H (300 MHz; CDCI3)

7.69 (1H, s, H4), 5.39 (1H, dd, 7 1.8, 7.8, HI'), 4.35 (1H, dd, 7

dd, 7 6.2, 9.3, H3'), 4.03 (1H, m, H4'), 3.79 (1H, dd, 7 3.1, 10.1, H5(a)'), 3.65 (1H,
7 4.9, 10.1, H5(b)'), 3.27 (1H, d, 7 7.8, OH1'), 3.22 (6H, 2s, OMe), 2.9 (1H, d, 7 5.7,
OH4'), 1.68 (3H, s, ThCMe), 1.50 (3H, s, Me), 1.32 (3H, s, Me), 0.9 (9H, s, CMe3),
0.09 (6H, s, 2SiMe); 8C (75.6 MHz; CDCI3) 172.0 (C), 140.9 (C), 140.1 (CH), 108.9
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(C), 101.0 (C), 79.6 (CH), 76.2 (CH), 69.3 (CH), 66.0 (CH), 64.2 (CH 2 ), 49.4 (Me),

49.3 (Me), 26.7 (Me), 25.8 (Me)3, 24.6 (Me), 24.1 (Me), 18.2 (C), -5.4 (Me), -5.5 (Me
HRMS (ES+ve) m/z 478.2294 (M+H+; (40%), C2lH40NO7SSi requires 478.2294), 446

(100%). 49 8H (300MHz; CDC13; Me4Si) 7.78 (1H, d, 7 0.7, H4), 5.13 (1H, dd, 7 3

9.14, HI'), 4.91 (1H, d, 73.04, OH1'), 4.27 (1H, dd, 75.33, 9.14, H2'), 4.13 (1H,

5.33, 9.45, H3'), 3.91 (1H, m, H5a'), 3.87 (1H, m, 7 3.3, H4'), 3.66 (1H, dd, 7 8.11,
10.81, H5b'), 3.39 (lH,d, 7 3.3, OH4'), 3.24 (6H, 2s, OMe), 1.71 (3H, s, ThCMe),

(3H, s, OCMe), 1.28 (3H, s, OCMe), 0.91 (9H, s, t-butyl), 0.096 (6H, s, 2SiMe);

(75.6MHz; CDCI3) 171.39 (C), 140.36 (C), 140.21 (CH), 109.13 (C), 101.02 (C

(CH), 77.131 (CH), 69.31 (CH), 66.52 (CH), 64.14 (CH2), 49.42 (Me), 49.35 (Me
28.01 (Me), 25.82 (Me)3, 25.35 (Me), 24.15 (Me), 18.27 (C), -5.40 (Me), -5.46
HRMS (ES +ve) m/z 478.2294 (M+H+; (40%), C2lH4oN07SSi requires 478.2294),
446 (100%).

2-Acetyl-5-[(17?, VR, 3'R, 4,#,5')-pentahydroxypentyl]thiazole (53)

OH OH

OH

OTBDMS
N^.S O

O

A

r

'O 50
\

HCI,
acetone0^\

N

<ys

OH

OH

OH

OH

53

A solution of 50 (200 mg, 0.42 mmol) in a 25 c m 50:50 mixture of acetone and

10% hydrochloric acid was heated to reflux for 2 h. Upon completion, the ac

removed in vacuo and the remaining aqueous solution was washed exhaustively

diethyl ether. The water was removed in vacuo, leaving the crude product, 53
yellow oil (106 mg, 91%). 1 H N M R analysis showed this product to be > 9 5 % pure. 8 H
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(300 M H z ; D 2 O ) 7.77 (1H, s, H4), 5.22 (1H, s, HI'), 3.73 (1H, dd, 73.3, 7.2, H2'), 3.67

(1H, dd, 74.4, 8.4, H4'), 3.56 (2H, m, H3' and H5a'), 3.45 (1H, dd, 7 7.5, 12, H5b');

(75.6MHz; D2O) 212.1 (C), 183.9 (C), 167.4 (C), 159.3 (C), 92.3 (CH), 90.9 (C

(CH), 85 (CH), 80.1 (CH2), 43.8 (Me) HRMS (ES -ve) m/z 276.0537 (M-H+; (35%)
C10H14NO6S requires 276.0538), 312 (HCI salt) (100%).

2-Acetyl-5-[(l'S, VR, 3'R, 47?,5')-pentahydroxypentyl]thiazole (52)
0H

?H OH OH OH

N<

O'

^S V
^

acet^
51

N

^S

O ^

OH OH
52

/

Compound 51 (200 mg, 0.42 mmol) was hydrolysed as described above for the

preparation of 2-(acetyl)-5-[(l'JR, TR, VR, 4'R, 5')-pentahydroxypentyl]th

The product, 52 was obtained as a dark yellow oil (103 mg, 89%). !H NMR ana

showed this product to be >95% pure. 8H (300 MHz; D2O) 7.77 (1H, s, H4), 5.

73.9, HI'), 3.78 (1H, dd, 7 4.1, 8.1, H2'), 3.61 (1H, m, H4'), 3.51 (1H, dd,
H5a'), 3.37 (1H, dd, 77.4, 11.9, H5b'), 3.14 (1H, dd, 74.5, 8.1, H3'); 8C (75.6 MHz;
D20) 212.1 (C), 184.7 (C), 164.4 (C), 160.6 (C), 91.7 (CH), 90.7 (CH), 90.1
(CH), 80.1 (CH2), 43.8 (Me) HRMS (ES -ve) m/z 276.0538 (M-H+; (40%)
C10H14NO6S requires 276.0538), 312 (HCI salt) (100%).
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2-Acetyl-5-[(17?, 2'R, 3'R, 4'R, 5')-pentaacetoxypentyl]thiazole (55)

OH

OH

OH

s

/
\
N^/S

I
OH
53

O

I
OH

OAc
Acetic anhydride,
glac. acetic acid
/
Perchloric acid/ " N ^ S
T
acetic anhydride (Cat.)
A^
O ^ ^

OAc

OAc

OAc

OAc

55

To a stirred solution of acetic anhydride (3 c m ) and glacial acetic acid (5 c m )

was added a sample of the pentol 53 (100 mg, 0.36 mmol). A perchloric acid/aceti
anhydride catalyst (1 g of 70% HCIO4 in 2.3 g of acetic anhydride) was added (4
and the mixture was stirred at 60 °C for 1 h before being poured into ice water

After extraction with ethyl acetate (3 x 20 cm3) the combined organic extracts w

dried over magnesium sulfate and concentrated in vacuo. The product 55 was purif
by semi-preparative TLC on silica gel plates, (eluent 50% ethyl acetate/hexane)

a pale yellow oil (110 mg, 63%). 8H (300MHz; CDCI3) 7.94 (1H, s, H4), 6.40 (1H, d

3.7, HI'), 5.44 (1H, dd, 7 3.7, 7.6, H2'), 5.33 (1H, dd, 7 4.0, 7.
3.3, 11.0, H4'), 4.33 (1H, dd, 7 3.3, 12.1, H5a'), 4.17 (1H, dd, 7 7.8, 12.1, H5b'), 2.68

(3H, s, Me), 2.16 (3H, s, Ac), 2.10 (3H, s, Ac), 2.094 (3H, s, Ac), 2.090 (3H
2.04 (3H, s, Ac) HRMS (CI+) 488.1226 m/z (M+H+; C20H26NO11S requires
488.1226) 428 (65%), 386 (77).
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2-Acetyl-5-[(l'S, VR, 3'R, 4'R, 5')-pentaacetoxypentyl]thiazole (54)

OH

N^.S

OH

OH
52

O<

^

OH

OH

OAc
Acetic anhydride,
glac. acetic acid
/
Perchloric acid/ * N ^ S
acetic anhydride (Cat.)

OAc

OAc

OAc

OAc

54

O^ \

The title compound was prepared from 2-acetyl-5-[(l'S, TR, VR, 4'R, 5')-

pentahydroxypentyl]thiazole (52) (100 mg, 0.36 mmol) as described previously.

product was purified by semi-preparative TLC on silica gel plates (eluent 50%

acetate/hexane) to yield 54, a pale yellow oil (101 mg, 58%). A crystal suita

diffraction analysis was grown from a saturated solution of 54 in diethyl eth

MHz; CDC13) 7.9 (1H, s, H4), 6.25 (1H, d, 7 4.6, HI'), 5.57 (1H, dd, 7 4.6, 6

5.24 (1H, m, 3.3, 6.7, H4'), 5.18 (1H, dd, 7 5.2, 6.2, H3'), 4.30 (1H, dd, 7 3

H5a'), 4.1 (1H, dd, 7 6.7, 12.2, H5b'), 2.69 (3H, s, Me), 2.16 (3H, s, Ac), 2.09 (3H, s

Ac), 2.07 (3H, s, Ac), 2.03 (3H, s, Ac), 2.01 (3H, s, Ac) HRMS (CI+) m/z 488.1
(M+H+; C20H26NO1 iS requires 488.1226) 428 (65%) 386 (37).
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7.2.2 Synthesis
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of

2-acetyl-4-[(l',

VR,

3>R,

4'R,59)-

pentahydroxypentyljthiazole

2,4-Dibromothiazole (32)130
,0 OH Br

r-4
\

K
s

/

Y

l \

POBr 3 , 150°C

s

~~ r — " r.

O

OH

Br

2,4-Thiazolidenedione (4.5 g, 38 mmol) and phosphorus oxybromide (33 g, 115

mmol, 3 equivalents) were combined and heated to 150 °C under nitrogen. After s

for 26 h, the reaction was cooled and quenched with ice water, before extractin
o

diethyl ether (3 x 150 c m ). The combined organic fractions were washed with saturated
sodium chloride solution (100 cm) and dried over magnesium sulfate before

concentrating in vacuo to yield the crude compound 32 (6.029 g, 65%) 8H (300 MHz
CDCI3) 7.21 (1H, s, H5)

2-Acetyl-4-bromothiazole (56)130

/Br

Br

/\ n-BuLi, ether, -78 °rC s/ \j
S \ ^ N 4-acetylmorpholine
N^
56

oo T
32

Br

0

<K
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2,4-Dibromothiazole 32 (6.0g, 24.7mmol) was dissolved in anhydrous diethyl
ether (55 cm3) and cooled to -78 °C while stirring under nitrogen. After addition

butyllithium (20 cm3, 1.5 M solution in hexanes, 1.2 equivalents, 30.2 mmol), stirri

was continued for 30 min before the dropwise addition of Af-acetylmorpholine (2.8

1 equivalent). The mixture was stirred at -78 °C for 90 min then diluted with diet
ether before the solution was washed with saturated sodium bicarbonate solution.
drying over magnesium sulfate and filtering, the solvent was removed in vacuo to

a dark yellow solid. Purification by column chromatography using gradient elution

100% hexane-100% ethyl acetate in 10% intervals, gave 56 as a white crystalline so
(3.003g, 59%), mp 87-89 °C (lit. 90-91 °C).130 8H (300MHz; CDCI3) 7.58 (1H, s, H5),
2.72 (3H, s, OCMe).

4-Bromo-2-(l,l-dimethoxyethyl]thiazole (57)269

Br
S
N MC(OMe)a, p-TsOH,
Y reflux
56

~^\ o'
O ^ ^

,N
S ^
57
"O
\

/

2-Acetyl-4-bromothiazole 56 (1.695 g, 8.23 mmol) was dissolved in dry

methanol (30 cm3) and the solution was added to a mixture of trimethylorthoformat
(7.5 cm3, 63 mmol) and p-toluenesulfonic acid (1.41 g, 8.23 mmol, 1 equivalent).

mixture was heated to reflux for 24 h. After cooling, the mixture was diluted wit
saturated sodium bicarbonate (50 cm3) and then extracted with diethyl ether (3 x
cm3). The combined ether extracts were washed with 1 M sodium hydroxide, then
saturated sodium chloride solution, and dried over magnesium sulfate before
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concentrating in vacuo. Purification by column chromatography using 1 0 % ethyl

acetate/hexane as eluent, gave a pale yellow solid, 57 (1.95g, 94%) mp 48-50 °C (l
49-50 °C).130 SH (300MHz; CDCI3) 7.23 (1H, s, H5), 3.25 (6H, s, 2(OMe)), 1.73 (3H, s,
C-Me).

2-((l,l-DimethoxyethyI)acetyl)-4-[(5-0-(tert-butyldimethylsilyI)-2,3-0isopropylidene-D-ribonolactono]thiazole (58 and 59)

TBDMSO

44
,0

O

P

O
^0
5' ,..(4* Y

B

x

rw

0 0

'H

N/

N^S

TBDMSO

n-BuLi, -78°C,

57

+

H

T

O'
/

TOH

5' M

tvsi
./

/

r" V r ^

V TBDMSO
"O
\

*0
/

\

58 Major isomer

59 Minor isomer

4-Bromo-2-(l,l-dimethoxyethyl]thiazole 57 (520 mg, 2.06 mmol) was dissolved

in anhydrous diethyl ether (10 cm3) and cooled to -78 °C before addition of n-BuLi

cm3, 1.4 M solution in hexanes, 3.1 mmol, 1.5 equivalents). After stirring at -78 °
30 min, a solution of 5-0-(?err-butyldimethylsilyl)-2,3-(9-isopropylidene-D-

ribonolactone 44 (623 mg, 2.06 mmol) in dry diethyl ether (5 cm3) was added dropwis

The reaction was left stirring at -78 °C for 90 min, before pouring into saturated
ammonium chloride solution (15 cm3) and extracting the aqueous layer with with

dichloromethane (3 x 25 cm3). The combined organic layers were washed with saturat

sodium chloride solution before drying over magnesium sulfate and concentrating in
vacuo to yield a yellow oil (433mg, 44%). *H NMR analysis showed this to be a
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mixture of isomers which included the thiazole C5 addition product 48. Purification of

the crude reaction mixture by column chromatography using 30% ethyl ac

as eluent gave 48 as a crystalline solid (142 mg, 14.5%) and 58 and 59

isomers (69:31 Syn:Anti). A small sample (50 mg) of this mixture was s

column chromatography using gradient elution from 100% hexane-100% eth

in 10%? intervals to give pure samples of 58 and 59. 59 8H (300 MHz; C

s, H5), 5.26 (1H, s, OH), 4.98 (1H, d, 7 6.8, H2'), 4.85 (1H, dd, J3.2,
(1H, ddd, 7 3.2, 4.2, 5.2, H4'), 3.77 (1H, dd, 7 5.2, 11, H5b'), 3.71 (1H, dd,

H5a'), 3.23 (3H, s, OMe), 3.18 (3H, s, OMe), 1.68 (3H, s, Me), 1.62 (3H, s, Me)

(3H, s, Me), 0.83 (9H, s, tert-bwtyl), 0.01 (3H, s, SiMe), -0.01 (3H, s,

(ES+ve) m/z 476.2128 (M+H+, C2lH38N07SSi requires 476.2128). 58 8H (300
CDCI3) 7.46 (1H, s, H5), 4.86 (1H, dd, 7 1.3, 5.8, H3'), 4.75 (1H, d,
(1H, s, OH), 4.38 (1H, ddd, 7 1.3, 3.5, 4.7, H4'), 3.86 (1H, dd, 74.7,

(1H, dd, 7 3.5, 10.8, H5a'), 3.21 (3H, s, OMe), 3.18 (3H, s, OMe), 1.68 (3H, s,

1.34 (3H, s, Me), 1.24 (3H, s, Me), 0.91 (9H, s, /erf-butyl), 0.11 (3H, s, S

s, SiMe) HRMS (ES+ve) m/z 476.2127 (M+H+; C2lH3gN07SSi requires 476.212

2-(l,l-Dimethoxyethyl)-4-[(l'S, VR, 3'R, 4'fl)-tetrahydroxy -2,3-0-iso
5-[(0-fe^-butyIdimethylsiloxy)pentyl]thiazole (60 and 61)

OTBDMS
NaBhh

1

9

(1fl)-60
(1S)-61
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Sodium borohydride (32 mg, 0.85 mmol, 1.5 equivalents) was added to a cooled,
stirred solution of a (69:31) mixture of 58 and 59 (269 mg, 0.56 mmol)

(5 cm3) over a period of 1 h. After stirring for 3h, the reaction was q

saturated ammonium chloride solution (3 x 10 cm3) and extracted with di

(3 x 25 cm ). The combined organic fractions were washed with saturated

chloride solution (3 x 50 cm3) and dried over magnesium sulfate. Concen

vacuo yielded the crude product as a mixture of isomers 60 and 61, in a

respectively. Purification by column chromatography (eluent 25% ethyl a

gave 60 as a white crystalline solid (56 mg, 21%) and 61 as an orange o
30%). 60 8H (300MHz; CDCI3) 7.26 (1H, s, H5), 5.07 (1H, dd, 7 4.1, 9.2,
(1H, d, 7 4.1, OH1'), 4.53 (1H, dd, 7 5.2, 9.2, H2'), 4.21 (1H, dd, 7 5.2, 9.5,

(1H, m, H4'), 3.92 (1H, dd, 7 2.9, 10.0,H5b'), 3.73 (1H, dd, 7 6.3, 10.0, H5a'
(1H, d, 73.6, OH4'), 3.25 (6H, 2s, 2(OMe)), 1.71 (3H, s, ThCMe), 1.36 (3H, s,

1.26 (3H, s, OCMe), 0.9 (9H, s, tert-butyl), 0.09 (6H, s, Si(Me)2); 8C (75.

CDCI3) 171.28, 156.23, 116.78, 108.65, 100.91, 79.91, 77.06, 69.48, 68.08

49.33, 27.99, 25.86, 25.42, 24.2, 18.325, -5.38. HRMS (ES+ve) m/z 478.229

C2lH40NO7SSi requires 478.2294). 61 8H (300MHz; CDCI3; Me4Si) 7.31 (1H, s

5.33 (1H, dd, 7 2.8, 6.7, HI'), 4.67 (1H, dd, 7 2.8, 5.9, H2'), 4.14 (1
H3'), 4.08 (1H, m, H4'), 3.85 (1H, dd, 7 3.1, 10.2, H5b'), 3.71 (1H, dd, 7 5.1,

H5a'),3.41 (lH,d,7 6.7,OHl'),3.21 (6H, 2s, 2(OMe)), 3.20 (1H, d, 7 5.4, O

(3H, s, ThCMe), 1.45 (3H, s, OCMe), 1.29 (3H, s, OCMe), 0.88 (9H, s, SiC(Me)3

(6H, s, Si(Me)2); 8C (75.61MHz, CDCI3) 171.63, 157.72, 115.64, 108.32, 10

78.92, 76.39, 69.24, 64.38, 49.40, 49.36, 27.26, 25.86, 24.89, 24.31, 18.3
HRMS (Cl+ve) m/z 478.2294 (M+H+; C2lH4QN07SSi requires 478.2294).
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2-Acetyl-4-[(l'JK, VR, 3'R, 4'R, 5')-pentahydroxypentyl]thiazole (62)

OH

OH

OH

OH

OH

OTBDMS
Acetone/10%HCI

A solution of the diol 60 (97 mg, 0.203 mmol) was heated to reflux in a 50:50
mixture (10 cm3) of acetone and 10% hydrochloric acid solution for 2 h. Upon
completion, the acetone was removed in vacuo and the remaining aqueous solution
washed with diethyl ether. The water was removed in vacuo, leaving 62, the crude
product as a dark yellow oil (49 mg, 87%).'H NMR analysis showed this product to
>95% pure. 8H (300MHz; D2O) 7.27 (1H, s, H5), 5.05 (1H, d, HI'), 3.4-3.95 (5H,
series of m, H2'-H6') 2.53(3H, s, Me) HRMS (ES -ve) m/z 276.0538 (45%) (M-H+;
C10H14NO6S requires 276.0538).

2-Acetyl-4-[(l'S, VR, 3'R, 4'R, 5')-pentahydroxypentyl]thiazoIe (61)

OH

OH

OH

OTBDMS
Acetone/10%HCI

S

\ ^

A

N

0 H

OH

63

A solution of the diol 61 (60 mg, 0.125 m m o l ) was treated as described above

for the preparation of 2-Acetyl-4-[(l'/?, TR, VR, 4'R, 5')-pentahydroxypentyl]thi
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62 to yield the title compound 63 as a dark yellow oil (30 mg, 86%). ! H N M R analysis
showed this compound to be >95% pure. 8H (300MHz; D2O; H2O) 7.74 (1H, s, H5),
5.08 (1H, d, 7 2.3, HI'), 3.87 (1H, dd, 7 2.3, 7.8, H2'), 3.80-3.67 (2H, m,
3.65 (1H, dd, 7 2.8, 11.9, H5b'), 3.52 (1H, dd, 7 7.0, 11.9, H5a'), 2.54 (3H, s, Me).
HRMS (ES -ve) m/z 276.0537 (50%) (M-H+; C10H14NO6S requires 276.0538)

2-Acetyl-4-[(l'S, VR, 3'R, 4'R, 5')-pentaacetoxypentyl]thiazole (65)

OH

OH

OH

OAc

Acetic anhydride,
OH
acetic acid,
and perchloric acidA
acetic anhydride (catalyst)

N ^

N

OAc

OAc

OAc

OAc

65
O'

'O

To a stirred solution of acetic anhydride (3 cm 3 ) and glacial acetic acid (5 cm 3 )

was added a sample of the pentol 63 (10 mg, 0.036 mmol). A perchloric acid/acet

anhydride catalyst (1 g of 70% HCIO4 in 2.3 g of acetic anhydride) was added (

and the mixture was stirred at 60 °C for 1 h before being poured into ice wate
o

After extraction with ethyl acetate (3 x 20 c m ) the combined organic extracts were

dried over magnesium sulfate and concentrated in vacuo. The product was purifi

semi preparative TLC on silica gel plates, (eluent: 50% ethyl acetate/hexane) t

as a finely crystalline product (11 mg, 63%). 8H (300MHz; CDCI3; Me4Si) 7.53 (1H

H5), 6.24 (1H, d, 7 4.1, HI'), 5.70 (1H, dd, 7 4.1, 7.7, H2'), 5.35 (1H,

H3'), 5.21 (1H, m, 7 3.4, 7.4, 11.00, H4'), 4.37 (1H, dd, 7 3.4, 12.1, H5b'), 4.15 (1

dd, 77.4, 12.1, H5a'), 2.68 (3H, s, Me), 2.15 (3H, s, Ac), 2.094 (3H, s, Ac), 2
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s, Ac), 2.058 (3H, s, Ac), 2.029 (3H, s, Ac). H R M S (CI+) m/z 488.122658 (M+H+;
C20H26NO] lS requires 488.122658).

2-Acetyl-4-[(l'#, VR, 3'R, 4'R, 5')-pentaacetoxypentyl]thiazole (64)

OH

OH

OH

OAc OAc

Acetic anhydride,
Ql_l
acid,
_ acetic
^^^_
^
*. S . ^ N
OAc
x
and perchloric acid/
^
64
acetic anhydride (catalyst)
O' *0

OAc

OAc

The pentol 62 (30 mg, 0.108 mmol) was treated as described above for the
preparation of 65 to yield a finely crystalline product 64 (30 mg, 57%).
CDCI3; Me4Si) 7.59 (1H, s, H5), 6.18 (1H, d, 7 5.5, HI'), 5.75 (1H, dd, 7
5.40 (1H, dd, 7 4.3, 5.9, H3'), 5.29 (1H, m, 7 3.0, 7.1, H4'), 4.35 (1H,

H5b'), 4.07 (1H, dd, 77.1, 12.1, H5a'), 2.63 (3H, s, Me), 2.18 (3H, s, Ac), 2.

Ac), 2.009 (3H, s, Ac), 2.001 (3H, s, Ac), 1.978 (3H, s, Ac). HRMS (CI+
488.122658 (M+H+; C20H26NO1 lS requires 488.122658).
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2-acetyl-5-(l',

2>R,

3'S,

4'R, 5'R, 6')-

hexahydroxyhexyl]thiazole

l£:3,4:5,6-Tri-0-isopropylidene-8-gluconolactone (77)234

242

Q ^ o

FeCI3,
x
HO * ^V^'OH acetone3
OH
68

X 0^2\^0
Ys X
X o77

8-Gluconolactone 68 (5.50 g, 30.855 mmol) was suspended in anhydrous

acetone (100 cm3) and stirred at room temperature while ferric chloride (1.65 g,

mmol) was added. Stirring was continued for 24 h by which time all of the solids

dissolved. The solution was quenched with saturated potassium carbonate solution
cm) and reduced to a syrup in vacuo. The syrup was extracted with chloroform (3
-J o

c m ). The organic extracts were combined and washed with distilled water (3 x 50 c m )
and dried over magnesium sulfate before filtering and concentrating in vacuo to

l,2:3,4:5,6-tri-(9-isopropylidene-8-gluconolactone 77 (4.9 g, 61%) as a white cr

solid, mp 106-109 °C (lit. 110 °C242 (from petroleum ether). (Found: C, 57.07; H, 7
C12H18O6 requires C, 56.93; H, 7.65%); 8H (300 MHz; CDCI3) 4.62 (1H, d, 7 1.5,

H2), 4.27 (1H, dd, 7 1.5, 8.3, H3), 4.14 (1H, m, H6a), 4.09 (1H, m, H5), 4.0 (1H,

H6b), 3.95 (1H, m, H4), 1.64 (3H, s, Me), 1.56 (3H, s, Me), 1.41 (3H, s, Me), 1.3

s, 2(Me)), 1.33 (3H, s, Me): 8C (75.6 MHz, CDC13) 170.6 (C), 111.44 (C), 110.3 (C
109.8 (C), 78. 7 (CH), 77.2 (CH), 76.4 (CH), 73.7 (CH), 67.9 (CH2), 27.1 (Me), 27.0
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(Me), 26.9 (Me), 26.7 (Me), 26.5 (Me), 25.2 (Me) H R M S (ES+) m/z 317.1593 ( M + H + ;
C 1 5 H 2 4 O 7 requires 317.1594) 259 (100%)

Chloromethylaluminium methoxymethylamine (0.67M solution) (84)
The hydrochloride salt of methoxymethylamine (1.95 g) was suspended in 20
m L anhydrous benzene at 5 °C. A n equimolar amount of trimethylaluminium (1.442 g,
0.02 mol) was dissolved in toluene (10 m L ) to give a 2 M solution which was slowly
added to the benzene suspension. After addition was complete, the reaction was warmed
gradually to room temperature and stirred for 2 h until gas evolution ceased, indicating
completion of the reaction. This product, 84 was not isolated and was used crude for the
next

reaction. This

literature

procedure

forms

a 0.67 M

solution of

chloromethylaluminium methoxymethylamine (0.67 M solution).253

N-(V, 2'R, 3'S, 4'R, 5'R, 6')-hexahydroxy-3,4:5,6-di-0-isopropylidene-llactonohexyl) methoxymethylamide (85)

N

X T ^ Y°
°*j^°V/

X J

MeCIAINMeOMe

HQmX

-VY
0

77

^ V

85

To a solution of l,2:3,4:5,6-tri-0-isopropylidene-8-gluconolactone 77
(200 m g ) in benzene (7.5 m L ) was added a 0.67 M solution of chloromethylaluminium
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methoxymethylamine in benzene (2.25 mL). The reaction was stirred under nitrogen gas
until all solids had dissolved (24 h). The mixture was then quenched with 5%
hydrochloric acid (10 mL). The organic layer was separated and put aside while

aqueous layer was extracted with ethyl acetate (3 x 20 mL). All organic fractio
combined and dried over magnesium sulfate and concentrated in vacuo to yield a

coloured oil. This crude mix was loaded onto a silica gel column and eluted seq

with 100 mL of petroleum ether, 25% ethyl acetate in petroleum ether, 50% petro

ether in ethyl acetate, 25% petroleum ether in ethyl acetate. The final two fra
combined and concentrated in vacuo to yield the title compound 85 in 75% yield

mg) 8H (300 MHz; CDCI3) 4.61 (1H, d, 7 9.7, H2), 4.25 (1H, m, H3), 4.15-4.10 (
series of m, H6a, H5, H6b), 3.97 (1H, m, H4'), 3.70 (3H, s, OMe), 3.50 (1H, d,

3.27 (3H, s, NMe), 1.45 (3H, s, Me), 1.42 (3H, s, Me), 1.37 (3H, s, Me), 1

Me); 8C (75.6 MHz, CDC13) 172.3 (C), 110.5 (C), 109.8 (C), 80.2 (CH), 77.7 (CH),
(CH), 68.2 (CH2), 67.6 (CH), 61.3 (OMe), 32.7 (NMe), 27.4 (Me), 26.9 (Me), 26.7
(Me), 25.6 (Me); HRMS (CI +ve) m/z 320.1709 (100%) (M+H+; C14H25NO7 requires
320.1709).

N-(V, VR, 3'S, 4'R, 5'R, 6')-hexahydroxy-3,4:5,6-di-0-isopropylidene-2-terfbutyldimethylsiloxy-1-Iactonohexyl) methoxymethylamide (86)

?

?

HoA- TBDMSCl
\y^
0^/""O o

X J 85 X

TBDMSO

Imidazole
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VS, 4'R, VR,

6')-hexahydroxy-3,4:5,6-di-0-isopropylidene-l-

lactonohexyl) methoxymethylamide 85 (85 mg) was dissolved in 5 mL anhydrous

dimethylformamide. Imidazole (91 mg) was added and allowed to dissolve before t

addition of terf-butyldimethylsilylchloride (100 mg). Stirring was continued wi
heating at 40°C for 72 h after which time the reaction mixture was poured into

ether (25 mL). The quenched mixture was washed with 1 M hydrochloric acid (50 m

The aqueous layer was washed with diethyl ether (3 x 25 mL) and all organic fra

combined. The combined organic fraction was washed with saturated sodium chlori
before drying over magnesium sulphate and concentrating in vacuo to give 86 as

orange oil (80 mg, 70%). 8H (300 MHz; CDCI3) 4.64 (1H, br. s, H2), 4.21 (1H, m,

4.15^1.10 (3H, series of m, H6a, H5, H6b), 3.80 (1H, m, H4'), 3.63 (3H, s, OM

(3H, br. s, NMe), 1.38 (6H, s, 2 Me), 1.37 (3H, s, Me), 1.35 (3H, s, Me

CDC13) 171.6 (C), 110.5 (C), 109.6 (C), 81.1 (CH), 77.4 (2CH), 77.3 (CH), 67.9 (CH2)
61.1 (OMe), 27.6 (NMe), 26.9 (Me), 26.7 (Me), 26.0 (3Me), 25.8 (Me), 25.5 (Me);
HRMS (CI +ve) m/z 434.2574 (100%) (M + H+; C20H40NO7Si requires 434.2567).

2-(l,l-Dimthoxyethyl)-5-[(l', VR, 3'S, 4'R, 5'R, 6')-hexahydroxy-3,4:5,6-di-0isopropylidene-2-0-tert-butyldimethylsiloxy-l-lactonohexyl]thiazole(87)
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2-(l,l-Dimethoxyethyl]thiazole 46 (21 mg, 0.1218 mmol, 1.2 equivalents) was
dissolved in dry tetrahydrofuran (5 cm3) and cooled to -78 °C under a nitrogen

atmosphere. n-BuLi (0.13 mmol, 0.15 mL x 0.9 M, 1.3 equivalents) was slowly adde

and the mixture was stirred at -78 °C for a period of 30 mins before the additi
2'fl, VS, 4'R, VR, 6')-hexahydroxy-3,4:5,6-di-0-isopropylidene-2-tert-

butyldimethylsiloxy-1-lactonohexyl) methoxymethylamide 86 solution (44 mg, 0.10

mmol in dry tetrahydrofuran (5 mL)). The reaction was stirred under N2 while wa

to room temperature over a period of 2 h, and then poured into saturated ammoniu
o

chloride solution (10 c m ). The aqueous fraction was extracted with dichloromethane (3

x 10 cm ). The combined organic fractions were washed with saturated sodium chl
solution (3 x 10 cm ) and dried over magnesium sulfate before concentrating in

give a yellow oil (95 mg) which was step eluted through a silica gel column usin

petroleum ether 100% to ethyl acetate 100% in 10% increments. 87, the title com

was isolated as a clear colourless oil. (13 mg, 11%). (Found: C, 54.98; H, 7.97
C25H43NOgSSi requires C, 55.0; H, 7.9; N, 2.6%); 8H (300MHz; CDCI3) 8.66 (1H, s,
H4), 4.63 (1H, d, 72.2, H2'), 4.25 (1H, m, 72.2, H3'), 4.19 (1H, m, 78.2, H6'),
(2H, m, H4' and H5'), 3.84 (1H, m, 7 8.2, H6'), 3.28 (3H, s, OMe), 3.24 (3H, s,

1.73 (3H, s, Me), 1.49 (3H, s, Me), 1.40 (3H, s, Me), 1.34 (3H, s, Me), 0.9 (9H,

butyl), 0.10 (3H, s, SiMe), -0.08 (3H, s, SiMe); 8C (75.6MHz, CDC13) 194.1 (C), 178.

(C), 150.0 (C), 137.4 (CH), 110.7 (C), 109.8 (C), 100.9 (C), 82.3 (CH), 78.6 (CH
(CH), 77.3 (CH), 68.3 (CH2), 49.5 (Me), 49.5 (Me), 27.3 (Me), 26.7 (Me), 26.4 (Me),

25.8 (Me), 25.1 (Me), 23.9 (Me), 18.2 (C), -4.7 (Me), -5.1 (Me); HRMS (CI +ve) m
546.2557 (M+H+; C25H44NOgSSi requires 546.2556), 514 (100%).
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N-4-[(V, VR, 3'S, 4'R, 5'R, 6')-hexahydroxy-3,4:5,6-di-0-isopropylidene-llactonohexyl) morpholine (88)

O'

p ^ 0

X o'V-o
X
P^/""°
X o77

N^O
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100°C
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l,2:3,4:5,6-Tri-CMsopropylidene-S-gluconolactone 77 (1.00 g, 3.16 mmol) and
o

morpholine (1.033 g, 1.013 c m , 11.86 mmol, 3.75 equivalents) were combined in a

sealed tube and heated to 100 °C for 24 h, after which the reaction was allowe

to room temperature. The solution was diluted with dichloromethane (25 cm3) an
washed with 0.1 M hydrochloric acid. The aqueous washings were extracted with

dichloromethane (3 x 15 cm3) and all organic fractions were combined. After wa

with distilled water (3 x 50 cm3) and drying over magnesium sulfate, the organ

fraction was concentrated in vacuo to yield the title compound 88 (1.033 g, 95
yellow syrup. 8H (300 MHz; CDCI3) 4.59 (1H, dd, 7 1.1, 9.3, H2'), 4.18 (1H, m,
4.08 (1H, m, H6a'), 4.06 (1H, m, H5'), 4.00 (1H, m, H6b'), 3.97 (1H, m, H4'), 3.79

(1H, d, 7 9.3, OH2'), 3.75-3.45 (8H, br.m, 2(0-CH2) and 2(N-CH2)), 1.44 (3H, s, M

1.42 (3H, s, Me), 1.39 (3H, s, Me), 1.34 (3H, s, Me); 8C (75.6 MHz, CDC13) 170.

110.6 (C), 109.5 (C), 80.4 (CH), 77.5 (CH), 77.4 (CH), 68.0 (CH2), 66.6 (O-CH2), 66.2
(O-CH2), 66.2 (CH), 45.4 (N-CH2), 42.8 (N-CH2), 27.1 (Me), 26.5 (Me), 26.3 (Me),
25.1 (Me). H R M S (EI +ve) m/z 345.1787 (M+H+; C 1 6 H 2 7 N O 7 requires 345.1787).
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W-4-[((l', VR, 3'S, 4'R, 5'R, 6')-hexahydroxy-3,4:5,6-di-0-isopropylidene-2-0-terfbutyldimethylsiloxy-l-lactonohexyl) morpholine (89)
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The alcohol (88) (1.097 g, 3.19 mmol) was dissolved in anhydrous
dimethylformamide (15 cm3) while stirring at room temperature. Imidazole (1.30 g,
19.1 mmol, 6.4 equivalents) was added and allowed to dissolve before addition of

butyldimethylsilyl chloride (800 mg, 6.9 mmol, 2.35 equivalents). This solution w

then stirred at 40 °C for 72 h before being poured into diethyl ether (100 cm ) a
washed with 0.5 M hydrochloric acid (50 cm3). The aqueous fraction was back

extracted with diethyl ether (3 x 50 cm3). The combined organic fractions were wa

with saturated sodium chloride solution (3 x 50 cm3) before drying over magnesium

sulfate and concentrating in vacuo to yield a white solid. Recrystallisation from

petroleum ether gave 89 (1.426 g, 97%) as large colourless crystals (mp 64-66 °C)
(Found: C, 57.58; H, 9.07; N, 2.96. C22H4lN07Si requires C, 57.48; H, 9.00; N,

3.05%); 8H (300MHz; CDCI3) 4.53 (1H, d, 72.5, H2'), 4.30 (1H, br.m, of morpholine),

4.19 (1H, dd, 7 2.5, 7.2, H3'), 4.14 (1H, dd, 7 6.1, 8.1, H6a'), 4.04 (1H, ddd, 7 6.1, 7.0,

7.8, H5'), 4.02 (1H, m, of morpholine), 3.96 (1H, dd, 7 7.2, 7.8, H4'), 3.78 (1H, dd
7.0, 8.1, H6b'), 3.76-3.5 (5H, br.m, of morpholine), 3.2 (1H, br.m, of morpholine),

(3H, s, Me), 1.36 (3H, s, Me), 1.34 (3H, s, Me), 1.33 (3H, s, Me), 0.92 (9H, s, C(Me)3
0.10 (3H, s, SiMe), 0.07 (3H, s, SiMe); 8C (75.6 MHz, CDC13) 169.7 (C), 109.8 (C),
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109.7 (C), 81.9 (CH), 77.1 (CH), 76.9 (CH), 75.7 (CH), 67.9 (CH 2 ), 67.1 (CH 2 ), 66.8
(CH2), 46.3 (CH2), 43.0 (CH2), 27.1 (Me), 26.6 (Me), 26.3 (Me), 25.6 (3(Mc)), 25.1

(Me), 18.0 (C), -5.0 (Me), -5.6 (Me). HRMS (ES +ve) m/z 460.2730 (100%) (M
C22H42N07Si requires 460.2730).

2-(l,l-Dimethoxyethyl)-5-[(l', VR, 3'S, 4'R, 5'R, 6')-hexahydroxy-3,4:5,6
isopropylidene-2-0-tert-butyldimethylsi!oxy-l-lactonohexyl]thiazole(87)
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2-(l,l-Dimethoxyethyl]thiazole46 (1 g, 5.773 mmol, 1.17 equivalents) was dissolved in

dry tetrahydrofuran (15 cm ) and cooled to -78 °C under a nitrogen atmosph
_ o

(7.52 mmol, 4.7 cm x 1.6 M, 1.52 equivalents) was slowly added and the mix

stirred at -78 °C for a period of 30 mins before the addition of a solutio
4.939 mmol in 15 cm3 dry tetrahydrofuran). The reaction was stirred under

warming to room temperature over a period of 2 h, and then poured into sat

ammonium chloride solution (30 cm3). The aqueous fraction was extracted wi

dichloromethane (3 x 30 cm ). The combined organic fractions were washed w
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saturated sodium chloride solution (3 x 30 cm ) and dried over magnesium sulfate

before concentrating in vacuo. Recrystallisation from diethyl ether yielded 87

37%) as clear colourless crystals (mp 102-105 °C). The starting material 89 (7

was also recovered by recrystallisation, in successive crystallisations of thi
solution. This gave an overall yield of 63% of the title compound taking into

the recovered starting material. (Found: C, 54.98; H, 7.97; N, 2.52. C25H43NOgS

requires C, 55.0; H, 7.9; N, 2.6%); 8H (300MHz; CDCI3) 8.66 (1H, s, H4), 4.63 (1H

7 2.2, H2'), 4.25 (1H, m, 7 2.2, H3'), 4.19 (1H, m, 7 8.2, H6'), 4.05 (2H, m, H

H5'), 3.84 (1H, m, 7 8.2, H6'), 3.28 (3H, s, OMe), 3.24 (3H, s, OMe), 1.73 (3H,

1.49 (3H, s, Me), 1.40 (3H, s, Me), 1.34 (3H, s, Me), 0.9 (9H, s, f-butyl), 0.10 (
SiMe), -0.08 (3H, s, SiMe); 8C (75.6MHz, CDC13) 194.1 (C), 178.4 (C), 150.0 (C),

137.4 (CH), 110.7 (C), 109.8 (C), 100.9 (C), 82.3 (CH), 78.6 (CH), 77.4 (CH), 7
(CH), 68.3 (CH2), 49.5 (Me), 49.5 (Me), 27.3 (Me), 26.7 (Me), 26.4 (Me), 25.8 (Me),

25.1 (Me), 23.9 (Me), 18.2 (C), -4.7 (Me), -5.1 (Me). HRMS (CI +ve) m/z 546.255
(M+H+; C25H44NOgSSi requires 546.2556), 514 (100%).

2-(l,l-DimethoxyethyI)-5-[(l'S, VR, 3'5, 4'R, 5'R, 6')-hexahydroxy-3,4:5,6-diisopropylidene-2-0-ter/-butyldimethylsiloxyhexyl]thiazole(9O)
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To a stirred solution of ketone 87 (230 mg, 0.42 mmol) in anhydrous diethyl ether (5

cm ) at -78°C was added dropwise a solution of diisobutylaluminium hydride (0

mmol). Stirring was continued for 1 h after which the reaction was quenched wi

methanol (5 cm3). A saturated solution of potassium tartrate (5 cm3) was adde

reaction stirred for 1.5 h. The organic phase was collected and the remaining

phase extracted with diethyl ether (3 x 10 cm). The organic phase and diethyl

extracts were combined before washing with saturated sodium bicarbonate solut

then distilled water, followed by drying over magnesium sulfate. Concentratio
vacuo yielded solely the (15)-alcohol 90 (208 mg, 90.1%) as clear colourless

mp 97-99°C. 90 8H (300MHz; CDCI3) 7.67 (1H, s, H4), 5.17 (1H, ddd, 7 1.1, 2.8,
HI'), 4.15 (1H, dd, 7 6, 8.3, H3'), 4.00 (4H, m, H2', H5', H6a\ H6b'), 3.88 (1H, dd, 7
6.3, 8.3, H4'), 3.49 (1H, d, 7 6.4, OH1'), 3.25 (3H, s, OMe), 3.24 (3H, s, OMe), 1.69
(3H, s, ThCMe), 1.42 (3H, s, OCMe), 1.41 (3H, s, OCMe), 1.34 (3H, s, OCMe), 1.32

(3H, s, OCMe), 0.83 (9H, s, t-Butyl), 0.09 (3H, s, SiMe), -0.12 (3H, s, SiMe); 8C (7

MHz, CDC13) 171.2 (C), 141.8 (C), 139.3 (CH), 109.9 (C), 109.3 (C), 101.0 (C)
(CH), 78.0 (CH), 77.3 (CH), 77.1 (CH), 68.8 (CH), 67.8 (CH2), 49.4 (Me), 49.4 (Me),

27.0 (Me), 26.9 (Me), 26.3 (Me), 25.9 (Me), 25.2 (Me), 24.2 (Me), 18.4 (C), -4
-4.8 (Me); HRMS (CI +ve) m/z 548.2713 (100%) (M+H+; C25H46NOsSSi requires
548.2713), 516 (90%).
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2-(l,l-Dimethoxyethyl)-5-[(l'S, VR, 3'S, 4'R, 5'R, 6')-hexahydroxy-3,4:5,6-di-0isopropyIidene-2-0-tert-butyIdimethylsiloxyhexyllthiazoIe (90) and 2-(l,lDimethoxyethyl)-5-[(l'i?, VR, 3'S, 4'R, 5'R, 6>hexahydroxy-3,4:5,6-di-0isopropylidene-2-0-tert-butyIdimethylsiIoxyhexyl]thiazole(91)
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T o a stirred solution of the ketone 87 (200 mg, 0.366 m m o l ) in anhydrous
methanol (10 cm3) at 0 °C was added sodium borohydride (70 mg, 1.85 mmol, 5
equivalents.) over a period of 1 h. The reaction was stirred until TLC analysis (15%

ethyl acetate in hexane on silica gel) indicated completion, after which the reaction
quenched with saturated ammonium chloride solution (10 cm3). The reaction was
extracted with dichloromethane (3 x 20 cm3) and the organic fractions combined before
washing with saturated sodium chloride solution and drying over magnesium sulfate.

Chapter 7- Experimental

222

Concentration in vacuo yielded a mixture of the (IS)- and (l/?)-diastereomeric alcohols

90 and 91 (172 mg, 86%) as a pale yellow solid (90:91=13:87). Recrystallisation

1:5 ethyl acetate / petroleum ether separated the alcohols 90 and 91 into whit

and a white powdery solid, respectively. 91 8H (300MHz; CDCI3; Me4Si) 7.67 (1H,

H4), 5.04 (1H, d, 75.1, HI'), 4.07 (1H, dd, 75.6, 8.6, H3'), 3.96 and 3.88 (4H,
H5\ H6a', H6b'), 3.79 (1H, ddd, 7 1.1, 5.6, 8.1, H2'), 3.24 (3H, s, OMe), 3.23 (3H, s,
OMe), 2.74 (1H, d, 7 8.1, OH), 1.72 (3H, s, ThMe), 1.37 (3H, s, CMe), 1.35 (3H, s,

CMe), 1.30 (3H, s, CMe), 1.29 (3H, s, CMe); 8C (75.6 MHz, CDC13) 172.3(C), 141.

(C), 140.1 (CH), 110.1 (2C), 101.3 (C), 79.1 (CH), 78.0 (CH), 77.5 (CH), 73.6 (
71.3 (CH), 68.2 (CH2), 49.3 (Me), 49.2 (Me), 27.5 (Me), 27.1 (Me), 27.0 (Me), 26.1

(Me), 25.7 (Me), 24.4 (Me), 18. 5 (C), -4.4 (Me), -4.7 (Me); HRMS (CI +ve) m/z
548.2713 (100%) (M+H+; C25H46N08SSi requires 548.2713), 516 (90%).

Using L-selectride:
To a stirred solution of the ketone 87 (36 mg, 0.066 mmol) in dry

tetrahydrofuran (5 cm3) at -78 °C was added a solution of L -selectride (0.2 mm
eq.). After stirring for 4 h the reaction was quenched with a solution of 10%
hydroxide and 30% hydrogen peroxide (2:1, 5 cm ). The reaction was stirred at

h, then diluted with saturated sodium chloride solution (10 cm ) and extracted

acetate (3 x 20 cm3). The organic fractions were combined and washed with dist

water and dried over magnesium sulfate. The reaction yielded a diastereoisomer
mixture of the alcohols 90 and 91 (32 mg, 88%, 17:83 1S:1R). The products had
identical H NMR spectra to those seen above for the reduction reactions using
borohydride and diisobutylaluminium hydride.
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Using K-selectride:
To a stirred solution of the ketone 87 (36 mg, 0.066 mmol) in dry
tetrahydrofuran (5 cm3) at -78 °C was added a solution of K-selectride (0.2 mmol,

3eq.). After stirring for 4 h the reaction was quenched with a solution of 10% sodi

hydroxide and 30% hydrogen peroxide (2:1, 5 cm3). The reaction was stirred at rt f

h, then diluted with saturated sodium chloride solution (10 cm3) and extracted wit

acetate (3 x 20 cm3). The organic fractions were combined and washed with distilled
water and dried over magnesium sulfate. The reaction yielded a diastereoisomeric
mixture of the alcohols 90 and 91 (30 mg, 83%, 15:1/?= 18:82). The products had
identical !H NMR spectra to those seen above for the reduction of 87 using sodium
borohydride, diisobutylaluminium hydride and L-Selectride.

2-Acetyl-5-[(l'S, VR, 3'S, 4'R, 5'R, 6')-hexahydroxyhexyl]thiazole (92)
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The alcohol 90 (31 mg, 0.056 mmol) was dissolved in a 1:1 mixture of acetone

and 10% hydrochloric acid (5 cm3) and the solution was heated to reflux for 2 h. T

acetone was removed in vacuo and the aqueous washed with diethyl ether, before th

remaining water was removed in vacuo to yield the hexol 92 (16 mg, 96% ) as a dar
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yellow oil. 8 H (300 M H z ; D 2 0 ) 7.80 (1H, s, H4), 5.09 (1H, d, HI'), 3.75-3.35 (6H,

series of m, H2'-H6a' and H6b') 2.48 (3H, s, ThCMe). HRMS (ES+ve) m/z 308.08
(M+H+; C11H18NO7S requires 308.0799) (100%).

2-Acetyl-5-[(l'U, VR, 3'S, 4'R, 5'R, 6')-hexahydroxyhexyl]thiazole (93)
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The alcohol 91 (31 mg, 0.056 mmol) was dissolved in a 1:1 mixture of acetone

and 10% hydrochloric acid (5 cm3) and was heated to reflux for 2 h. The ace

removed in vacuo and the aqueous washed with diethyl ether, before the rema

water was removed in vacuo to yield the hexol 93 (17 mg, 98% ) as a dark y
8H (300MHZ; D2O) 7.74 (1H, s, H4), 5.08 (1H, d, 7 2.3, HI'), 3.87 (1H, dd, 7 2.3, 7.8,

H2'), 3.80-3.67 (2H, m, H3' and H4'), 3.65 (1H, dd, 7 2.8, 11.9, H5b'), 3.52 (
7.0, 11.9, H5a'), 2.54 (3H, s, Me). HRMS (ES+ve) m/z 308.0797 (35%) (M+H+;
C11H18NO7S requires 308.0799).
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2-Acetyl-5-[(l'S, VR, 3'S, 4'R, 5'R, 6')-hexaacetyIhexyl]thiazole (94)
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To a stirred solution of acetic anhydride (3 cm3) and glacial acetic acid (5 cm3)

was added the hexol 92 (45 mg, 0.146 mmol). A perchloric acid-acetic an

catalyst (1 g of 70% perchloric acid in 2.3 g acetic anhydride) was ad

the mixture stirred for 1 h before pouring into ice-water (20 cm3). Th

extracted with ethyl acetate (3 x 30 cm ) and the organic fractions co

magnesium sulfate and concentrated in vacu. Purification was carried o

preparative TLC using silica gel plates with 15% ethyl acetate in hexa

to yield 94, a pale yellow oil (62 mg, 75%). 8H (300MHz; CDCI3) 7.91 (1

6.34 (1H, d, 73.9, HI'), 6.01 (1H, m, H4'), 5.87 (1H, dd, 73.7, 6.8, H3

7 3.9, 6.8, H2'), 5.49 (1H, m, 7 3.35, 7.6, H5'), 4.41 (1H, dd, 7 3.35, 11.9, H

(1H, dd, 7 7.6, 11.9, H6b'), 2.72 (3H, s, Me), 2.18 (3H, s, Ac), 2.08 (6H, s, 2

(3H, s, Ac), 2.04 (6H, s, 2Ac); HRMS (CI+) m/z 559.1351 (M+H+; C23H29N
requires 559.1351).

2-AcetyI-5-[(l'/?, VR, 3'S, 4'R, 5'R, 6')-hexaacetylhexyl]thiazole (95)
OH OH OH OAc OAc OAc
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N

V

S

.*K

0 A c

95

0 A c

0Ac
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To a stirred solution of acetic anhydride (3 c m ) and glacial acetic acid (5 c m )
was added the hexol 93 (100 mg, 0.325 mmol). A perchloric acid-acetic anhydride

catalyst (1 g of 70% perchloric acid in 2.3 g acetic anhydride) was added (4 dro
the mixture stirred for 1 h before pouring into ice-water (20 cm3). The mixture

extracted with ethyl acetate (3 x 30 cm3) and the organic fractions combined, dr

magnesium sulfate and concentrated in vacuo. Purification by semi-preparative TL

using 15% ethyl acetate in hexanes as the eluent yielded a pale yellow oil, 95 (
85%) SH (300MHz; CDCI3) 7.87 (1H, s, H5), 6.23 (1H, d, 7 4.2, HI'), 6.06 (1H, m,

3.4, H4'), 5.81 (1H, dd, 7 3.4, 7.0, H3'), 5.67 (1H, dd, 74.2, 7.0, H2'),
2.9, 6.3, H5'), 4.39 (1H, dd, 7 2.9, 11.1, H6a'), 4.15 (1H, dd, 7 6.3, 11.1, H6b'), 2.74
(3H, s, Me), 2.11 (6H, s, 2Ac), 2.10 (3H, s, Ac), 2.07 (3H, s, Ac), 2.06
HRMS (CI+) m/z 559.1349 (M+H+; C23H29NO13S requires 559.1351).

7.2.4 Synthesis

of

2-acetyl-5-[(l',

VS,

hexahydroxyhexyl]thiazole

2,3:5,6-Di-0-isopropyIidene-mannolactone(99)

OH
Ag9COa/Celite ^
Benzene

3'S, 4'R, 5'R,

6>
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Silver carbonate on celite270 (125 g, 219 mmol A g 2 C 0 3 (1 mmol/570 mg), 28

equivalents) was added to a solution of 2,3:5,6-diisopropylidene-mannolactone

(2.062 g, 7.922 mmol) in benzene (50 cm3) and the mixture was heated at reflu

After cooling to rt the mixture was filtered and the filtrate was washed exhau

with hot benzene. The benzene fractions were combined and concentrated in vacu

yield solely 99 as a white powdery solid (1.850 g, 90.4%, mp 109-111 °C). 8H (3

MHz; CDCI3) 4.88 (1H, dd, 7 3.2 and 5.3, H3), 4.84 (1H, d, 7 5.3, H2), 4.44 (1

3.7, 5.7 and 8.2, H5), 4.36 (1H, dd, 7 3.2 and 8.2, H4), 4.15 (1H, dd, 7 5.7 a

H6(a)), 4.08 (1H, dd, 7 3.7 and 9.2, H6(b)), 1.49 (3H, s, Me), 1.47 (3H, s, Me), 1.4

(3H, s, Me), 1.39 (3H, s, Me); 8C (75.6 MHz, CDC13) 173.7 (C), 114.8 (C), 110.
78.4 (CH), 76.3(CH), 76.0 (CH), 72.8 (CH), 66.7 (CH2), 27.3 (Me), 27.0 (Me), 26.2
(Me), 25.3 (Me); HRMS (Cl+ve) m/z 259.1187 (100%) (M+H+; C12H19O6 requires
259.1176).

2-(l,l-Dimethoxyethyl)-5-[(l', VS, 3'S, 4'R, 5'R, 6')-hexahydroxy-2,3:5,6-diisopropylidene-l-lactono]thiazole(100)

r\
n-BuLi, T H F

O'
46

o

X
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A solution of n-BuLi (2.5 cm 3 x 1.25 M solution in hexanes, 3.15 mmol, 1.25
equivalents) was added with stirring to a cooled (-78 °C) solution of 2-(l,l-

dimethoxyethyljthiazole 46 (480 mg, 2.77 mmol, 1.1 equivalents) in dry tetrahyd
(10 cm3). After stirring for 40 min, a solution of 2,3:5,6-(diisopropylidenemannolactone 99 (650 mg, 2.51 mmol) in dry tetrahydrofuran (10 cm3) was added

dropwise and stirring was continued at -78 °C for 1 h then at rt for 3 h before

mixture was quenched by pouring into saturated ammonium chloride solution (50 c

The reaction was exhaustively extracted with dichloromethane and the organic fr
combined. The organic fractions were then washed with distilled water (3 x 100

then saturated sodium chloride solution (3 x 100 cm3) before drying over magnes

sulfate. Concentration in vacuo yielded a dark orange oil (1.06 g, 97.6%) which

then purified by column chromatography using gradient elution (hexane: ethyl ac

from 100:0-0:100 in 10% intervals) to give the title compound 100 as a light ye
(906 mg, 83.5%). 8H (300 MHz; CDC13) 7.77 (1H, s, 4H), 5.27 (1H, br.s, OH1'), 4.91
(1H, dd, 73.9 and 5.8, H3'), 4.62 (1H, d, 75.8, H2'), 4.43 (1H, m, 77.0, H5'),
dd, 7 3.9 and 7.0, H4'), 4.01 (2H, m, H6a' and H6b'), 3.22 (3H, s, OMe), 3.18 (3H, s,

OMe), 1.43 (6H, s, 2Me), 1.34 (3H, s, Me), 1.27 (3H, s, Me); 8C (75.6 MHz, CDC13

173.2 (C), 140.7 (C), 138.5 (CH), 112.9 (C), 109.1 (C), 103.9 (C), 100.8 (C), 8
80.2 (CH), 78.8 (CH), 73.1 (CH), 66.3 (CH2), 49.2 (2Me), 26.7 (Me), 25.5 (Me), 25.1
(Me), 24.1 (Me), 24.0 (Me); HRMS (Cl+ve) m/z 432.1692 (M+H+; C19H3oN08S
requires 432.1692) (95%), 414 Ci9H28N07S (75%), 400 C18H26N07S (100%).
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2-(l,l-Dimethoxyethyl)-5-[(l>/?, VS, 3'S, 4'R, 5'R, 6')-hexahydroxy-2,3:5,6-di-0isopropylidene]thiazole (101) and 2-(l,l-DimethoxyethyI)-5-[(l'S, VS, 3'S, 4'R,
5'R, 6')-hexahydroxy-2,3:5,6-di-0-isopropylidene]thiazole (102)

OH

OH

r

X X

N<v.S O. ,0 C\ ,0

Q^O

O'

101

NaBH4)
MeOH, 0°C

Sodium borohydride (200 mg, 5.2 mmol, 7.5 equivalents) was added to a stirred,

cooled (0 °C) solution of 100 (300 mg, 0.695 mmol) in dry methanol (15 cm3) over a

period of 1 h. The reaction was stirred at 0 °C for 3 h before quenching with satur
ammonium chloride solution (50 cm3) and extracting with dichloromethane (3 x 50

cm3). The organic fractions were combined and washed with saturated sodium chloride

solution (3 x 100 cm3), before drying over magnesium sulfate. Concentration in vacu

yielded the title compounds as a mixture of isomers (295 mg, 98%, (1I?);(1S) = 85:1
The isomers were separated by column chromatography using gradient elution (100%

hexanes to 100% ethyl acetate at 10% intervals) to give the pure isomers (101 237 m

78.7%, (102; 44 mg, 14.6%) as clear, colourless oils. 101: 8H (300 MHz; CDCI3) 7.75
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(1H, s, H4), 5.27 (1H, dd, 74.6 8.2, HI'), 4.44 (1H, dd, 7 1.4 6.4, H3'), 4.28 (1H, dd,

6.4 8.2, H2'), 4.24 (1H, br. d, 4.6, OH1'), 4.06 (2H, m, H6a' and H6b'), 4.02 (1H

H4'), 3.95 (1H, m, H5'), 3.23 (3H, s, OMe), 3.22 (3H, s, OMe), 2.95 (1H

OH4'), 1.68 (3H, s, Me), 1.49 (3H, s, Me), 1.35 (3H, s, Me), 1.35 (3H, s, Me), 1.

s, Me); 8C (75.6 MHz, CDC13) 172.2 (C), 141 (C), 140.2 (C), 109.7 (C), 10
101.2 (C), 80.0 (C), 76.4 (C), 75.9 (C), 69.6 (C), 67.3 (C), 67.1 (C),

(Me), 27.4 (Me), 27.0 (Me), 25.5 (Me), 25.2 (Me), 24.4 (Me); HRMS (ES+ve

434.1838 (70%) (M+H+; Ci^oNOgS requires 434.1840), 402 C18H28N07S (100%).

102: SH (300 MHz; CDCI3) 7.75 (1H, s, H4), 5.30 (1H, dd, 7 3.0, 3.4, HI'
dd, 70.9,7.3, H3'), 4.42 (1H, dd, 73.0, 7.3, H2'). 4.15 (1H, dd, 77.1, 14.4,

(2H, m, H6a' and H6b'), 4.05 (1H, dd, 72.5, 5.1, H4'), 3.64 (1H, br.m, H5'), 3.45

br.m, OH4'), 3.25 (3H, s, OMe), 3.23 (3H, s, OMe), 1.69 (3H, s, Me (of thiazol
(3H, s, CMe), 1.38 (3H, s, CMe), 1.34 (6H, s, C(Me)2); 8C (75.6 MHz, CDC13)

(C), 140.9 (C), 139.6 (C), 109.6 (C), 109.2 (C), 101.2 (C), 80.3 (C), 7

70.0 (C), 67.2 (C), 66.51 (C), 49.7 (Me), 49.7 (Me), 27.0 (Me), 26.5 (M
25.1 (Me), 24.4 (Me); HRMS (ES+ve) m/z 434.1841 (70%) (M+H+; Ci9H3oN08S
requires 434.1840), 402 (100%).

2-Acetyl-5-[(l'S, VS, 3'S, 4'R, 5'R, 6')-tiexahydroxyhexyl]thiazole (10

OH
lix >

0\ .O o\ ^'O 1:1Acetone/10%HCL, £
Reflux

^ X "X'
T

102

~\

g

QH

V

cr^

104

OH

QH

OH

0H
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The diol 102 (295 mg, 0.7 mmol) was dissolved in a 1:1 mixture of acetone and

10% HCI solution (20 cm3) and the solution was heated to reflux for 2 h. Aceto

removed in vacuo and the remaining aqueous fraction washed exhaustively with d

ether. The aqueous fraction was then concentrated in vacuo to yield 104, the t
compound as a dark yellow oil (205 mg, 88%). SH (300 MHz; CDCI3) 7.72 (1H, s,

5.66 (1H, d, 7 5.6, HI' ), 4.18 (1H, m, 7 5.6, H2'), 3.75-3.4 (5H, several b
H5' H6a', H6b'), 2.67 (3H, s, Me); HRMS (ES+ve) m/z 308.0804 (50%) (M+H+;
CnHi8N07S requires 308.0799).

2-Acetyl-5-[(l'fl, 2'S, 3'S, 4'R, 5'R, 6')-hexahydroxyhexyl]thiazole (103)

?H

|\U ^S O

O'
/

°

?H

.OO

OH

A

r. .

^O 1:1 Acetone/10%HCL

/

x x —™™—
101

\

OH

=

OH

,

,

I

I

S OH 0M 0H

^

O^^

103

The diol 101 (60 mg, 0.14 mmol) was dissolved in a 1:1 mixture of acetone and

10% HCI solution (20 cm3) and heated to reflux for 2 h. Acetone was removed in
and the remaining aqueous fraction washed exhaustively with diethyl ether.

Concentration of the aqueous fraction in vacuo yielded 103, the title compound

dark yellow oil (38 mg, 81%). SH (300 MHz; CDCI3) 7.72 (1H, s, H4), 5.57 (1H, d
5.5, HI* ), 4.21 (1H, m, H2'), 3.72, 3.59, 3.41 (5H, 3m, H3\ H4\ H5', H6a', H6b');
HRMS (ES+ve) m/z 308.0797 (45%) (M+H+; CnH18N07S requires 308.0799).
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2-Acetyl-5-[(l'S, VR, 3'S, 4'R, 5'R, 6')-hexaacetylhexyl]thiazoIe (106)

OH
,—.
/ \
N
^/S
O^

\

OH

i
0H
•j 04

OH

OAc

r
|

i

0H

0H

Acetic anhydride,
olac acetic acid
/"
N
Perchloric acid/ *" ^ s
acetic anhydride (Cat.)
O<^\

OAc

OAc

OAc OAc OAc
106

To a stirred solution of acetic anhydride (3 cm 3 ) and glacial acetic acid (5 cm 3 )

was added the hexol 104 (45 mg, 0.146 mmol). A perchloric acid-acetic anhydri

catalyst (1 g of 70% perchloric acid in 2.3 g acetic anhydride) was added (

the mixture stirred for 1 h before pouring into ice-water (20 cm3). The mixt

extracted with ethyl acetate (3 x 30 cm3) and the organic fractions combined

magnesium sulfate and concentrated in vacuo to yield 106 as a pale yellow o
75%). SH (300 MHz; CDCI3) 7.87 (1H, s, H4), 6.17 (1H, d, 7 3.2, HI'), 6.12

6.4, 7.0, H4'), 5.83 (1H, dd, 7 5.8, 6.4, H3'), 5.68 (1H, dd, 7 3.2, 5.8, H2

74.1, H5'), 4.40 (1H, dd, 74.1, 10.2, H6a'), 4.09 (1H, dd, 7 6.9, 10.2, H6b'), 2.69 (

s, Me), 2.16 (3H, s, Ac), 2.12 (3H, s, Ac), 2.07 (9H, br.s, 3Ac), 2.05 (3H,
(CI+) m/z 559.1352 (30%) (M+H+; C23H29NO13S requires 559.1351).

2-Acetyl-5-[(l'#, VR, 3'S, 4'R, 5'R, 6')-hexaacetylhexyl]thiazole (105)
OH OH OH OAc OAc OAc
Acetic anhydride,
N^.S
I 103
O

OH

OH

OH

glac. acetic acid
N.\ .S OAc OAc OAc
Perchloric acid/
acetic anhydride (Cat.)
105
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To a stirred solution of acetic anhydride (3 cm 3 ) and glacial acetic acid (5 cm 3 )

was added the hexol 103 (45 mg, 0.146 mmol). A perchloric acid-acetic anhydrid

catalyst (1 g of 70% perchloric acid in 2.3 g acetic anhydride) was added (4 d

the mixture stirred for 1 h before pouring into ice-water (20 cm3). The mixture

extracted with ethyl acetate (3 x 30 cm3) and the organic fractions combined, d

magnesium sulfate and concentrated in vacuo to yield a yellow oil, 105 (59 mg,

8H (300 MHz; CDCI3) 7.85 (1H, s, H4), 6.17 (1H, d, 7 4.0, HI'), 6.12 (1H, dd, 7
5.6, H4'), 5.73 (2H, m, H2' and H3'), 5.61 (1H, m, 74.2, 5.6, 7.3, H5'), 4.33
4.2, 10.5, H6a'), 4.11 (1H, dd, 77.3, 10.5, H6b'), 2.72 (3H, s, Me), 2.15 (6H, s, 2Ac),

2.13 (6H, s, 2Ac), 2.10 (3H, br.s, Ac), 2.07 (3H, s, Ac); HRMS (CI+) m/z 559.1
(30%) (M+H+; C23H29NO13S requires 559.1351).
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